<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cardiology - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Medicine
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">179</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 6601,
    "choices": [
      {
        "id": 26373,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary vasospasm </span></span></span></p>"
      },
      {
        "id": 26374,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microvascular dysfunction </span></span></span></p>"
      },
      {
        "id": 26375,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy </span></span></span></p>"
      },
      {
        "id": 26376,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 33-year-old woman 3 months postpartum presents with recurrent exertional chest pain. Cardiac catheterization shows normal coronary arteries, and cardiac MRI reveals diffuse perfusion abnormalities. What is the most likely cause?</span></span></span></p>",
    "unique_key": "Q2050913",
    "question_audio": null,
    "question_video": null,
    "map_id": 30686,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Microvascular dysfunction</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In women with angina and normal coronary arteries on angiography, microvascular dysfunction is a common cause. It involves dysfunction of the small coronary vessels, leading to impaired blood flow and ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coronary vasospasm</span></strong><span style=\"font-size:12.0pt\">: This would cause transient ST-elevation on ECG. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Peripartum cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Presents with heart failure symptoms, not typically isolated chest pain. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Spontaneous coronary artery dissection</span></strong><span style=\"font-size:12.0pt\">: More common in the peripartum period but would typically have abnormal coronary angiography findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider microvascular dysfunction as a potential cause of angina in women with normal coronary arteries on angiography.</span></span></span></p>",
    "correct_choice_id": 26374,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54144,
    "choices": [
      {
        "id": 216045,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dobutamine echocardiography </span></span></span></p>"
      },
      {
        "id": 216046,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
      },
      {
        "id": 216047,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise single-photon emission CT (SPECT) </span></span></span></p>"
      },
      {
        "id": 216048,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vasodilator myocardial perfusion imaging (MPI)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 71-year-old man with a history of coronary artery bypass graft (CABG) presents with worsening exertional chest pain. He is on aspirin, metoprolol, sublingual nitroglycerin, and rosuvastatin. ECG shows LBBB. Which is the most appropriate test?</span></span></p>",
    "unique_key": "Q3891536",
    "question_audio": null,
    "question_video": null,
    "map_id": 30653,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Vasodilator myocardial perfusion imaging (MPI)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with LBBB, vasodilator MPI is preferred over exercise or dobutamine stress testing as it minimizes septal artifacts that can occur with exercise or dobutamine (both of which increases HR and worsen septal artefacts in LBBB) and lead to false-positive results.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dobutamine echocardiography</span></strong><span style=\"font-size:12.0pt\">: Not ideal due to the presence of LBBB, which can hinder image interpretation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: LBBB limits the interpretability of exercise ECG for ischemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Exercise SPECT</span></strong><span style=\"font-size:12.0pt\">: Exercise increases heart rate which can worsen artefacts due to LBBB.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the evaluation of patients with chest pain, vasodilator myocardial perfusion imaging with adenosine, regadenoson, or dipyridamole minimizes septal abnormalities frequently seen with exercise or dobutamine myocardial perfusion imaging.</span></span></span></p>",
    "correct_choice_id": 216048,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 54146,
    "choices": [
      {
        "id": 216053,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aortic stenosis </span></span></span></p>"
      },
      {
        "id": 216054,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis </span></span></span></p>"
      },
      {
        "id": 216055,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery disease </span></span></span></p>"
      },
      {
        "id": 216056,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Restrictive cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 42-year-old woman with a history of radiation therapy for Hodgkin lymphoma presents with exertional dyspnea and a burning sensation in her throat.</span><span style=\"font-size:12.0pt\"> She has no history of hypertension, hyperlipidemia, or diabetes and she is a non-smoker. </span><span style=\"font-size:12.0pt\">Physical examination and chest X-ray are normal. What is the most likely diagnosis?</span></span></span></p>",
    "unique_key": "Q9507121",
    "question_audio": null,
    "question_video": null,
    "map_id": 30654,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Coronary artery disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiation therapy to the chest can cause accelerated atherosclerosis and premature coronary artery disease (CAD). This patient&#39;s history of mantle radiation and symptoms of exertional dyspnea and throat burning (which could be atypical angina) make CAD the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aortic stenosis</span></strong><span style=\"font-size:12.0pt\">: Valvular diseases are possible after radiation but less likely given the normal physical exam. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Constrictive pericarditis&nbsp;</strong>and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>D</strong>. <strong>Restrictive cardiomyopathy</strong>: These can occur after radiation but typically present with additional signs like elevated JVP, edema, or diastolic dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cancer survivors who received chest radiotherapy are at risk for the late development of cardiovascular complications, including pericardial constriction, valvular heart disease, restrictive cardiomyopathy, and coronary artery disease.</span></span></span></p>",
    "correct_choice_id": 216055,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 54148,
    "choices": [
      {
        "id": 216061,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography</span></span></span></p>"
      },
      {
        "id": 216062,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG</span></span></span></p>"
      },
      {
        "id": 216063,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pharmacologic myocardial perfusion imaging</span></span></span></p>"
      },
      {
        "id": 216064,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No further testing is required</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 66-year-old woman 6-month history of right shoulder pain on exertion and it is relieved by rest. Her ECG shows LBBB. She has no known comorbidities and not on any regular medications. What is the most appropriate test?</span></span></p>",
    "unique_key": "Q3216748",
    "question_audio": null,
    "question_video": null,
    "map_id": 30655,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Pharmacologic myocardial perfusion imaging</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Due to the LBBB, exercise ECG may have limited diagnostic accuracy for ischemia. Pharmacologic stress testing with imaging (e.g., myocardial perfusion imaging) is the preferred method to assess for ischemia in these patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coronary angiography</span></strong><span style=\"font-size:12.0pt\">: Not the initial test for stable angina. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It should be reserved for patients with a high pretest likelihood of CAD and unstable symptoms, or for those in whom optimal medical therapy has been ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: LBBB limits interpretation of ECG changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No further testing:</span></strong><span style=\"font-size:12.0pt\"> Inappropriate as the patient has exertional chest pain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">tress testing with imaging is indicated in patients with an inability to exercise, baseline ECG abnormalities that limit interpretation of the exercise ECG, or indeterminate findings on the exercise ECG.</span></span></span></p>",
    "correct_choice_id": 216063,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 54150,
    "choices": [
      {
        "id": 216069,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary plaque rupture </span></span></span></p>"
      },
      {
        "id": 216070,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary vasospasm </span></span></span></p>"
      },
      {
        "id": 216071,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism </span></span></span></p>"
      },
      {
        "id": 216072,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man presents with severe chest pain and diaphoresis. His ECG is shown below. His cardiac troponins were elevated and he was started on aspirin, ticagrelor and UFH. He experiences recurrent chest pain, hypotension and hence coronary angiogram was done which was normal. What is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-174059.png\" style=\"height:266px; width:300px\" /></span></span></p>",
    "unique_key": "Q5828115",
    "question_audio": null,
    "question_video": null,
    "map_id": 30656,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Coronary vasospasm</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ECG patterns in patients with coronary artery spasm may suggest STEMI; severe cases of multivessel spasm may be associated with widespread ST-segment elevation (like in this case).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Treatment of coronary artery vasospasm with calcium channel blockade and/or nitrates can rapidly reverse coronary vasoconstriction, with improvement in myocardial perfusion, symptoms, ECG abnormalities, and hemodynamics.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coronary plaque rupture</span></strong><span style=\"font-size:12.0pt\">: Would be visible on angiography. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pulmonary embolism</span></strong><span style=\"font-size:12.0pt\">: Usually presents with pleuritic chest pain and dyspnea. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stress cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: More common in elderly women and usually triggered by stress.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary vasospasm can mimic ACS and may present with recurrent chest pain, ECG changes, and even troponin elevation, despite normal coronary arteries.</span></span></span></p>",
    "correct_choice_id": 216070,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 54156,
    "choices": [
      {
        "id": 216093,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypertrophic cardiomyopathy</span></span></span></p>"
      },
      {
        "id": 216094,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ischemic coronary artery disease</span></span></span></p>"
      },
      {
        "id": 216095,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Normal test result</span></span></span></p>"
      },
      {
        "id": 216096,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rate-dependent conduction defect</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old woman is evaluated for atypical chest pain. Exercise stress testing is performed. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-174936.png\" style=\"height:346px; width:400px\" /></span></span></p>",
    "unique_key": "Q4198466",
    "question_audio": null,
    "question_video": null,
    "map_id": 30657,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>B) Ischemic coronary artery disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Although the resting ECG is normal, the exercise ECG demonstrates horizontal ST depressions in multiple leads, including II, III, aVF, and V4 through V5. The most likely cause of the ST depressions following exercise is ischemic coronary artery disease. Ischemia is defined by the development of horizontal or downsloping ST-segment depression of at least 1 mm occurring 80 ms after the J point on exercise ECG. Unlike ST segment changes in the setting of acute coronary syndrome, ST-segment depression on exercise testing cannot localize ischemia.</span></span></span></p>",
    "correct_choice_id": 216094,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 54161,
    "choices": [
      {
        "id": 216113,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arterial duplex ultrasonography </span></span></span></p>"
      },
      {
        "id": 216114,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
      },
      {
        "id": 216115,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Emergent right leg amputation </span></span></span></p>"
      },
      {
        "id": 216116,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate Heparin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old man with a history of peripheral artery disease (PAD) presents with acute right leg pain. On examination, the right foot is cool and pedal pulses are absent. Sensation and muscle strength are normal. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q4848078",
    "question_audio": null,
    "question_video": null,
    "map_id": 30658,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Initiate Heparin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with acute limb ischemia (ALI), a surgical emergency caused by a sudden decrease in arterial blood flow to the limb. The absence of sensory and motor deficits indicates that the ischemia is not yet irreversible, but prompt revascularization is crucial to salvage the limb. The immediate priority in ALI is to prevent further clot propagation and embolization. Intravenous heparin is initiated as soon as ALI is suspected to achieve this goal. Following heparin invasive angiography is preferred for definitive management.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Arterial duplex ultrasonography:</span></strong><span style=\"font-size:12.0pt\"> While useful for diagnosing PAD, it is not the immediate priority in acute limb ischemia. Revascularization should be initiated before obtaining imaging studies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CT angiography:</span></strong><span style=\"font-size:12.0pt\"> This can provide a detailed view of the arterial anatomy and identify the location of the occlusion, but it should not delay revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Emergent right leg amputation:</span></strong><span style=\"font-size:12.0pt\"> This is a last resort if revascularization fails or is not possible. Amputation should not be considered until all revascularization options have been exhausted.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prompt initiation of anticoagulation with heparin in ALI to prevent further thrombus formation and limb loss.</span></span></span></p>",
    "correct_choice_id": 216116,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54162,
    "choices": [
      {
        "id": 216117,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ankle-brachial index (ABI) </span></span></span></p>"
      },
      {
        "id": 216118,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lower extremity CT angiography </span></span></span></p>"
      },
      {
        "id": 216119,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Toe-brachial index (TBI) </span></span></span></p>"
      },
      {
        "id": 216120,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with diabetes and PAD has a right foot ulcer and feeble pulses. Ankle Brachial Index (ABI) on the right is 1.65. What is the next step?</span></span></p>",
    "unique_key": "Q6831255",
    "question_audio": null,
    "question_video": null,
    "map_id": 30659,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Toe-brachial index (TBI)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When the ABI is uninterpretable due to non-compressible vessels (ABI &gt;1.40), the toe-brachial index (TBI) is a reliable alternative to assess for peripheral arterial disease (PAD). A TBI &lt;0.70 indicates significant PAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Exercise ABI</span></strong><span style=\"font-size:12.0pt\">: Not useful when resting ABI is uninterpretable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lower Extremity CT angiography</span></strong><span style=\"font-size:12.0pt\">: Helpful for planning revascularization, but TBI is the more appropriate initial test in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Evaluates for venous disease, not arterial.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Toe-brachial index (TBI) is useful in diagnosing PAD when ankle-brachial index (ABI) is uninterpretable due to non-compressible vessels.</span></span></span></p>",
    "correct_choice_id": 216119,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 54163,
    "choices": [
      {
        "id": 216121,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenosine single-photon emission CT </span></span></span></p>"
      },
      {
        "id": 216122,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery calcium scoring </span></span></span></p>"
      },
      {
        "id": 216123,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise electrocardiography </span></span></span></p>"
      },
      {
        "id": 216124,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress echocardiography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">52-year-old woman complains of chest tightness after walking for 2-3 km and relieved with rest.&nbsp; Her resting ECG is normal. She is known case of hypertension and dyslipidemia and currently taking ramipril and atorvastatin. What is the most appropriate diagnostic test?</span></span></p>",
    "unique_key": "Q6859475",
    "question_audio": null,
    "question_video": null,
    "map_id": 30660,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Exercise electrocardiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with a normal resting ECG and the ability to exercise, exercise ECG is the recommended initial test for evaluating suspected coronary artery disease (CAD). It provides valuable information about exercise capacity and ischemic response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adenosine single-photon emission CT</span></strong><span style=\"font-size:12.0pt\">: Reserved for patients who cannot exercise or have uninterpretable ECGs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coronary artery calcium scoring</span></strong><span style=\"font-size:12.0pt\">: Used for risk stratification in asymptomatic patients especially to know the need for a statin. The patient is already on atorvastatin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stress echocardiography</span></strong><span style=\"font-size:12.0pt\">: Can be considered if exercise ECG is inconclusive. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG is the first-line test for evaluating suspected CAD in patients with typical angina and a normal resting ECG.</span></span></span></p>",
    "correct_choice_id": 216123,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 54164,
    "choices": [
      {
        "id": 216125,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add carvedilol </span></span></span></p>"
      },
      {
        "id": 216126,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
      },
      {
        "id": 216127,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add digoxin</span></span></span></p>"
      },
      {
        "id": 216128,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRT-D</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with ischemic cardiomyopathy (EF 20%) and NYHA class III heart failure is on maximally tolerated doses of ACE inhibitor, furosemide, and empagliflozin. ECG shows LBBB with a QRS duration of 130 ms. What is the most appropriate additional treatment?</span></span></p>",
    "unique_key": "Q5229798",
    "question_audio": null,
    "question_video": null,
    "map_id": 30661,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Add carvedilol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers are part of guideline-directed medical therapy (GDMT) for HFrEF and sh</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ould be added to the patient&#39;s regimen. While CRT might be considered in the future if symptoms persist despite optimal medical therapy, adding a beta-blocker is the most appropriate initial step.&nbsp;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Current GDMT for HFrEF includes ARNi/ACEi or ARB, Beta blockers, MRA and SGLT2i. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add Ivabradine</span></strong><span style=\"font-size:12.0pt\">: Indicated only after maximally tolerated beta-blocker dose. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CRT-D</span></strong><span style=\"font-size:12.0pt\">: Considered if LVEF remains &le;35%, QRS duration &ge;150 ms, and NYHA class II-IV symptoms despite optimal medical therapy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add digoxin</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">: Considered for primary prevention of sudden cardiac death in patients with LVEF &le;35% despite optimal medical therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate beta-blocker therapy in patients with HFrEF who are not already on it, as part of guideline-directed medical therapy.</span></span></span></p>",
    "correct_choice_id": 216125,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54165,
    "choices": [
      {
        "id": 216129,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediate endovascular stenting </span></span></span></p>"
      },
      {
        "id": 216130,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immediate open surgical repair </span></span></span></p>"
      },
      {
        "id": 216131,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV labetalol </span></span></span></p>"
      },
      {
        "id": 216132,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat CT angiography in 12 hours</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old woman presents with acute type B aortic dissection involving the descending thoracic aorta with a maximal aortic diameter of 6.8 cm. Her BP is 173/99 mm Hg and PR is 90/min. What is the most appropriate initial management?</span></span></p>",
    "unique_key": "Q2175334",
    "question_audio": null,
    "question_video": null,
    "map_id": 30662,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) IV labetalol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In acute type B aortic dissection, the immediate priority is to aggressively control blood pressure and heart rate to limit the propagation of the dissection. IV labetalol is a combined alpha- and beta-blocker that is effective in rapidly reducing blood pressure and heart rate, making it the most appropriate initial management in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While surgery or endovascular stenting may be indicated in the future, they are not the immediate priority. The patient should be stabilized first with medical management before considering invasive interventions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immediate endovascular stenting:</span></strong><span style=\"font-size:12.0pt\"> Endovascular stenting can be used to treat patients with descending aortic aneurysms; however, there is scant evidence to support this as an initial treatment option for aneurysm with dissection. After medical stabilization, thoracic endovascular aortic repair (TEVAR) with stent grafting can be used; typical indications include descending aortic aneurysm diameter greater than 6.0 cm, rapid growth (&gt;0.5 cm/year), or end-organ damage. TEVAR has the advantage over surgical operation of lower morbidity and shorter hospital stay, although there may be complications, including stroke, spinal ischemia, and aortic graft endoleaks. This patient should be treated with stent implantation only after medical stabilization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Immediate open surgical repair:</span></strong><span style=\"font-size:12.0pt\"> Open surgical repair of the descending aorta is not recommended in patients with uncomplicated type B aortic dissection because of high rates of morbidity (such as paraplegia) and mortality. This patient has no signs or symptoms of complications that would prompt immediate surgical repair.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Repeat CT angiography in 12 hours:</span></strong><span style=\"font-size:12.0pt\"> Repeat CT angiography at 12 hours is not indicated unless the patient does not stabilize with medical therapy. Serial imaging (usually magnetic resonance angiography) is typically performed in asymptomatic patients at the time of discharge and then periodically in patients who do not have an indication for aneurysmal repair to screen for extension or recurrence of the dissection, aneurysm formation, and leakage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with uncomplicated type B aortic dissection may be initially treated with medical therapy, including &beta;-blockers, sodium nitroprusside, and opioids.</span></span></span></p>",
    "correct_choice_id": 216131,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54166,
    "choices": [
      {
        "id": 216133,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel now </span></span></span></p>"
      },
      {
        "id": 216134,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel in 5 months </span></span></span></p>"
      },
      {
        "id": 216135,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel in 11 months </span></span></span></p>"
      },
      {
        "id": 216136,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel and aspirin in 11 months</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 81-year-old woman had a drug-eluting stent (DES) for chronic stable angina 1 month ago. She is currently on aspirin and clopidogrel. She is a known case of hypertension, dyslipidaemia, CKD and peptic ulcer disease and was on medications for the same. She wants to minimize DAPT in view of her age and comorbidities. How long should she continue DAPT?</span></span></p>",
    "unique_key": "Q1428459",
    "question_audio": null,
    "question_video": null,
    "map_id": 30663,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Discontinue clopidogrel in 5 months</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Guidelines suggest a minimum of 6 months of DAPT after elective DES placement. Given this patient&#39;s high bleeding risk, it is reasonable to discontinue clopidogrel after 6 months (5 additional months) while continuing aspirin indefinitely for secondary prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Discontinuing clopidogrel in 1 month can be done in case of bare metal stents (BMS) and not DES.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> 12 months of DAPT is recommended in patient with ACS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. Aspirin should be continued indefinitely in patients with CAD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dual antiplatelet therapy is recommended for at least 6 months after drug-eluting stent placement for treatment of stable angina.</span></span></span></p>",
    "correct_choice_id": 216134,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 54167,
    "choices": [
      {
        "id": 216137,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Another bolus of atropine </span></span></span></p>"
      },
      {
        "id": 216138,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">IV Norepinephrine </span></span></span></p>"
      },
      {
        "id": 216139,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">IV Dopamine</span></span></span></p>"
      },
      {
        "id": 216140,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV Dobutamine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old male with recent post-CABG (coronary artery bypass graft) status presents with chest pain. On arrival, his blood pressure is 60/30 mmHg with a heart rate of 30/min. The ECG shows a narrow complex arrhythmia. The patient has already received three boluses of IV atropine. While awaiting transcutaneous pacing, which of the following is the next appropriate step in management?</span></span></p>",
    "unique_key": "Q2925354",
    "question_audio": null,
    "question_video": null,
    "map_id": 30664,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) IV Dopamine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is experiencing symptomatic bradycardia (low heart rate) with severe hypotension, likely due to a post-operative complication. The maximum dose of atropine has already been given with no adequate response. The next best step is cardiac pacing. But while awaiting pacing, one can try chronotropic drugs like dopamine, epinephrine in the ER. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Another bolus of atropine:</span></strong><span style=\"font-size:12.0pt\"> As per ACLS guidelines, a maximum of three boluses of atropine are recommended for symptomatic bradycardia. Further doses are unlikely to be effective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IV Norepinephrine:</span></strong><span style=\"font-size:12.0pt\"> While norepinephrine is a potent vasopressor, it can also worsen bradycardia due to its reflex bradycardia effect (baroreceptor response).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Opion D. IV Dobutamine:</span></strong><span style=\"font-size:12.0pt\"> Dobutamine primarily acts on beta-1 receptors, increasing heart rate and contractility, but it can also cause vasodilation (beta-2 effects), potentially worsening hypotension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronotropic drugs like dopamine can be tried while awaiting pacing in symptomatic bradycardia with hypotension, especially when atropine has been ineffective. </span></span></span></p>",
    "correct_choice_id": 216139,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54168,
    "choices": [
      {
        "id": 216141,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac magnetic resonance perfusion scan </span></span></span></p>"
      },
      {
        "id": 216142,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CT angiography </span></span></span></p>"
      },
      {
        "id": 216143,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SPECT MPI </span></span></span></p>"
      },
      {
        "id": 216144,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise echocardiography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following non-invasive tests has the best accuracy in detecting coronary stenosis?</span></span></p>",
    "unique_key": "Q5605081",
    "question_audio": null,
    "question_video": null,
    "map_id": 30665,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Coronary CT angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Accuracy in diagnostic tests is often determined by considering both sensitivity and specificity. Coronary CT angiography is the most accurate as it has the highest sensitivity and specificity. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-091702.png\" style=\"height:355px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CMR perfusion</span></strong><span style=\"font-size:12.0pt\"> have high sensitivity, but their specificity is not as high as Coronary CTA, meaning they might produce more false-positive results.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise echocardiography</span></strong><span style=\"font-size:12.0pt\"> and </span><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>C.&nbsp;SPECT MPI</strong> have lower sensitivity and specificity than Coronary CTA, indicating a higher chance of both false negatives and false positives.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CTA is a highly accurate non-invasive test for detecting coronary stenosis due to its excellent sensitivity and specificity. It is a valuable tool for diagnosing and evaluating CAD.</span></span></span></p>",
    "correct_choice_id": 216142,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 54169,
    "choices": [
      {
        "id": 216145,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronotropic incompetence </span></span></span></p>"
      },
      {
        "id": 216146,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HFpEF </span></span></span></p>"
      },
      {
        "id": 216147,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung disease </span></span></span></p>"
      },
      {
        "id": 216148,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal aging</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Xavier, a 72-year-old retired judge, experiences increased fatigue during walking. His physical exam, vitals, baseline ECG and 2D Echo are normal. Exercise ECG shows a peak heart rate of 96 beats/min with no ST changes. What is the most likely cause of his symptoms?</span></span></p>",
    "unique_key": "Q4441261",
    "question_audio": null,
    "question_video": null,
    "map_id": 30666,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Chronotropic incompetence</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronotropic incompetence is the inability of the heart rate to increase adequately during exercise. Mr. Xavier&rsquo;s peak heart rate of 96 beats/min during exercise is below the expected maximum for his age (</span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 148/min), and he is experiencing exertional fatigue, indicating chronotropic incompetence.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HFpEF</span></strong><span style=\"font-size:12.0pt\">: Unlikely given the normal echocardiogram, especially the normal atrial size.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lung disease</span></strong><span style=\"font-size:12.0pt\">: Unlikely given the normal chest X-ray and absence of respiratory symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Normal aging</span></strong><span style=\"font-size:12.0pt\">: While aging can cause some decline in exercise tolerance, this patient&#39;s significant fatigue suggests a pathological cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Predicted maximal HR </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 220-Age</span></span></span></p>",
    "correct_choice_id": 216145,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 54170,
    "choices": [
      {
        "id": 216149,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dual-chamber pacemaker implantation </span></span></span></p>"
      },
      {
        "id": 216150,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG test </span></span></span></p>"
      },
      {
        "id": 216151,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start isoprenaline 10mg TID </span></span></span></p>"
      },
      {
        "id": 216152,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stop metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Venkatesh, a 40-year-old man with hypertension treated with hydrochlorothiazide and metoprolol, presents with fatigue. His physical exam is normal except for a heart rate of 40 beats/min. ECG shows sinus bradycardia. Lab tests, including thyroid function and hemoglobin, are normal. What is the most reasonable next step?</span></span></p>",
    "unique_key": "Q4870810",
    "question_audio": null,
    "question_video": null,
    "map_id": 30667,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Stop metoprolol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mr. Venkatesh&rsquo;s fatigue and bradycardia are likely due to sinoatrial (SA) node dysfunction, possibly exacerbated by his metoprolol (a beta-blocker) use. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta blockers and calcium channel blockers increase sinus node recovery time. Therefore, particularly in patients with subacute SA node dysfunction, anti-arrhythmic drugs with class I and III action may promote SA node exit block and create symptomatic bradycardia. In general, such agents should be discontinued before decisions regarding the need for permanent pacing in patients with SA node disease are made.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Therefore, stopping metoprolol is the most reasonable next step to assess if the medication is contributing to his symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dual chamber Pacemaker implantation</span></strong><span style=\"font-size:12.0pt\">: This may be indicated later if the bradycardia persists or is symptomatic after discontinuing the beta-blocker.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG test</span></strong><span style=\"font-size:12.0pt\">: This may be helpful to assess the chronotropic response, but the priority is to address the potential medication-induced bradycardia first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Start isoprenaline 10mg TID</span></strong><span style=\"font-size:12.0pt\">: This is a pure beta agonist with chronotropic effects and is not a first-line treatment for bradycardia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta blockers and calcium channel blockers increase sinus node recovery time and can cause severe sinus bradycardia in some individuals.</span></span></span></p>",
    "correct_choice_id": 216152,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54171,
    "choices": [
      {
        "id": 216153,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adenosine 6 mg IV </span></span></span></p>"
      },
      {
        "id": 216154,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carotid body massage </span></span></span></p>"
      },
      {
        "id": 216155,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Metoprolol 5 mg IV </span></span></span></p>"
      },
      {
        "id": 216156,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Valsalva maneuver</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old man with bacterial pneumonia experiences a sudden lightheadedness. His BP is stable, and the rhythm strip is shown. Which of the following is most likely to lead to sustained improvement in heart rate?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-182921.png\" style=\"height:108px; width:400px\" /></span></span></p>",
    "unique_key": "Q6519677",
    "question_audio": null,
    "question_video": null,
    "map_id": 30668,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Metoprolol 5 mg IV</strong> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has focal atrial tachycardia. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Focal atrial tachycardia (FAT) accounts for ~10% of PSVTs in patients referred for catheter ablation (most common is AVNRT responsible for ~60% of PSVTs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The arrows (which are a nice clue in the question!) indicate the ectopic atrial activity. While one could consider that this might be sinus tachycardia, the rate far exceeds the patient&rsquo;s maximal predicted heart rate (220 &ndash; age) and obviates the possibility of any sinus rhythm. Any maneuver or pharmacologic therapy aimed at producing transient atrioventricular (AV) nodal block (e.g., Valsalva, carotid massage, adenosine) may briefly slow the ventricular response. However, since focal atrial tachycardia does not rely on the AV node for continuation it is rare that transient AV nodal block will terminate the arrhythmia. Beta blockers or non-dihydropyridine calcium channel blockers can lead to sustained improvement in heart rate.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adenosine 6 mg IV</span></strong><span style=\"font-size:12.0pt\">: Primarily used for supraventricular tachycardia (SVT) and may not be effective in FAT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carotid body massage</span></strong><span style=\"font-size:12.0pt\">: A vagal maneuver that may temporarily slow the heart rate but is not a definitive treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Valsalva maneuver</span></strong><span style=\"font-size:12.0pt\">: A vagal maneuver that may temporarily slow the heart rate but is not a definitive treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Focal atrial tachycardia is not dependent on the AV node and beta-blockers or non-dihydropyridine CCBs are the preferred treatment options for rate control. </span></span></span></p>",
    "correct_choice_id": 216155,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 54172,
    "choices": [
      {
        "id": 216157,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium ryanodine receptor </span></span></span></p>"
      },
      {
        "id": 216158,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmosomal proteins </span></span></span></p>"
      },
      {
        "id": 216159,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Potassium channel </span></span></span></p>"
      },
      {
        "id": 216160,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Sarcomere proteins</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You are called to the ER for a young patient in cardiac arrest during exercise. ECG showed bidirectional VT and it was cardioverted immediately. ECG post-cardioversion is normal. 2D Echo and cardiac MRI are also normal. Mutations in which protein are responsible for this?</span></span></p>",
    "unique_key": "Q6165127",
    "question_audio": null,
    "question_video": null,
    "map_id": 30669,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Calcium ryanodine receptor</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s young age, cardiac arrest during exercise (with bidirectional VT), normal resting ECG and normal structural heart on imaging strongly suggest CPVT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Desmosomal proteins:</span></strong><span style=\"font-size:12.0pt\"> Mutations in desmosomal proteins cause arrhythmogenic right ventricular cardiomyopathy (ARVC), which is a structural heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Potassium channel:</span></strong><span style=\"font-size:12.0pt\"> Mutations in potassium channels can cause long QT syndrome. In this case resting ECG would have showed long QTc. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sarcomere proteins:</span></strong><span style=\"font-size:12.0pt\"> Mutations in sarcomere proteins cause hypertrophic cardiomyopathy (HCM), which would have resulted in structural heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize bidirectional VT as a hallmark of CPVT, an inherited arrhythmia syndrome caused by mutations in the cardiac ryanodine receptor (RyR2).</span></span></span></p>",
    "correct_choice_id": 216157,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 54173,
    "choices": [
      {
        "id": 216161,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antibody-mediated rejection </span></span></span></p>"
      },
      {
        "id": 216162,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cellular rejection </span></span></span></p>"
      },
      {
        "id": 216163,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery disease </span></span></span></p>"
      },
      {
        "id": 216164,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Endocarditis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Vadivel, a 5-year post-heart transplant patient with no prior rejection episodes, presents with progressive exertional dyspnea and chest discomfort. He is on tacrolimus, mycophenolate mofetil, and low-dose prednisolone. 2D Echo shows normal LV function and no valvular abnormalities. What is the most likely cause of his symptoms?</span></span></p>",
    "unique_key": "Q3285864",
    "question_audio": null,
    "question_video": null,
    "map_id": 30670,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Coronary artery disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac allograft recipients, even with young donor hearts, are prone to developing coronary artery disease (CAD). This CAD is often diffuse and differs from typical atherosclerotic CAD. Risk factors include immune injury, dyslipidemia, diabetes, and cytomegalovirus infection (which the patient had). The lack of angina is common due to the denervated heart.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antibody-mediated rejection</span></strong><span style=\"font-size:12.0pt\">: Rare this far out from transplant, especially without prior rejection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cellular rejection</span></strong><span style=\"font-size:12.0pt\">: Unlikely with normal LV function and no arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Endocarditis</span></strong><span style=\"font-size:12.0pt\">: Less likely without fever or new murmur.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize that coronary artery disease is a major cause of late mortality in heart transplant recipients, even in the absence of typical risk factors or angina.</span></span></span></p>",
    "correct_choice_id": 216163,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 54174,
    "choices": [
      {
        "id": 216165,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eccentric lesions </span></span></span></p>"
      },
      {
        "id": 216166,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Minimal calcification </span></span></span></p>"
      },
      {
        "id": 216167,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Poor collaterals </span></span></span></p>"
      },
      {
        "id": 216168,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microvasculature affected</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac allograft vasculopathy (CAV) is different from atherosclerotic CAD. Which of the following regarding CAV is false?</span></span></p>",
    "unique_key": "Q1130461",
    "question_audio": null,
    "question_video": null,
    "map_id": 30671,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Eccentric lesions</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Here is a difference between CAV and CAD -</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-183458.png\" style=\"height:357px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Minimal calcification:</span></strong><span style=\"font-size:12.0pt\"> CAV lesions often have minimal calcification, particularly in the early stages, which can make them difficult to detect on standard coronary angiography.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Poor collaterals:</span></strong><span style=\"font-size:12.0pt\"> The development of collateral vessels is often impaired in CAV, making the heart more vulnerable to ischemia and infarction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong><span style=\"font-size:12.0pt\"> <strong>d. Microvasculature affected:</strong> CAV can affect both the epicardial coronary arteries and the microvasculature, leading to diffuse myocardial dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CAV is different from CAD and difficult to treat. </span></span></span></p>",
    "correct_choice_id": 216165,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 54175,
    "choices": [
      {
        "id": 216169,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
      },
      {
        "id": 216170,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heparin </span></span></span></p>"
      },
      {
        "id": 216171,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol </span></span></span></p>"
      },
      {
        "id": 216172,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitroglycerin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 67-year-old man with a history of hypertension and hyperlipidemia presents with severe chest pain. His ECG shows ST-segment depression and his initial troponin level is elevated. He is currently taking aspirin, amlodipine, simvastatin, and tadalafil. Which of the following medications should NOT be administered?</span></span></p>",
    "unique_key": "Q5200704",
    "question_audio": null,
    "question_video": null,
    "map_id": 30672,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Nitroglycerin </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is suffering from a NSTEMI. The two cornerstones of pharmacologic therapy in NSTEMI management are reduction of myocardial oxygen demand and antithrombotic therapy. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin in combination with a P2Y12 receptor blocker (e.g., clopidogrel, ticagrelor, or prasugrel) are appropriate antiplatelet options. Options for anticoagulants include (1) unfractionated heparin (2) enoxaparin (3) bivalirudin and (4) fondaparinux</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">To reduce myocardial oxygen demand, beta-blockade administration targeting a heart rate of 60 beats/min is reasonable, though it should be used with caution or avoided in the presence of heart failure (not present in this patient). Likewise, nitroglycerin is a commonly used and effective anti-anginal therapy. However, a direct contraindication is the use of phosphodiesterase inhibitors (such as tadalafil in this patient), and co-administration can result in catastrophic hypotension.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: P2Y12 inhibitor, indicated in NSTEMI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Heparin IV</span></strong><span style=\"font-size:12.0pt\">: Anticoagulation, indicated in NSTEMI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Metoprolol IV</span></strong><span style=\"font-size:12.0pt\">: Beta-blocker, indicated in NSTEMI unless contraindicated (e.g., heart failure).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Be aware of the contraindication of nitroglycerin in patients taking phosphodiesterase-5 inhibitors due to the risk of severe hypotension.</span></span></span></p>",
    "correct_choice_id": 216172,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54176,
    "choices": [
      {
        "id": 216173,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Two anginal episode in 24 hours. </span></span></span></p>"
      },
      {
        "id": 216174,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Age. </span></span></span></p>"
      },
      {
        "id": 216175,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Daily aspirin use. </span></span></span></p>"
      },
      {
        "id": 216176,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the above confer increased risk.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You are seeing a 75-year-old man admitted for non-ST-elevation myocardial infarction. He has a history of CAD and takes daily aspirin. He&#39;s had multiple angina episodes in the past few days, has ST-segment depression on ECG, and elevated troponin. Which of the following details does NOT confer increased risk of poor outcomes?</span></span></p>",
    "unique_key": "Q2058178",
    "question_audio": null,
    "question_video": null,
    "map_id": 30673,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) All of the above confer increased risk</strong>.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with documented non&ndash;ST-elevation acute coronary syndrome (ACS) exhibit a wide spectrum of early (30 days) risk of death, ranging from 1 to 10%, and a recurrent ACS rate of 5&ndash;15% during the first year. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Assessment of risk can be accomplished by clinical risk scoring systems such as that developed from the Thrombolysis in Myocardial Infarction (TIMI) Trials, which includes seven independent risk factors (age &ge;65 years, 3 or more of the traditional risk factors for CAD, known history of CAD or coronary stenosis &ge; 50%, daily aspirin use in the prior week, more than one anginal episode in the past 24 hours, ST-segment deviation of at least 0.5 mm, and an elevated cardiac specific biomarker above the upper limit of normal). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Additional risk factors include diabetes, LV dysfunction, renal dysfunction, and elevated BNP. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Two anginal episode in 24 hours</span></strong><span style=\"font-size:12.0pt\">: High risk indicating loss of ischemic preconditioning and an active/ongoing ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Age</span></strong><span style=\"font-size:12.0pt\">: Advanced age is the SINGLE most important risk factor in ACS.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Daily aspirin use</span></strong><span style=\"font-size:12.0pt\">: While aspirin is cardioprotective, ACS despite use of aspirin indicates high thrombus burden and hence, high risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TIMI score for NSTE-ACS is important!</span></span></span></p>",
    "correct_choice_id": 216176,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 54177,
    "choices": [
      {
        "id": 216177,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amlodipine </span></span></span></p>"
      },
      {
        "id": 216178,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
      },
      {
        "id": 216179,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long-acting oral nitrates</span></span></span></p>"
      },
      {
        "id": 216180,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diltiazem</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman experiences recurrent chest pain with transient ST elevations during episodes. Angiography shows normal coronary arteries, but pain is worse during hyperventilation. Which of the following is NOT a reasonable treatment for her condition?</span></span></p>",
    "unique_key": "Q5573942",
    "question_audio": null,
    "question_video": null,
    "map_id": 30674,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Aspirin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has Prinzmetal variant angina. Nitrates and calcium channel blockers are the main therapeutic agents. Aspirin may actually increase the severity of ischemic episodes, possibly as a result of the sensitivity of coronar tone to modest changes in the synthesis of prostacyclin. Statin therapy has been shown to reduce the risk of major adverse events, although the precise mechanism is not established. The response to beta blockers is variable. Coronary revascularization may be helpful in patients who also have discrete, flow-limiting, proximal fixed obstructive lesions. Patients who have had ischemia-associated ventricular fibrillation despite maximal medical therapy should receive an implantable cardioverter-defibrillator</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amlodipine &amp; Option D. Diltiazem</span></strong><span style=\"font-size:12.0pt\"> (calcium channel blockers): These relax the smooth muscle in the coronary arteries, preventing or reversing vasospasm.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Long-acting oral nitrates:</span></strong><span style=\"font-size:12.0pt\"> These medications help to dilate the coronary arteries and reduce the frequency of vasospastic episodes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin is C/I in Prinzmetal&#39;s angina due to its potential to worsen vasospasm.</span></span></span></p>",
    "correct_choice_id": 216178,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54178,
    "choices": [
      {
        "id": 216181,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECG </span></span></span></p>"
      },
      {
        "id": 216182,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CT Angiography</span></span></span></p>"
      },
      {
        "id": 216183,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiogram </span></span></span></p>"
      },
      {
        "id": 216184,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum troponin I level</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Sengutuvel, a 57-year-old man with risk factors for CAD, presents with crushing chest pain, diaphoresis, and shortness of breath. Which diagnostic test will most rapidly guide therapeutic management?</span></span></p>",
    "unique_key": "Q4718765",
    "question_audio": null,
    "question_video": null,
    "map_id": 30675,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) ECG</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is presenting with classic ischemic chest pain by history. When present in such a classic manner, it should be unmistakable. After obtaining this history, the clinical working diagnosis is acute coronary syndrome (ACS). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The next most important step in the decision tree is to determine whether the patient is having an STEMI or NSTE-ACS. This determination can only be accomplished by an ECG.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum biomarkers (troponin) take minutes to hours to return, and may not be elevated in the initial several hours of an infarction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contemporary urgent reperfusion strategies necessitate making a decision (based largely on a combination of clinical and ECG findings) before the results of blood tests are available.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-184050.png\" style=\"height:257px; width:600px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coronary CT angiography</span></strong><span style=\"font-size:12.0pt\">: Coronary CT angiography is not warranted in a patient having active ischemic pain. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Echocardiogram</span></strong><span style=\"font-size:12.0pt\">: Can show wall motion abnormalities but cannot differentiate between STEMI and NSTEMI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum troponin I level</span></strong><span style=\"font-size:12.0pt\">: A key biomarker for MI, but it takes time to elevate, and ECG is crucial for immediate decision-making.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with suspected ACS, a 12-lead ECG is the most rapid and crucial test to guide immediate management decisions, especially regarding the need for urgent reperfusion therapy.</span></span></span></p>",
    "correct_choice_id": 216181,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 54179,
    "choices": [
      {
        "id": 216185,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ankle-brachial index (ABI) testing </span></span></span></p>"
      },
      {
        "id": 216186,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive angiography </span></span></span></p>"
      },
      {
        "id": 216187,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnetic resonance angiography (MRA) </span></span></span></p>"
      },
      {
        "id": 216188,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Segmental lower extremity blood pressure testing</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with a history of smoking presents with progressive bilateral calf pain that worsens with walking and improves with rest. He has normal resting ankle-brachial index (ABI) values. What is the most appropriate next test?</span></span></p>",
    "unique_key": "Q4735747",
    "question_audio": null,
    "question_video": null,
    "map_id": 30676,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Exercise ankle-brachial index (ABI) testing</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ABI testing is indicated in patients with normal or borderline resting ABI but with symptoms suggestive of peripheral artery disease (PAD). It can reveal a drop in ABI after exercise, confirming the diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Invasive angiography</span></strong><span style=\"font-size:12.0pt\">: Not the initial test, reserved for patients with severe PAD or when revascularization is planned. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MRA</span></strong><span style=\"font-size:12.0pt\">: Another option for anatomic imaging, but exercise ABI is a less invasive first step. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Segmental lower extremity blood pressure testing</span></strong><span style=\"font-size:12.0pt\">: Used to localize PAD, but not necessary as the initial test when the ABI is normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% of patients with typical claudication symptoms have a normal or borderline ankle-brachial index.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ABI testing is useful to evaluate for peripheral artery disease in patients with normal ABI values (&gt;0.90 and &le;1.40) and high suspicion of PAD.</span></span></span></p>",
    "correct_choice_id": 216185,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 54180,
    "choices": [
      {
        "id": 216189,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol </span></span></span></p>"
      },
      {
        "id": 216190,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evolocumab </span></span></span></p>"
      },
      {
        "id": 216191,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor </span></span></span></p>"
      },
      {
        "id": 216192,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No additional treatment</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man is evaluated one month after atherectomy and stenting of the right superficial femoral artery for severe claudication. He is now asymptomatic and on guideline-directed medical therapy (GDMT) for peripheral artery disease (PAD). Lab results show total cholesterol 120 mg/dL, LDL 50 mg/dL, and HDL 48 mg/dL. What is the most appropriate additional treatment?</span></span></p>",
    "unique_key": "Q2595133",
    "question_audio": null,
    "question_video": null,
    "map_id": 30677,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) No additional treatment</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is already on appropriate GDMT for PAD, which includes lifestyle modifications, antiplatelet therapy (aspirin and rivaroxaban), statin therapy, and blood pressure control. His lipid profile is well-controlled, and he is asymptomatic. Therefore, no additional treatment is necessary at this time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cilostazol</span></strong><span style=\"font-size:12.0pt\">: Used to improve walking distance in patients with claudication, but not necessary for asymptomatic patients. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Evolocumab</span></strong><span style=\"font-size:12.0pt\">: A PCSK9 inhibitor used to further lower LDL cholesterol in high-risk patients. Not indicated in this patient with well-controlled LDL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ticagrelor</span></strong><span style=\"font-size:12.0pt\">: A more potent antiplatelet agent, not routinely recommended for PAD in addition to aspirin. May be added in high risk PAD (e.g., if associated CAD). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Guideline-directed medical therapy for peripheral artery disease includes exercise; an antiplatelet agent; and aggressive management of atherosclerotic risk factors, including smoking, hypertension, diabetes mellitus, and dyslipidemia.</span></span></span></p>",
    "correct_choice_id": 216192,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54181,
    "choices": [
      {
        "id": 216193,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Depression screening and treatment </span></span></span></p>"
      },
      {
        "id": 216194,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose aspirin </span></span></span></p>"
      },
      {
        "id": 216195,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking cessation counseling and varenicline </span></span></span></p>"
      },
      {
        "id": 216196,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Weight loss</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with hyperlipidemia, prediabetes, and a significant smoking history is seeking cardiovascular risk reduction. Which intervention is most likely to have the greatest impact on his risk?</span></span></p>",
    "unique_key": "Q5772209",
    "question_audio": null,
    "question_video": null,
    "map_id": 30678,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Smoking cessation counseling and varenicline</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking cessation is the single most effective intervention to reduce cardiovascular risk. Varenicline is a medication that has been shown to significantly improve smoking cessation rates.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Depression screening and treatment</span></strong><span style=\"font-size:12.0pt\">: Important, but smoking cessation has a more immediate and significant impact on cardiovascular risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Low-dose aspirin</span></strong><span style=\"font-size:12.0pt\">: Controversial and not routinely recommended for primary prevention in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Weight loss</span></strong><span style=\"font-size:12.0pt\">: Beneficial for cardiovascular health but less impactful than smoking cessation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking cessation substantially reduces cardiovascular risk within 2 years, with risk returning to the level of a nonsmoker after </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\">15 years.</span></span></span></p>",
    "correct_choice_id": 216195,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54182,
    "choices": [
      {
        "id": 216197,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiography </span></span></span></p>"
      },
      {
        "id": 216198,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apixaban </span></span></span></p>"
      },
      {
        "id": 216199,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Unfractionated heparin </span></span></span></p>"
      },
      {
        "id": 216200,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old man with a history of atrial fibrillation, diabetes, and peripheral artery disease presents with acute left leg pain, absent pulses, and cold, mottled skin. What is the most appropriate next step?</span></span></p>",
    "unique_key": "Q1884464",
    "question_audio": null,
    "question_video": null,
    "map_id": 30679,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Unfractionated heparin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with acute limb ischemia (ALI). Immediate anticoagulation with unfractionated heparin is crucial to prevent further thrombus propagation while awaiting definitive intervention (angiography).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Angiography:</span></strong><span style=\"font-size:12.0pt\"> Essential for diagnosis and planning revascularization, but anticoagulation should be started first. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Apixaban</span></strong><span style=\"font-size:12.0pt\">: Oral anticoagulant, not appropriate in the acute setting of ALI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Not indicated for ALI, which is an arterial problem.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treat acute limb ischemia with anticoagulation.</span></span></span></p>",
    "correct_choice_id": 216199,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54183,
    "choices": [
      {
        "id": 216201,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atorvastatin </span></span></span></p>"
      },
      {
        "id": 216202,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colestipol </span></span></span></p>"
      },
      {
        "id": 216203,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ezetimibe </span></span></span></p>"
      },
      {
        "id": 216204,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Icosapent ethyl</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with peripheral artery disease (PAD) was prescribed atorvastatin. He has read in a newspaper that statins can cause muscle aches and stopped taking atorvastatin after he developed worsening leg pain upon walking. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q1772279",
    "question_audio": null,
    "question_video": null,
    "map_id": 30680,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Atorvastatin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Statin therapy is crucial for secondary prevention in PAD. Reintroducing atorvastatin with proper education about potential side effects and strategies for management is the best approach. Patients with PAD may confuse symptoms of intermittent claudication with adverse effects of statins (myalgia), which may contribute to the low adherence rate. The most appropriate treatment is patient education and reintroduction of atorvastatin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Colestipol</span></strong><span style=\"font-size:12.0pt\"> (bile acid resin): Not a first-line agent for PAD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ezetimibe</span></strong><span style=\"font-size:12.0pt\"> (cholesterol absorption inhibitor): Monotherapy with ezetimibe is NOT a substitute for statin therapy. Can be used as an add on if LDL-C is not adequately reduced. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Icosapent ethyl</span></strong><span style=\"font-size:12.0pt\"> (fish oil): Used for triglyceride lowering, which may be considered in addition to statins to lower CV risk (in patients with triglycerides of 135-499 mg/dL). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Peripheral artery disease is considered a clinical atherosclerotic cardiovascular disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Statin therapy is recommended for secondary prevention of atherosclerotic cardiovascular disease in patients with peripheral artery disease.</span></span></span></p>",
    "correct_choice_id": 216201,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54184,
    "choices": [
      {
        "id": 216205,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ABI testing </span></span></span></p>"
      },
      {
        "id": 216206,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lower extremity CT angiography </span></span></span></p>"
      },
      {
        "id": 216207,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Toe-brachial index testing </span></span></span></p>"
      },
      {
        "id": 216208,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No additional testing</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with a recent non-ST-elevation myocardial infarction (NSTEMI) and peripheral artery disease (PAD) is on dual antiplatelet therapy (DAPT), an ACE inhibitor, a statin, and a beta-blocker. He is asymptomatic. His resting ankle-brachial index (ABI) is low bilaterally. What is the most appropriate next step in management?</span></span></p>",
    "unique_key": "Q5866350",
    "question_audio": null,
    "question_video": null,
    "map_id": 30681,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) No additional testing</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is already on appropriate medical therapy for both PAD and coronary artery disease (CAD). He is asymptomatic and has a confirmed diagnosis of PAD based on the low resting ABI. No further testing is needed at this time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Exercise ABI testing</span></strong><span style=\"font-size:12.0pt\">: Indicated for symptomatic patients with normal or borderline resting ABI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lower extremity CT angiography</span></strong><span style=\"font-size:12.0pt\">: Considered if revascularization is planned. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Toe-brachial index testing</span></strong><span style=\"font-size:12.0pt\">: Used when ABI is unreliable due to non-compressible arteries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The American College of Cardiology recommends resting ankle-brachial index testing in patients with history or physical examination findings suggestive of peripheral artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Patients with both coronary artery disease and peripheral artery disease are at higher risk for major adverse cardiovascular events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Also, avoid unnecessary testing in a patient with asymptomatic peripheral artery disease.</span></span></span></p>",
    "correct_choice_id": 216208,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54185,
    "choices": [
      {
        "id": 216209,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
      },
      {
        "id": 216210,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pentoxifylline </span></span></span></p>"
      },
      {
        "id": 216211,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Revascularization </span></span></span></p>"
      },
      {
        "id": 216212,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Supervised exercise training</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with a history of hypertension, hyperlipidemia, and CAD presents with a 3-month history of progressive left calf discomfort exacerbated by walking stairs but absent at rest. He is a smoker and he is currently on aspirin, rosuvastatin, metoprolol, and amlodipine. His left ABI is 0.68. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q2915729",
    "question_audio": null,
    "question_video": null,
    "map_id": 30682,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Supervised exercise training</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with intermittent claudication, a classic symptom of peripheral artery disease (PAD). Supervised exercise training is the first-line treatment for claudication, as it has been shown to significantly improve functional status and quality of life by increasing walking distance and reducing symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CT angiography</span></strong><span style=\"font-size:12.0pt\">: While CT angiography is used for diagnosis and pre-procedural planning in PAD, it is not the first-line treatment for claudication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pentoxifylline</span></strong><span style=\"font-size:12.0pt\">: Not recommended for PAD treatment as it lacks evidence of benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Revascularization</span></strong><span style=\"font-size:12.0pt\">: Revascularization (either surgical or endovascular) may be considered if symptoms are refractory to exercise and medical therapy. However, it&#39;s not the initial step in management.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Supervised exercise training is the most effective initial treatment to increase walking distance for patients with intermittent claudication due to PAD.</span></span></span></p>",
    "correct_choice_id": 216212,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54186,
    "choices": [
      {
        "id": 216213,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pentoxifylline </span></span></span></p>"
      },
      {
        "id": 216214,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Revascularization </span></span></span></p>"
      },
      {
        "id": 216215,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stop canagliflozin </span></span></span></p>"
      },
      {
        "id": 216216,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch olmesartan to ramipril</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old woman with peripheral artery disease (PAD) has persistent claudication despite supervised exercise and optimal medical therapy. Her current medications are aspirin, metformin, canagliflozin, cilostazol, atorvastatin, and olmesartan. CT angiogram reveals an 80% stenosis in the left iliac artery. What is the best treatment?</span></span></p>",
    "unique_key": "Q1603429",
    "question_audio": null,
    "question_video": null,
    "map_id": 30683,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Revascularization</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Revascularization is indicated for patients with lifestyle-limiting claudication despite optimal medical therapy and exercise. The goal is to improve symptoms and quality of life.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pentoxifylline</span></strong><span style=\"font-size:12.0pt\">: Not recommended for PAD treatment due to lack of efficacy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stop canagliflozin</span></strong><span style=\"font-size:12.0pt\">: SGLT2 inhibitors should be used with caution in PAD but not discontinued unless there are specific complications. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Switching to a different antihypertensive</span></strong><span style=\"font-size:12.0pt\">: ACEi or ARBs can provide survival benefit in ASCVD but unlikely to significantly improve symptoms which is the priority in this case.</span></span></span></p>",
    "correct_choice_id": 216214,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54187,
    "choices": [
      {
        "id": 216217,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inferior vena cava thrombosis</span></span></span></p>"
      },
      {
        "id": 216218,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Livedo reticularis</span></span></span></p>"
      },
      {
        "id": 216219,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral artery disease</span></span></span></p>"
      },
      {
        "id": 216220,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous insufficiency</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old man is evaluated for right leg tiredness and cramping when walking 25 yards. His feet are shown following elevation (left) and during dependent positioning (right). Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-094723.png\" style=\"height:166px; width:500px\" /></span></span></p>",
    "unique_key": "Q6105721",
    "question_audio": null,
    "question_video": null,
    "map_id": 30684,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Peripheral artery disease</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis is peripheral artery disease involving the right extremity. The patient has right foot pallor with elevation and dependent rubor. Previously known as the Buerger test, the patient&#39;s foot color is observed when it is elevated and again when it is dependent. The likelihood ratio of a positive finding (elevation pallor and dependent rubor) in the symptomatic extremity is 2.8 for peripheral artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diagnose peripheral artery disease.</span></span></span></p>",
    "correct_choice_id": 216219,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 54188,
    "choices": [
      {
        "id": 216221,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer a direct oral anticoagulant (DOAC) </span></span></span></p>"
      },
      {
        "id": 216222,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer intravenous thrombolytic therapy </span></span></span></p>"
      },
      {
        "id": 216223,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obtain blood cultures and begin empiric antibiotics</span></span></span></p>"
      },
      {
        "id": 216224,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent surgical excision</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman presents with recurrent fevers, night sweats, weight loss, and a transient ischemic attack (TIA). ECG is normal and echo is shown in the video. CT head is normal as well. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q3587586",
    "question_audio": null,
    "question_video": null,
    "map_id": 30685,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Urgent surgical excision</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and echocardiographic findings (rounded mass with attachment to interatrial septum) are consistent with a left atrial myxoma, a benign cardiac tumor that can cause embolic events like TIA. Urgent surgical excision is the definitive treatment to prevent further embolization and potentially fatal complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. DOAC</span></strong><span style=\"font-size:12.0pt\">: Anticoagulation may be considered temporarily before surgery (or if the patient has atrial fibrillation) but is not definitive treatment in this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Thrombolytic therapy</span></strong><span style=\"font-size:12.0pt\">: Not indicated for TIA caused by a cardiac tumor. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Blood cultures and antibiotics</span></strong><span style=\"font-size:12.0pt\">: Not appropriate for a cardiac myxoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Patients with a myxoma may present with valvular occlusive symptoms, such as dyspnea and syncope; embolic phenomena, including stroke or transient ischemic events; and/or constitutional symptoms, such as fever, anorexia, and weight loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with atrial myxoma and a central nervous system embolic event, urgent cardiac surgical evaluation and excision are indicated.</span></span></span></p>",
    "correct_choice_id": 216224,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6659,
    "choices": [
      {
        "id": 26605,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol </span></span></span></p>"
      },
      {
        "id": 26606,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
      },
      {
        "id": 26607,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evolocumab </span></span></span></p>"
      },
      {
        "id": 26608,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pentoxifylline</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 76-year-old man with peripheral artery disease (PAD) and persistent claudication despite exercise and optimal medical therapy (aspirin, statin, enalapril). What is the most appropriate additional treatment?</span></span></p>",
    "unique_key": "Q1213381",
    "question_audio": null,
    "question_video": null,
    "map_id": 30630,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Cilostazol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol is a phosphodiesterase inhibitor that improves walking distance and reduces symptoms in patients with claudication due to PAD. It&#39;s recommended in addition to standard medical therapy for PAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Dual antiplatelet therapy is not routinely recommended for PAD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Evolocumab</span></strong><span style=\"font-size:12.0pt\">: PCSK9 inhibitors are for patients with high LDL cholesterol despite statin therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pentoxifylline</span></strong><span style=\"font-size:12.0pt\">: Not proven effective for claudication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with peripheral artery disease and intermittent claudication, cilostazol is recommended to improve limb symptoms in addition to smoking cessation, aspirin, statin therapy, and supervised exercise.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cilostazol is contraindicated in patients with heart failure.</span></span></span></p>",
    "correct_choice_id": 26605,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6661,
    "choices": [
      {
        "id": 26613,
        "text": "<p><span style=\"font-size:12.0pt;\">Reteplase</span></p>"
      },
      {
        "id": 26614,
        "text": "<p><span style=\"font-size:12.0pt;\">Tirofiban</span></p>"
      },
      {
        "id": 26615,
        "text": "<p><span style=\"font-size:12.0pt;\">Enoxaparin</span></p>"
      },
      {
        "id": 26616,
        "text": "<p><span style=\"font-size:12.0pt;\">Emergent coronary angiography</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 62-year-old woman with acute chest pain for the last 3 hours. Aspirin and clopidogrel was given in the ambulance. ECG is taken in ER and shown below. What is the next step?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-171044.png\" alt=\"\" width=\"400\" height=\"204\"></span></p>",
    "unique_key": "Q1878728",
    "question_audio": null,
    "question_video": null,
    "map_id": 30632,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>C) Enoxaparin</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">ECG shows widespread ST segment depression, suggesting a diagnosis of acute coronary syndrome (ACS) without ST-elevation (NSTE-ACS). In patients with suspected NSTE-ACS, early administration of anticoagulation is crucial to prevent further thrombus formation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation</u>:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Reteplase</strong>: This is a thrombolytic agent used in STEMI and not in NSTE-ACS.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Tirofiban</strong>: GpIIb/IIIa inhibitor used primarily during PCI under special circumstances.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Emergent Coronary angiography</strong>: While angiography is crucial to confirm the diagnosis and guide further management, immediate anticoagulation with enoxaparin should be initiated first. In this patient with ST depression (a high risk factor), URGENT coronary angiography is optimal (&lt; 24h) rather than immediate (&lt; 2h).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In patients with suspected NSTE-ACS, early administration of enoxaparin is crucial to prevent further thrombus formation while awaiting coronary angiography.</span></p>",
    "correct_choice_id": 26615,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6666,
    "choices": [
      {
        "id": 26633,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery bypass grafting (CABG) </span></span></span></p>"
      },
      {
        "id": 26634,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Medical therapy without revascularization </span></span></span></p>"
      },
      {
        "id": 26635,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myocardial viability testing </span></span></span></p>"
      },
      {
        "id": 26636,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Percutaneous coronary intervention (PCI)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with exertional chest pain and a positive stress test undergoes angiography revealing complex multivessel coronary artery disease (CAD) involving the left main. He has a left ventricular ejection fraction (LVEF) of 42%. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q3897808",
    "question_audio": null,
    "question_video": null,
    "map_id": 30637,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Coronary artery bypass grafting (CABG)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CABG is the preferred revascularization strategy for patients with complex multivessel CAD, especially involving the left main, and with reduced LVEF. It offers superior survival benefits compared to medical therapy alone or PCI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Medical therapy</span></strong><span style=\"font-size:12.0pt\">: Insufficient for complex CAD and reduced LVEF, carries a higher risk of adverse events. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Viability testing</span></strong><span style=\"font-size:12.0pt\">: Not necessary before revascularization in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PCI</span></strong><span style=\"font-size:12.0pt\">: Less favorable than CABG for complex multivessel disease, especially with left main involvement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with multivessel coronary artery disease, coronary artery bypass grafting is associated with enhanced survival compared with medical therapy alone.</span></span></span></p>",
    "correct_choice_id": 26633,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 6712,
    "choices": [
      {
        "id": 26817,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Furosemide </span></span></span></p>"
      },
      {
        "id": 26818,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitroglycerin </span></span></span></p>"
      },
      {
        "id": 26819,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil </span></span></span></p>"
      },
      {
        "id": 26820,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CPAP</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with a history of hypertension and coronary artery disease presents with acute decompensated heart failure. He is dyspneic at rest and has bibasilar crackles on lung auscultation. Which of the following medications is NOT appropriate for initial </span></span></p>",
    "unique_key": "Q7218827",
    "question_audio": null,
    "question_video": null,
    "map_id": 30645,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Verapamil</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil is a non-dihydropyridine calcium channel blocker. These medications are contraindicated in acute decompensated heart failure (ADHF) because they have negative inotropic effects, meaning they weaken the heart&#39;s ability to contract. This can worsen the patient&#39;s cardiac output and exacerbate heart failure symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Furosemide</span></strong><span style=\"font-size:12.0pt\">: Loop diuretic, cornerstone of therapy in ADHF to reduce fluid overload. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nitroglycerin</span></strong><span style=\"font-size:12.0pt\">: Vasodilator, used to reduce preload and afterload, improving cardiac function in ADHF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CPAP</span></strong><span style=\"font-size:12.0pt\">: Non-invasive ventilation, often used in ADHF to improve oxygenation and decrease the work of breathing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-dihydropyridine calcium channel blockers (like verapamil) are C/I in acute decompensated heart failure due to their negative inotropic effects</span></span></span></p>",
    "correct_choice_id": 26819,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6754,
    "choices": [
      {
        "id": 26985,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel</span></span></span></p>"
      },
      {
        "id": 26986,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose aspirin </span></span></span></p>"
      },
      {
        "id": 26987,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prasugrel </span></span></span></p>"
      },
      {
        "id": 26988,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with stable angina and aspirin allergy is undergoing lifestyle counseling and antianginal therapy. What is the most appropriate cardioprotective treatment?</span></span></p>",
    "unique_key": "Q7745718",
    "question_audio": null,
    "question_video": null,
    "map_id": 30651,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Clopidogrel</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel is recommended for secondary prevention in patients with stable ischemic heart disease who are intolerant or allergic to aspirin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Low-dose aspirin</span></strong><span style=\"font-size:12.0pt\">: Contraindicated due to aspirin allergy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Prasugrel</span></strong><span style=\"font-size:12.0pt\"> and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>D. Ticagrelor</strong>: More potent antiplatelet agents, typically used in acute coronary syndrome or after PCI, not as monotherapy for stable angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All patients with stable ischemic heart disease should receive guideline-directed therapies consisting of lifestyle modification, cardioprotective therapy, and antianginal medication.&nbsp;</span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with stable ischemic heart disease should receive antiplatelet therapy (low-dose aspirin or clopidogrel in aspirin-intolerant patients) for secondary prevention of cardiovascular events.</span></span></span></p>",
    "correct_choice_id": 26985,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6577,
    "choices": [
      {
        "id": 26277,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous milrinone </span></span></span></p>"
      },
      {
        "id": 26278,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous nitroglycerin </span></span></span></p>"
      },
      {
        "id": 26279,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase furosemide </span></span></span></p>"
      },
      {
        "id": 26280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start CVVH (Continuous venovenous hemofiltration)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 72-year-old man with decompensated heart failure is hospitalized and treated with a maximal dose of IV furosemide. He has minimal urine output and persistent signs of volume overload. What is the most appropriate next step?</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>",
    "unique_key": "Q9337004",
    "question_audio": null,
    "question_video": null,
    "map_id": 30644,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Start CVVH (Continuous venovenous hemofiltration)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute decompensated heart failure (ADHF) who are unresponsive to maximal diuretic therapy (as evidenced by minimal urine output and persistent volume overload), the next step is to initiate ultrafiltration. CVVH is a form of renal replacement therapy that gently removes excess fluid over a longer period, making it well-suited for patients who may not tolerate the rapid fluid shifts of hemodialysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Add intravenous milrinone:</span></strong><span style=\"font-size:12.0pt\"> Milrinone is an inotrope used to improve cardiac contractility. While it may help with cardiac output, it doesn&#39;t directly address the volume overload and can worsen renal function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add intravenous nitroglycerin:</span></strong><span style=\"font-size:12.0pt\"> Nitroglycerin is a vasodilator that can reduce preload and afterload, but it&#39;s not the primary treatment for volume overload when diuretics fail.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase furosemide:</span></strong><span style=\"font-size:12.0pt\"> The patient is already on the maximal dose of furosemide, so further increases would not be effective and could lead to adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with ADHF who are unresponsive to maximal diuretic therapy, CVVH is a crucial intervention to manage volume overload and prevent further complications.</span></span></span></p>",
    "correct_choice_id": 26280,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6602,
    "choices": [
      {
        "id": 26377,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">1 month </span></span></span></p>"
      },
      {
        "id": 26378,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3 months </span></span></span></p>"
      },
      {
        "id": 26379,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6 months </span></span></span></p>"
      },
      {
        "id": 26380,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">12 months</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with diabetes mellitus received a drug-eluting stent for non-ST elevation acute coronary syndrome (NSTE-ACS). She was started on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the recommended minimum duration of her antiplatelet therapy?</span></span></p>",
    "unique_key": "Q2994818",
    "question_audio": null,
    "question_video": null,
    "map_id": 30649,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) 12 months</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with diabetes who have received a drug-eluting stent for NSTE-ACS, the recommended minimum duration of DAPT (aspirin plus a P2Y12 inhibitor like clopidogrel) is <strong>12 months</strong>. This is due to the increased risk of stent thrombosis and major adverse cardiovascular events in patients with diabetes compared to those without.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 1 month:</span></strong><span style=\"font-size:12.0pt\"> This duration is too short and would significantly increase the risk of stent thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 3 months:</span></strong><span style=\"font-size:12.0pt\"> While some studies suggest shorter durations may be safe in select patients, the standard recommendation for patients with diabetes is 12 months.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. 6 months:</strong> This is the minimum duration for patients without diabetes who have received a drug-eluting stent for ACS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand the recommended duration of dual antiplatelet therapy in patients with diabetes who have undergone percutaneous coronary intervention (PCI) with drug-eluting stents for acute coronary syndrome. </span></span></span></p>",
    "correct_choice_id": 26380,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6756,
    "choices": [
      {
        "id": 26993,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of clopidogrel </span></span></span></p>"
      },
      {
        "id": 26994,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of isosorbide mononitrate </span></span></span></p>"
      },
      {
        "id": 26995,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography </span></span></span></p>"
      },
      {
        "id": 26996,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise echocardiography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 69-year-old man with persistent angina despite maximally tolerated antianginal therapy. He has orthostatic hypotension and current BP and PR are 100/60 mm Hg and 54/min respectively. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q1856672",
    "question_audio": null,
    "question_video": null,
    "map_id": 30652,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary angiography is the most appropriate step to assess for obstructive coronary artery disease and guide potential revascularization to improve symptoms and quality of life.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Addition of Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Not indicated for stable angina without recent revascularization. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Addition of Isosorbide mononitrate</span></strong><span style=\"font-size:12.0pt\">: Adding more antianginal medication may not be helpful if the patient is already on maximally tolerated doses. Addition of nitrate in this patient may worsen orthostatic hypotension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise echocardiography</span></strong><span style=\"font-size:12.0pt\">: May provide prognostic information but doesn&#39;t identify lesions for revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the setting of persistent symptoms despite maximally tolerated medical therapy, invasive imaging for revascularization assessment is appropriate to improve symptom status and quality of life.</span></span></span></p>",
    "correct_choice_id": 26995,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19783,
    "choices": [
      {
        "id": 79093,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Abdominal aortography</span></span></span></p>"
      },
      {
        "id": 79094,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACE inhibitor therapy </span></span></span></p>"
      },
      {
        "id": 79095,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
      },
      {
        "id": 79096,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Open abdominal aortic aneurysm repair</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man with a 6.1 cm abdominal aortic aneurysm (AAA) detected on routine USG screening. What is the most appropriate next step in management?</span></span></p>",
    "unique_key": "Q2672989",
    "question_audio": null,
    "question_video": null,
    "map_id": 30646,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) CT angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography is the preferred imaging modality for accurately assessing the size, location, and morphology of the AAA, which is crucial for planning repair.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Abdominal aortography</span></strong><span style=\"font-size:12.0pt\">: Invasive and less commonly used for AAA evaluation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ACE inhibitor therapy</span></strong><span style=\"font-size:12.0pt\">: Doesn&#39;t address the need for repair of a large AAA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Open AAA repair</span></strong><span style=\"font-size:12.0pt\">: Premature before confirming the location and suitability for repair with CTA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The U.S. Preventive Services Task Force recommends one-time screening with duplex ultrasonography in all men aged 65 to 75 years who have smoked at least 100 cigarettes in their lifetime and selective screening in men in this age group who have never smoked.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography or magnetic resonance angiography is the imaging procedure of choice to identify the exact location of an abdominal aneurysm and plan operative repair.</span></span></span></p>",
    "correct_choice_id": 79095,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19784,
    "choices": [
      {
        "id": 79097,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
      },
      {
        "id": 79098,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chest compressions </span></span></span></p>"
      },
      {
        "id": 79099,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous atropine </span></span></span></p>"
      },
      {
        "id": 79100,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Isoproterenol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with Alzheimer&#39;s disease, on donepezil, presents with somnolence, hypotension (70/40 mmHg), and sinus bradycardia (30/min). What is the next treatment?</span></span></p>",
    "unique_key": "Q1533560",
    "question_audio": null,
    "question_video": null,
    "map_id": 30647,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Intravenous atropine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In a patient with symptomatic bradycardia (altered mental status, hypotension), intravenous atropine is the first-line treatment to increase heart rate and improve perfusion. Donepezil, a cholinesterase inhibitor used in Alzheimer&#39;s, is a common cause of drug-induced bradycardia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug, not indicated for bradycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chest compressions</span></strong><span style=\"font-size:12.0pt\">: Not indicated if the patient has a pulse. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Isoproterenol</span></strong><span style=\"font-size:12.0pt\">: Second-line chronotropic agent, considered if atropine is ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The treatment of hemodynamically unstable bradycardia with a pulse is intravenous atropine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common extrinsic cause of sinus bradycardia is medication use (&beta;-blockers, donepezil, neostigmine, pyridostigmine).</span></span></span></p>",
    "correct_choice_id": 79099,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19785,
    "choices": [
      {
        "id": 79101,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiography </span></span></span></p>"
      },
      {
        "id": 79102,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Apixaban </span></span></span></p>"
      },
      {
        "id": 79103,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Unfractionated heparin </span></span></span></p>"
      },
      {
        "id": 79104,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Venous duplex ultrasonography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old man with a history of atrial fibrillation, diabetes, and peripheral artery disease presents with acute left leg pain, absent pulses, and cold, mottled skin. What is the most appropriate next step?</span></span></p>",
    "unique_key": "Q4623786",
    "question_audio": null,
    "question_video": null,
    "map_id": 30648,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Unfractionated heparin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with acute limb ischemia (ALI). Immediate anticoagulation with unfractionated heparin is crucial to prevent further thrombus propagation while awaiting definitive intervention (angiography).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Angiography</span></strong><span style=\"font-size:12.0pt\">: Essential for diagnosis and planning revascularization, but anticoagulation should be started first. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Apixaban</span></strong><span style=\"font-size:12.0pt\">: Oral anticoagulant, not appropriate in the acute setting of ALI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Venous duplex ultrasonography</span></strong><span style=\"font-size:12.0pt\">: Not indicated for ALI, which is an arterial problem.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treat acute limb ischemia with anticoagulation.</span></span></span></p>",
    "correct_choice_id": 79103,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19786,
    "choices": [
      {
        "id": 79105,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
      },
      {
        "id": 79106,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
      },
      {
        "id": 79107,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propranolol </span></span></span></p>"
      },
      {
        "id": 79108,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reassurance</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with no medical history presents with frequent, bothersome palpitations that subside with exercise and in the nights. ECG is shown. Echo and baseline lab tests including CBC and TFT are normal. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-172502.png\" style=\"height:138px; width:300px\" /></span></span></p>",
    "unique_key": "Q2886254",
    "question_audio": null,
    "question_video": null,
    "map_id": 30650,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Propranolol</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has symptomatic premature ventricular contractions (PVCs) that are bothersome. Beta-blockers are the first-line treatment for symptomatic PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential toxicity, not first-line for simple PVCs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: Not helpful for diagnosing PVCs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reassurance</span></strong><span style=\"font-size:12.0pt\">: Not sufficient for bothersome symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers are the first-line treatment for symptomatic PVCs in patients without structural heart disease.</span></span></span></p>",
    "correct_choice_id": 79107,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 54145,
    "choices": [
      {
        "id": 216049,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography </span></span></span></p>"
      },
      {
        "id": 216050,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eplerenone </span></span></span></p>"
      },
      {
        "id": 216051,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oxygen per nasal cannula </span></span></span></p>"
      },
      {
        "id": 216052,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent coronary angiography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man presents with recurrent chest pain and elevated troponin. ECG is shown. remains in pain despite aspirin, clopidogrel, heparin, and nitroglycerin. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-173300.png\" style=\"height:256px; width:300px\" /></span></span></p>",
    "unique_key": "Q9684555",
    "question_audio": null,
    "question_video": null,
    "map_id": 30629,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Urgent coronary angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has NSTE-ACS with refractory angina despite medical therapy. Urgent coronary angiography is indicated to identify the culprit lesion and potentially perform revascularization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Echocardiography</span></strong><span style=\"font-size:12.0pt\">: May be helpful, but not the immediate priority. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eplerenone</span></strong><span style=\"font-size:12.0pt\">: Indicated in certain post-MI patients, but not the immediate priority for refractory angina. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oxygen per nasal cannula</span></strong><span style=\"font-size:12.0pt\">: Indicated only if the patient is hypoxic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urgent or immediate diagnostic angiography with intent to perform revascularization is indicated in patients with NSTE-ACS who have refractory angina or hemodynamic or electrical instability.</span></span></span></p>",
    "correct_choice_id": 216052,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 54147,
    "choices": [
      {
        "id": 216057,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
      },
      {
        "id": 216058,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
      },
      {
        "id": 216059,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin </span></span></span></p>"
      },
      {
        "id": 216060,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pramlintide</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with type 2 diabetes, hypertension, hyperlipidemia, and aortofemoral bypass surgery 2 years ago has an HbA1c of 7.1%. His current medications are metformin, atenolol, ramipril, amlodipine, aspirin, rivaroxaban, and atorvastatin. Which medication is most appropriate to add for cardiovascular risk reduction?</span></span></p>",
    "unique_key": "Q8365159",
    "question_audio": null,
    "question_video": null,
    "map_id": 30631,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Liraglutide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GLP-1 receptor agonists like liraglutide have been shown to reduce cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), which this patient has due to his history of bypass surgery. Liraglutide also promotes weight loss, which can be beneficial for this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Patient is already on rivaroxaban and aspirin. Addition of clopidogrel would not provide any additional benefit and only increase the bleeding risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: No longer recommended for routine use due to lack of benefit and side effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pramlintide</span></strong><span style=\"font-size:12.0pt\">: Amylin analog used for glycemic control, no proven cardiovascular benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists are associated with reduced rates of adverse cardiovascular events, including stroke, myocardial infarction, and cardiovascular death, compared with placebo.</span></span></span></p>",
    "correct_choice_id": 216058,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54149,
    "choices": [
      {
        "id": 216065,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin</span></span></span></p>"
      },
      {
        "id": 216066,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ezetimibe </span></span></span></p>"
      },
      {
        "id": 216067,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Niacin</span></span></span></p>"
      },
      {
        "id": 216068,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No changes in management</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 59-year-old man with type 2 diabetes and a history of stroke is on aspirin, metformin, olmesartan, and rosuvastatin. His LDL-C is 66 mg/dL, HDL-C is 28 mg/dL and HbA1c is 6.8%. What additional medication should be considered for CV risk reduction?</span></span></p>",
    "unique_key": "Q1218758",
    "question_audio": null,
    "question_video": null,
    "map_id": 30633,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Empagliflozin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors like empagliflozin have been shown to reduce cardiovascular events in patients with type 2 diabetes and established ASCVD. They are recommended as part of a comprehensive cardiovascular risk reduction strategy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ezetimibe</span></strong><span style=\"font-size:12.0pt\">: Not indicated as LDL cholesterol is already well-controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Niacin</span></strong><span style=\"font-size:12.0pt\">: Can increase HDL but no longer recommended for routine use due to lack of benefit and side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No changes in management</span></strong><span style=\"font-size:12.0pt\">: Inadequate as SGLT2 inhibitors provide additional CV benefit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider adding SGLT2 inhibitors to the treatment regimen for patients with type 2 diabetes and established ASCVD to reduce CV risk.</span></span></span></p>",
    "correct_choice_id": 216065,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54151,
    "choices": [
      {
        "id": 216073,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add amlodipine </span></span></span></p>"
      },
      {
        "id": 216074,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decrease lisinopril dosage </span></span></span></p>"
      },
      {
        "id": 216075,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduce isosorbide mononitrate&nbsp;dosage&nbsp;to once daily </span></span></span></p>"
      },
      {
        "id": 216076,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat coronary angiography</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old man with CAD and diabetes mellitus experiences worsening angina. He is currently on ramipril, diltiazem, metformin, atorvastatin and isosorbide mononitrate twice daily. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q4464879",
    "question_audio": null,
    "question_video": null,
    "map_id": 30634,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Reduce isosorbide mononitrate dosage to once daily</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is likely experiencing nitrate tolerance, a common side effect of long-acting nitrates like isosorbide mononitrate. Reducing the frequency to once daily with a nitrate-free interval helps restore nitrate efficacy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adding amlodipine</span></strong><span style=\"font-size:12.0pt\">: Not the first-line option when nitrate tolerance is suspected. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreasing lisinopril</span></strong><span style=\"font-size:12.0pt\">: Not indicated as blood pressure is controlled. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Repeat coronary angiography</span></strong><span style=\"font-size:12.0pt\">: Not necessary unless there is a suspicion of new coronary lesions or progression of existing ones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Long-acting nitrates provide a constant level of vasodilation and symptom relief throughout the day, but a nitrate-free interval is required to avoid tolerance.</span></span></span></p>",
    "correct_choice_id": 216075,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54152,
    "choices": [
      {
        "id": 216077,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
      },
      {
        "id": 216078,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperbaric oxygen treatment </span></span></span></p>"
      },
      {
        "id": 216079,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive angiography </span></span></span></p>"
      },
      {
        "id": 216080,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary below-the-knee amputation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 80-year-old man with diabetes, hypertension, and hyperlipidemia presents with a 6-week history of resting foot pain and a non-healing ulcer. His ankle-brachial index (ABI) is 0.44 on the right and 0.62 on the left. What is the most appropriate next step?</span></span></p>",
    "unique_key": "Q5414900",
    "question_audio": null,
    "question_video": null,
    "map_id": 30635,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Invasive angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has chronic limb-threatening ischemia (CLTI) based on his rest pain and non-healing ulcer. Invasive angiography is the most appropriate next step to assess the arterial anatomy and determine the best revascularization strategy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CT angiography</span></strong><span style=\"font-size:12.0pt\">: Can be helpful but is not the first step for patients with CLTI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hyperbaric oxygen treatment</span></strong><span style=\"font-size:12.0pt\">: Not a primary treatment for CLTI, but may be adjunctive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Primary amputation</span></strong><span style=\"font-size:12.0pt\">: Not the initial approach in patients with potentially salvageable limbs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chronic limb-threatening ischemia (CLTI) is characterized by more than 2 weeks of ischemic rest pain, nonhealing wound/ulcers, or gangrene in one or both legs that is attributable to objectively proven peripheral artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In patients with CLTI, immediate invasive angiography with endovascular revascularization is often the most effective strategy to preserve tissue viability.</span></span></span></p>",
    "correct_choice_id": 216079,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54153,
    "choices": [
      {
        "id": 216081,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery calcium scoring </span></span></span></p>"
      },
      {
        "id": 216082,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary CT angiography </span></span></span></p>"
      },
      {
        "id": 216083,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive coronary angiography </span></span></span></p>"
      },
      {
        "id": 216084,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old woman with chest pain over 24 hours and it is worsening despite multiple doses of NTG. She is known case of hypertension and dyslipidaemia and on enalapril and rosuvastatin. Her ECG 3 months ago was normal and her current ECG in the ER is shown. Her initial troponin is normal. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-174508.png\" style=\"height:219px; width:400px\" /></span></span></p>",
    "unique_key": "Q1938886",
    "question_audio": null,
    "question_video": null,
    "map_id": 30636,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Invasive coronary angiography</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Coronary angiography should also be considered for patients with ischemic symptoms that are refractory to medication, such as this patient with unstable angina refractory to medical therapy. If culprit lesions amenable to intervention are identified during diagnostic coronary angiography, percutaneous revascularization can be performed</span><span style=\"font-size:12.0pt\">.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Coronary artery calcium scoring</span></strong><span style=\"font-size:12.0pt\">: No use in patients who are already receiving statins and not helpful in the acute setting.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coronary CT angiography</span></strong><span style=\"font-size:12.0pt\">: May be considered, but invasive angiography is preferred for immediate diagnosis and potential intervention. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise ECG</span></strong><span style=\"font-size:12.0pt\">: C/I in the context of acute/ongoing ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive coronary angiography is the preferred diagnostic test in patients with refractory angina to assess coronary anatomy and guide potential revascularization. </span></span></span></p>",
    "correct_choice_id": 216083,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 54154,
    "choices": [
      {
        "id": 216085,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ambulatory ECG monitoring </span></span></span></p>"
      },
      {
        "id": 216086,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Discontinue flecainide </span></span></span></p>"
      },
      {
        "id": 216087,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Discontinue metoprolol </span></span></span></p>"
      },
      {
        "id": 216088,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise stress testing</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 56-year-old man presents with inferior STEMI and he is successfully treated with PCI. He has a history of paroxysmal AF and was taking flecainide. He was also started on rivaroxaban, metoprolol, and ramipril post PCI. He is currently asymptomatic and now planned for discharge from the hospital. What is the most appropriate management?</span></span></span></p>",
    "unique_key": "Q8773956",
    "question_audio": null,
    "question_video": null,
    "map_id": 30638,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Discontinue flecainide</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This patient has ischemic heart disease and previously diagnosed paroxysmal atrial fibrillation (AF). Amiodarone, dofetilide, flecainide, propafenone, sotalol, and dronedarone may be used to maintain sinus rhythm in patients with AF. Antiarrhythmic drug selection is guided by the patient&#39;s comorbid conditions and safety considerations. Flecainide is a class IC antiarrhythmic agent and, along with propafenone, is absolutely contraindicated in patients with ischemic heart disease, given the increased risk for ventricular arrhythmias in this population. This patient also has evidence of left ventricular (LV) dysfunction on a post&ndash;myocardial infarction echocardiogram, which may be due to infarcted myocardium and may lead to increased long-term risk for ventricular arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ambulatory ECG monitoring</span></strong><span style=\"font-size:12.0pt\">: Helpful for assessing AF burden but doesn&#39;t address the contraindication of flecainide. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Discontinue metoprolol</span></strong><span style=\"font-size:12.0pt\">: Not ideal as it&#39;s essential for managing ischemic heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Exercise stress testing</span></strong><span style=\"font-size:12.0pt\">: Not recommended immediately post-MI, especially with existing conduction abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IC antiarrhythmics like flecainide are C/I in patients with ischemic heart disease due to an increased risk of ventricular arrhythmias and death. </span></span></span></p>",
    "correct_choice_id": 216086,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54155,
    "choices": [
      {
        "id": 216089,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinuation of cardioprotective medications </span></span></span></p>"
      },
      {
        "id": 216090,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Improvement in symptoms </span></span></span></p>"
      },
      {
        "id": 216091,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased survival </span></span></span></p>"
      },
      {
        "id": 216092,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced risk for myocardial infarction</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 58-year-old man with stable angina has persistent symptoms despite maximally tolerated medical therapy. Coronary Angiogram shows 70% proximal RCA stenosis and 80% obtuse marginal artery stenosis. What benefit can the patient expect from CABG?</span></span></span></p>",
    "unique_key": "Q3206084",
    "question_audio": null,
    "question_video": null,
    "map_id": 30639,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Improvement in symptoms</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The primary goal of revascularization in patients with stable angina is symptom relief and improved quality of life. While CABG may also offer a survival benefit in patients with multivessel disease or left main stenosis and/or LV dysfunction, this patient&#39;s anatomy does not meet those criteria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinuation of medications</span></strong><span style=\"font-size:12.0pt\">: Not recommended after CABG. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased survival</span></strong><span style=\"font-size:12.0pt\">: Less likely in this patient without multivessel or left main disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reduced risk of MI</span></strong><span style=\"font-size:12.0pt\">: Possible, but not the primary goal in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary goal of revascularization instable angina is symptom relief.</span></span></span></p>",
    "correct_choice_id": 216090,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 54157,
    "choices": [
      {
        "id": 216097,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ranolazine </span></span></span></p>"
      },
      {
        "id": 216098,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&beta;-Blockers </span></span></span></p>"
      },
      {
        "id": 216099,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
      },
      {
        "id": 216100,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nitrates</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old man with a history of hypertension and hypercholesterolemia has chronic stable angina. Which of the following medications have been shown to reduce mortality and risk of myocardial infarction (MI)?</span></span></p>",
    "unique_key": "Q2389135",
    "question_audio": null,
    "question_video": null,
    "map_id": 30640,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Aspirin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with chronic stable angina, aspirin (ASA) has been shown to reduce the risk of myocardial infarction (MI) and mortality. Apart from ASA, statins and ACEi (in selected patients) have shown to reduce mortality as well. Surprisingly, none of the antianginals have shown to improve survival (they provide symptomatic benefit though). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ranolazine:</span></strong><span style=\"font-size:12.0pt\"> Ranolazine is a newer anti-anginal medication that works by reducing myocardial oxygen demand. While it is effective in relieving angina symptoms, it has not been shown to reduce mortality or MI risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. &beta;-Blockers:</span></strong><span style=\"font-size:12.0pt\"> Beta-blockers are first-line therapy for chronic stable angina. They reduce myocardial oxygen demand by decreasing heart rate and contractility. While they are effective in controlling angina symptoms and improving exercise tolerance, their impact on mortality is less clear.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nitrates:</span></strong><span style=\"font-size:12.0pt\"> Nitrates are potent vasodilators that improve myocardial blood flow and reduce angina symptoms. They are primarily used for symptom relief and do not have a significant impact on mortality or MI risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin reduces mortality and MI risk in patients with chronic stable angina.</span></span></span></p>",
    "correct_choice_id": 216099,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 54158,
    "choices": [
      {
        "id": 216101,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
      },
      {
        "id": 216102,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac catheterization</span></span></span></p>"
      },
      {
        "id": 216103,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardioversion </span></span></span></p>"
      },
      {
        "id": 216104,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old man with a history of hypertension and CAD presents with recurrent atrial flutter. He is on dabigatran, metoprolol, ramipril, aspirin, and atorvastatin. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q4144421",
    "question_audio": null,
    "question_video": null,
    "map_id": 30641,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Catheter ablation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the definitive treatment for typical atrial flutter, with a high success rate (&gt; 95%) and low complication rate. It&#39;s the most appropriate option for this patient with recurrent symptomatic atrial flutter despite rate control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone</span></strong><span style=\"font-size:12.0pt\">: Antiarrhythmic drug with potential for toxicity, not the first-line treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cardiac catheterization</span></strong><span style=\"font-size:12.0pt\">: Not needed for treating atrial flutter at this point. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Cardioversion</span></strong><span style=\"font-size:12.0pt\">: May provide temporary relief but is not definitive treatment in this case where the patient is experiencing recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the best treatment for recurrent typical atrial flutter.</span></span></span></p>",
    "correct_choice_id": 216104,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54159,
    "choices": [
      {
        "id": 216105,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase carvedilol </span></span></span></p>"
      },
      {
        "id": 216106,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase digoxin </span></span></span></p>"
      },
      {
        "id": 216107,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase lisinopril </span></span></span></p>"
      },
      {
        "id": 216108,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start Noradrenaline</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 75-year-old woman with ischemic cardiomyopathy presents with progressive dyspnea, edema and confusion. Her medications include low-dose aspirin, furosemide, carvedilol, ramipril, digoxin, and spironolactone. Her BP is 84/52 mm Hg, PR is 118/min, RR is 28/min and SpO2 is 95 in room air. Her reports are shown below. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ALT - 172 U/L, AST - 163 U/L, S. Creatinine - 2.9 mg/dL , S. K - 4.7 mEq/L, S. Na - 132 mEq/L &amp; S. Digoxin - 0.3 ng/mL.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the most appropriate initial treatment?</span></span></span></p>",
    "unique_key": "Q5304020",
    "question_audio": null,
    "question_video": null,
    "map_id": 30642,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Start Nonadrenaline</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has cardiogenic shock due to acute decompensated heart failure (ADHF). Noradrenaline (NA), an inotrope, is indicated to improve cardiac output in this scenario. Once NA is added, other inotropes like dobutamine and/or milrinone can be added sequentially to ensure adequate support. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increase carvedilol</span></strong><span style=\"font-size:12.0pt\">: Beta-blockers are contraindicated in cardiogenic shock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Increase digoxin</span></strong><span style=\"font-size:12.0pt\">: Not effective in cardiogenic shock and potentially harmful with AKI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase lisinopril</span></strong><span style=\"font-size:12.0pt\">: Afterload reduction may be considered later, but inotropic support is the priority in this patient with cardiogenic shock.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with cardiogenic shock, inotropes such as Noradrenaline, dobutamine or milrinone may be considered to improve cardiac function.</span></span></span></p>",
    "correct_choice_id": 216108,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 54160,
    "choices": [
      {
        "id": 216109,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add clopidogrel </span></span></span></p>"
      },
      {
        "id": 216110,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add oral anticoagulation </span></span></span></p>"
      },
      {
        "id": 216111,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue aspirin and begin oral anticoagulation </span></span></span></p>"
      },
      {
        "id": 216112,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No change in therapy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old asymptomatic woman with CAD, diabetes and hypertension presents with palpitations. ECG shows AF. She is on metoprolol, telmisartan, aspirin, and atorvastatin. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q2690057",
    "question_audio": null,
    "question_video": null,
    "map_id": 30643,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Discontinue aspirin and begin oral anticoagulation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has AF and is at high risk for stroke (CHA2DS2-VASc score of 5). Oral anticoagulation is indicated for stroke prevention. Aspirin should be discontinued as it provides no additional benefit and increases bleeding risk when combined with anticoagulants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adding clopidogrel</span></strong><span style=\"font-size:12.0pt\">: Not indicated, as the patient has no recent ACS or stent. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adding oral anticoagulation without discontinuing aspirin</span></strong><span style=\"font-size:12.0pt\">: Increases bleeding risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No change in therapy</span></strong><span style=\"font-size:12.0pt\">: Inadequate as the patient needs anticoagulation for stroke prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For most patients with high-risk atrial fibrillation and stable coronary artery disease, oral anticoagulation therapy without an antiplatelet agent is sufficient for prevention of both acute coronary syndromes and thromboembolism.</span></span></span></p>",
    "correct_choice_id": 216111,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6653,
    "choices": [
      {
        "id": 26581,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin high-intensity statin therapy </span></span></span></p>"
      },
      {
        "id": 26582,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Begin high-intensity statin therapy and ezetimibe </span></span></span></p>"
      },
      {
        "id": 26583,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calculate 10-year risk for ASCVD </span></span></span></p>"
      },
      {
        "id": 26584,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Repeat lipid profile while fasting</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman with normal blood pressure and no significant medical history has a lipid profile showing total cholesterol of 241 mg/dL, HDL of 49 mg/dL, LDL of 116 mg/dL, and triglycerides of 128 mg/dL. What is the most appropriate next step?</span></span></p>",
    "unique_key": "Q3940986",
    "question_audio": null,
    "question_video": null,
    "map_id": 19649,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Calculate 10-year risk for ASCVD</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ACC/AHA guidelines recommend that adults aged 40 to 75 years without diabetes mellitus and with an LDL cholesterol level of 70 to 189 mg/dL (1.81-4.89 mmol/L) should undergo risk assessment with the Pooled Cohort Equations to classify 10-year risk as low (&lt;5%), borderline (5% to &lt;7.5%), intermediate (&ge;7.5% to &lt;20%), or high (&ge;20%).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Begin high-intensity statin therapy&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option B. Begin high-intensity statin therapy and ezetimibe</span></strong><span style=\"font-size:12.0pt\">: Starting statin therapy (with or without ezetimibe) is premature without assessing risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Repeat lipid profile while fasting</span></strong><span style=\"font-size:12.0pt\">: While fasting lipid profile is preferred, the non-fasting results do not warrant immediate repeat testing before risk assessment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiovascular risk scores can be used to assess a patient&#39;s future risk for major cardiovascular events and to identify preventive interventions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The American College of Cardiology/American Heart Association Pooled Cohort Equations are commonly used to calculate the 10-year risk for atherosclerotic cardiovascular disease.</span></span></span></p>",
    "correct_choice_id": 26583,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6657,
    "choices": [
      {
        "id": 26597,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PCI to LAD and RCA </span></span></span></p>"
      },
      {
        "id": 26598,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PCI to LAD </span></span></span></p>"
      },
      {
        "id": 26599,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PCI to RCA </span></span></span></p>"
      },
      {
        "id": 26600,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent CABG</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old woman undergoes successful primary percutaneous coronary intervention (PCI) for an acute anterior STEMI and cardiogenic shock. Angiography reveals a 100% occlusion of mid LAD and a 70% stenosis of mid-right coronary artery (RCA). What is the most appropriate management?</span></span></p>",
    "unique_key": "Q1386253",
    "question_audio": null,
    "question_video": null,
    "map_id": 19650,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) PCI to LAD</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients presenting with STEMI and cardiogenic shock, the primary goal is to restore blood flow to the infarct-related artery (IRA) as quickly as possible. In this case, the IRA is the LAD, which is 100% occluded. Therefore, PCI of the LAD is the priority to improve hemodynamic stability and reduce mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The 70% RCA stenosis is a non-culprit lesion and should be addressed in a staged procedure later, after the patient has stabilized.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. PCI to LAD and RCA</span></strong><span style=\"font-size:12.0pt\">: While both lesions need to be addressed, the priority is to revascularize the culprit lesion (LAD) first to stabilize the patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PCI to RCA</span></strong><span style=\"font-size:12.0pt\">: The RCA is not the infarct-related artery and should not be prioritized over the LAD in this scenario. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Urgent CABG</span></strong><span style=\"font-size:12.0pt\">: CABG is an option for multivessel disease, but PCI of the culprit lesion is the immediate priority in a patient with cardiogenic shock.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In STEMI with cardiogenic shock, the immediate priority is to restore blood flow to the infarct-related artery with primary PCI. Non-culprit lesions can be addressed later in a staged procedure.</span></span></span></p>",
    "correct_choice_id": 26598,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6664,
    "choices": [
      {
        "id": 26625,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atherosclerotic plaque rupture</span></span></span></p>"
      },
      {
        "id": 26626,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy</span></span></span></p>"
      },
      {
        "id": 26627,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection (SCAD) </span></span></span></p>"
      },
      {
        "id": 26628,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress-induced (takotsubo) cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 28-year-old woman 2 weeks postpartum presents with chest pain, ST-segment elevation in anterior leads, and elevated troponin. She has no risk factors for atherosclerosis. What is the most likely diagnosis?</span></span></span></p>",
    "unique_key": "Q9616697",
    "question_audio": null,
    "question_video": null,
    "map_id": 19651,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Spontaneous coronary artery dissection (SCAD)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SCAD is a common cause of myocardial infarction in young women, especially in the peripartum period. The absence of atherosclerotic risk factors and the timing of the event make SCAD the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atherosclerotic plaque rupture</span></strong><span style=\"font-size:12.0pt\">: Unlikely in a young woman with no risk factors. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Peripartum cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Presents with heart failure symptoms and global LV dysfunction, not ST-elevation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Takotsubo cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Typically triggered by stress, often presents with apical ballooning on echo. Common in post-menopausal women (not young women).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection is the most common cause of pregnancy-associated myocardial infarction and occurs most commonly in the first month postpartum</span></span></span></p>",
    "correct_choice_id": 26627,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6665,
    "choices": [
      {
        "id": 26629,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intra-aortic balloon pump placement </span></span></span></p>"
      },
      {
        "id": 26630,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous dobutamine </span></span></span></p>"
      },
      {
        "id": 26631,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous 0.9% saline </span></span></span></p>"
      },
      {
        "id": 26632,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old man presents with a 3-hour history of chest pain. His BP is 80/50 mmHg, HR is 120/min and has elevated JVP and clear lungs. ECG is shown. What is the most appropriate treatment?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-101859.png\" style=\"height:352px; width:400px\" /></span></span></p>",
    "unique_key": "Q6150699",
    "question_audio": null,
    "question_video": null,
    "map_id": 19652,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Intravenous 0.9% saline</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is likely experiencing right ventricular (RV) infarction, a complication of inferior MI. The key features suggestive of RV infarction are hypotension, elevated central venous pressure, clear lungs, and ST-segment elevation in lead V4R. Intravenous fluids are the first-line treatment to increase RV preload and improve cardiac output.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intra-aortic balloon pump</span></strong><span style=\"font-size:12.0pt\">: Indicated in cardiogenic shock with LV dysfunction, but not the first-line treatment for RV infarction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intravenous dobutamine:</span></strong><span style=\"font-size:12.0pt\"> Inotrope may be considered if fluids are ineffective, but not the initial management. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Oral metoprolol</span></strong><span style=\"font-size:12.0pt\">: Beta-blockers can worsen hypotension and should be avoided in RV infarction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A patient with an inferior myocardial infarction with right ventricular involvement and hypotension should receive intravenous fluids.</span></span></span></p>",
    "correct_choice_id": 26631,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6667,
    "choices": [
      {
        "id": 26637,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atherosclerotic plaque rupture</span></span></span></p>"
      },
      {
        "id": 26638,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy</span></span></span></p>"
      },
      {
        "id": 26639,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection (SCAD) </span></span></span></p>"
      },
      {
        "id": 26640,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress-induced (takotsubo) cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman 2 weeks postpartum presents with chest pain, ST-segment elevation in anterior leads, and elevated troponin. She has no risk factors for atherosclerosis. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q4706353",
    "question_audio": null,
    "question_video": null,
    "map_id": 19653,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Spontaneous coronary artery dissection (SCAD)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SCAD is a common cause of myocardial infarction in young women, especially in the peripartum period. The absence of atherosclerotic risk factors and the timing of the event make SCAD the most likely diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atherosclerotic plaque rupture</span></strong><span style=\"font-size:12.0pt\">: Unlikely in a young woman with no risk factors. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Peripartum cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Presents with heart failure symptoms and global LV dysfunction, not ST-elevation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Takotsubo cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Typically triggered by stress, often presents with apical ballooning on echo. Common in post menopausal women (not young women).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection is the most common cause of pregnancy-associated myocardial infarction and occurs most commonly in the first month postpartum</span></span></span></p>",
    "correct_choice_id": 26639,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6668,
    "choices": [
      {
        "id": 26641,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac tamponade </span></span></span></p>"
      },
      {
        "id": 26642,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic liver disease </span></span></span></p>"
      },
      {
        "id": 26643,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis </span></span></span></p>"
      },
      {
        "id": 26644,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Restrictive cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 74-year-old man with a history of CABG presents with progressive fatigue, dyspnea, elevated jugular venous pressure with Kussmaul&#39;s sign, and a pericardial knock. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q4180215",
    "question_audio": null,
    "question_video": null,
    "map_id": 19654,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Constrictive pericarditis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of Kussmaul&#39;s sign (lack of decrease or paradoxical increase in JVP during inspiration), pericardial knock, and signs of right heart failure (elevated JVP, edema, ascites) in a patient with prior cardiac surgery strongly suggest constrictive pericarditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cardiac tamponade</span></strong><span style=\"font-size:12.0pt\">: Would not present with Kussmaul&#39;s sign or pericardial knock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chronic liver disease</span></strong><span style=\"font-size:12.0pt\">: Can cause ascites and edema but not the other findings. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Restrictive cardiomyopathy</span></strong><span style=\"font-size:12.0pt\">: Can mimic constrictive pericarditis, but the history of CABG makes the latter more likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Kussmaul sign and pericardial knock, if present, are helpful clues to the presence of constrictive pericarditis.</span></span></span></p>",
    "correct_choice_id": 26643,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6670,
    "choices": [
      {
        "id": 26649,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT angiography </span></span></span></p>"
      },
      {
        "id": 26650,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombolysis and admission to a telemetry bed </span></span></span></p>"
      },
      {
        "id": 26651,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombolysis and transfer to a PCI center </span></span></span></p>"
      },
      {
        "id": 26652,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Transfer to a tertiary care center</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old man presents with an chest pain, nausea and diaphoresis. ECG is shown. The nearest tertiary care center is 140 minutes away. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-102708.png\" style=\"height:227px; width:400px\" /></span></span></p>",
    "unique_key": "Q4247628",
    "question_audio": null,
    "question_video": null,
    "map_id": 19655,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Thrombolysis and transfer to a PCI center</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When primary PCI cannot be performed within 120 minutes of first medical contact (FMC), thrombolytic therapy is recommended for STEMI patients. While undergoing thrombolysis, the patient should be transferred to a PCI center for further evaluation and potential rescue PCI if needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. CT angiography</span></strong><span style=\"font-size:12.0pt\">: Delays reperfusion therapy, which is crucial in STEMI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Thrombolyse and admit</span></strong><span style=\"font-size:12.0pt\">: Does not allow for timely angiography and potential rescue PCI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Transfer to tertiary care center</span></strong><span style=\"font-size:12.0pt\">: Delays reperfusion and worsens outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">For patients with STEMI, thrombolytic therapy is recommended if symptom onset is within 12 hours and PPCI is not available within 120 minutes of FMC.</span></span></span></p>",
    "correct_choice_id": 26651,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6673,
    "choices": [
      {
        "id": 26661,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atropine </span></span></span></p>"
      },
      {
        "id": 26662,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tenecteplase </span></span></span></p>"
      },
      {
        "id": 26663,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary Angioplasty</span></span></span></p>"
      },
      {
        "id": 26664,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Temporary pacing</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old woman presents with severe chest pain for the last 3 hours. She is diaphoretic and appears drowsy. Her BP is 80/60 mm Hg and PR is 60/min. ECG is shown below. She was started on aspirin, clopidogrel and heparin. What is the next step?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-102907.png\" style=\"height:222px; width:400px\" /></span></span></p>",
    "unique_key": "Q5848565",
    "question_audio": null,
    "question_video": null,
    "map_id": 19656,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Temporary pacing</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is presenting with an acute anterior MI complicated by cardiogenic shock and high-grade AV block (Mobitz II).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The immediate priority in this situation is to stabilize the patient&#39;s hemodynamic status and address the conduction abnormality. Temporary pacing is the most appropriate next step to provide electrical support and maintain adequate cardiac output until definitive revascularization can be performed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atropine:</span></strong><span style=\"font-size:12.0pt\"> Atropine may be useful for bradycardia but is unlikely to be effective in the setting of high-grade AV block. Additionally, it does not address the underlying myocardial ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tenecteplase:</span></strong><span style=\"font-size:12.0pt\"> While fibrinolysis with tenecteplase may be considered in some STEMI cases, it is not the first-line therapy in this case. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Primary Angioplasty:</span></strong><span style=\"font-size:12.0pt\"> Primary PCI is the preferred reperfusion strategy for STEMI, but it should be performed after stabilizing the patient&#39;s hemodynamics with temporary pacing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anterior<strong> </strong>MI related bradyarrhythmias are inherently unstable and need temporary pacing. </span></span></span></p>",
    "correct_choice_id": 26664,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6674,
    "choices": [
      {
        "id": 26665,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discharge on ibuprofen and colchicine </span></span></span></p>"
      },
      {
        "id": 26666,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discharge on prednisone </span></span></span></p>"
      },
      {
        "id": 26667,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hospitalize and begin ibuprofen and colchicine </span></span></span></p>"
      },
      {
        "id": 26668,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hospitalize and begin methylprednisolone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with subacute pericarditis, fever, pulsus paradoxus, and pericardial friction rub. ECG shows diffuse ST-segment elevation. Echocardiogram shows a small pericardial effusion. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q7550388",
    "question_audio": null,
    "question_video": null,
    "map_id": 19657,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Hospitalize and begin ibuprofen and colchicine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">First-line therapy for acute idiopathic pericarditis is aspirin or NSAIDs and colchicine. If patients have associated high risk features, its better to hospitalize.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">High-risk features: Temperature &gt; 38.0 &deg;C (100.4 &deg;F), subacute onset, a large pericardial effusion or tamponade at presentation, oral anticoagulation therapy, or lack of response to treatment, may require hospitalization.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Outpatient treatment</span></strong><span style=\"font-size:12.0pt\">: Not appropriate for high-risk pericarditis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prednisone</span></strong><span style=\"font-size:12.0pt\">: Reserved for recurrent or refractory pericarditis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Methylprednisolone</span></strong><span style=\"font-size:12.0pt\">: High-dose steroids are not first-line for initial treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hospitalize patients with acute pericarditis and high-risk features for initial treatment and monitoring.</span></span></span></p>",
    "correct_choice_id": 26667,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6675,
    "choices": [
      {
        "id": 26669,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digoxin </span></span></span></p>"
      },
      {
        "id": 26670,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intra-aortic balloon pump (IABP) placement</span></span></span></p>"
      },
      {
        "id": 26671,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol </span></span></span></p>"
      },
      {
        "id": 26672,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urgent cardiac transplantation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 71-year-old woman presents with cardiogenic shock. ECG showed ST depressions in multiple leads and her Troponins were elevated. PCI was performed successfully but she continues to be in cardiogenic shock and she is on aspirin, prasugrel and norepinephrine. Which of the following is the most appropriate additional management?</span></span></p>",
    "unique_key": "Q9704389",
    "question_audio": null,
    "question_video": null,
    "map_id": 19658,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Intra-aortic balloon pump (IABP) placement</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Treatment of cardiogenic shock initially focuses on reversing the cause of shock, such as reperfusion in the setting of acute coronary syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In cardiogenic shock, appropriate therapies to support cardiac output include inotropes, vasopressors, and mechanical support (such as balloon pumps, percutaneous ventricular assist devices, and extracorporeal membrane oxygenation).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin</span></strong><span style=\"font-size:12.0pt\">: Weak inotrope, unlikely to be effective in cardiogenic shock. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Metoprolol</span></strong><span style=\"font-size:12.0pt\">: Beta-blocker, contraindicated in cardiogenic shock due to negative inotropic effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Urgent cardiac transplantation</span></strong><span style=\"font-size:12.0pt\">: Not feasible in the acute setting. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IABP is a mechanical circulatory support device that can temporarily improve hemodynamics in patients with cardiogenic shock after MI by reducing afterload and improving coronary perfusion.</span></span></span></p>",
    "correct_choice_id": 26670,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6680,
    "choices": [
      {
        "id": 26689,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clopidogrel </span></span></span></p>"
      },
      {
        "id": 26690,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prasugrel </span></span></span></p>"
      },
      {
        "id": 26691,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reteplase </span></span></span></p>"
      },
      {
        "id": 26692,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tirofiban</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 77-year-old woman with COPD and prior stroke presents with intermittent chest pain. She is on aspirin, atorvastatin, MDI salbutamol and MDI tiotropium. ECG is taken and shown. Initial troponin is elevated and she was started on enoxaparin. What is the most appropriate additional treatment?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-105337.png\" style=\"height:222px; width:400px\" /></span></span></p>",
    "unique_key": "Q4882040",
    "question_audio": null,
    "question_video": null,
    "map_id": 19659,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Clopidogrel</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has NSTE-ACS. Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor like clopidogrel is recommended for all patients with NSTE-ACS, regardless of reperfusion strategy. Ticagrelor is preferred if no increased bleeding risk, but this patient has COPD, making clopidogrel a better choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Prasugrel</span></strong><span style=\"font-size:12.0pt\">: Absolutely C/I in patients with prior stroke and have to be carefully used in elderly patients who are aged &gt; 75. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Reteplase</span></strong><span style=\"font-size:12.0pt\">: Thrombolytic therapy, not indicated for NSTE-ACS. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tirofiban</span></strong><span style=\"font-size:12.0pt\">: Gp IIb/IIIa inhibitor, typically used during PCI under special circumstances.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All patients with non&ndash;ST-elevation acute coronary syndrome should be treated with aspirin and a P2Y12 inhibitor regardless of reperfusion strategy.</span></span></span></p>",
    "correct_choice_id": 26689,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6682,
    "choices": [
      {
        "id": 26697,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin plus clopidogrel </span></span></span></p>"
      },
      {
        "id": 26698,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin plus ticagrelor</span></span></span></p>"
      },
      {
        "id": 26699,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin plus rivaroxaban plus ticagrelor</span></span></span></p>"
      },
      {
        "id": 26700,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rivaroxaban plus ticagrelor</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 69-year-old woman with a history of NSTEMI and AF underwent a successful PCI with a drug eluting stent. What is the most appropriate management of her antithrombotic therapy?</span></span></p>",
    "unique_key": "Q3000601",
    "question_audio": null,
    "question_video": null,
    "map_id": 19660,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Rivaroxaban plus ticagrelor</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The AUGUSTUS trial demonstrated that dual therapy with a direct oral anticoagulant (DOAC) like rivaroxaban and a P2Y12 inhibitor like ticagrelor resulted in lower bleeding rates without an increase in ischemic events (when compared with triple therapy - DOAC + aspirin + P2Y12 inhibitor) in patients with atrial fibrillation (AF) undergoing PCI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin plus clopidogrel:</span></strong><span style=\"font-size:12.0pt\"> This is traditional dual antiplatelet therapy (DAPT) and does not address the need for anticoagulation in AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Aspirin plus ticagrelor:</span></strong><span style=\"font-size:12.0pt\"> Similar to option a, it lacks anticoagulation for AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Aspirin plus rivaroxaban plus ticagrelor:</span></strong><span style=\"font-size:12.0pt\"> Triple therapy is no longer recommended as it increases bleeding risk without significant additional benefit compared to dual therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Among patients with atrial fibrillation who have undergone percutaneous coronary intervention for acute coronary syndrome, double therapy with clopidogrel or ticagrelor plus a direct oral anticoagulant is recommended over triple therapy with an oral anticoagulant, aspirin, and P2Y12 inhibitor to reduce the risk for bleeding.</span></span></span></p>",
    "correct_choice_id": 26700,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6683,
    "choices": [
      {
        "id": 26701,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Completed anterior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 26702,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Completed inferior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 26703,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Completed lateral myocardial infarction</span></span></span></p>"
      },
      {
        "id": 26704,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Completed posterior myocardial infarction</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman is evaluated for a 6-week history of persistent fatigue and occasional exertional dyspnea. ECG is shown. Which of the following abnormalities best describes the findings on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-110228.png\" style=\"height:220px; width:400px\" /></span></span></p>",
    "unique_key": "Q1298841",
    "question_audio": null,
    "question_video": null,
    "map_id": 19661,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Completed lateral myocardial infarction</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG shows a completed lateral myocardial infarction, with initial deep Q waves in leads I, aVL, and V6. There is also an inverted T wave in these leads.</span></span></span></p>",
    "correct_choice_id": 26703,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6684,
    "choices": [
      {
        "id": 26705,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">There is a greater chance of finding an occlusive thrombus in a NSTEMI </span></span></span></p>"
      },
      {
        "id": 26706,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with STEMI have more developed coronary collateral networks </span></span></span></p>"
      },
      {
        "id": 26707,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A person with a STEMI is more likely to have single-vessel disease than a person with a NSTEMI </span></span></span></p>"
      },
      {
        "id": 26708,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The thrombus in STEMI is more platelet-rich compared to that of NSTEMI</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is true when comparing ST-segment elevation myocardial infarctions (STEMI) versus non&ndash;ST-segment elevation myocardial infarctions (NSTEMI)?</span></span></p>",
    "unique_key": "Q1899981",
    "question_audio": null,
    "question_video": null,
    "map_id": 19662,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) A person with a STEMI is more likely to have single-vessel disease than a person with a NSTEMI</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">STEMI typically involves the complete occlusion of a single coronary artery, leading to transmural infarction and ST-segment elevation on the ECG. NSTEMI, on the other hand, is often associated with multi-vessel disease or less severe occlusion of a single vessel, resulting in subendocardial or non-transmural infarction and ST-segment depression or T-wave inversion on the ECG.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. There is a greater chance of finding an occlusive thrombus in a NSTEMI:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. STEMI is caused by a complete occlusive thrombus, while NSTEMI may have partial or intermittent occlusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Patients with STEMI have more developed coronary collateral networks:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. Collateral circulation is more likely to develop in patients with chronic ischemia, such as those with chronic stable angina or NSTEMI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. The thrombus in STEMI is more platelet-rich compared to that of NSTEMI:</span></strong><span style=\"font-size:12.0pt\"> Thrombus in STEMI is more fibrin rich and the thrombus in NSTEMI is more platelet rich.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand that while both STEMI and NSTEMI involve myocardial infarction, STEMI is more often associated with single-vessel disease and complete coronary artery occlusion, while NSTEMI is often associated with multi-vessel disease or less severe occlusion.</span></span></span></p>",
    "correct_choice_id": 26707,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 6685,
    "choices": [
      {
        "id": 26709,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recurrent MI</span></span></span></p>"
      },
      {
        "id": 26710,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early Pericarditis</span></span></span></p>"
      },
      {
        "id": 26711,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dressler&#39;s Syndrome</span></span></span></p>"
      },
      {
        "id": 26712,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Severe GERD due to aspirin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 51-year-old male presents with chest pain, 4 days after he was diagnosed with an ST elevation myocardial infarction (STEMI). It is severe, central chest pain with radiation to the trapezius and worse with deep inspiration. The pain woke him from sleep and has improved slightly after getting up out of bed. His Troponin levels were unchanged and ECG showed new saddle-shaped ST elevations in inferior and lateral leads. What is the likely cause?</span></span></p>",
    "unique_key": "Q8176879",
    "question_audio": null,
    "question_video": null,
    "map_id": 19663,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Early Pericarditis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is most consistent with early pericarditis, which is a common complication of STEMI occurring within the first few days after the infarction. The typical features include:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Chest pain:</span></strong><span style=\"font-size:12.0pt\"> Sharp, pleuritic (worse with inspiration), and positional (relieved by sitting up or leaning forward).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">ECG changes:</span></strong><span style=\"font-size:12.0pt\"> Diffuse ST-segment elevation with a concave or saddle-shaped morphology.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Unchanged troponin:</span></strong><span style=\"font-size:12.0pt\"> Troponin levels are usually not elevated in pericarditis, as it is an inflammatory process and not a myocardial infarction.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Recurrent MI:</span></strong><span style=\"font-size:12.0pt\"> While possible, the unchanged troponin and the specific characteristics of the chest pain make it less likely.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dressler&#39;s Syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is a post-MI syndrome occurring weeks to months after the infarction, characterized by fever, pericarditis, pleuritis, and leukocytosis. It is too early for this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Severe GERD due to aspirin:</span></strong><span style=\"font-size:12.0pt\"> GERD can cause chest pain, but the pain is typically burning and not pleuritic. Additionally, the ECG changes are not consistent with GERD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early pericarditis is a common complication of STEMI that typically occurs in the first week after MI. </span></span></span></p>",
    "correct_choice_id": 26710,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 6573,
    "choices": [
      {
        "id": 26261,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart failure </span></span></span></p>"
      },
      {
        "id": 26262,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stent thrombosis </span></span></span></p>"
      },
      {
        "id": 26263,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor side effect </span></span></span></p>"
      },
      {
        "id": 26264,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ventricular septal rupture</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old woman experiences shortness of breath after a recent MI that was treated with a drug-eluting stent. Her current medications are aspirin, ticagrelor, enalapril, metoprolol, and atorvastatin. Her physical examination, chest X-ray, and ECG are normal. Which of the following is the most likely cause of her dyspnea?</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> </span></span></p>",
    "unique_key": "Q9965554",
    "question_audio": null,
    "question_video": null,
    "map_id": 19664,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Ticagrelor side effect</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ticagrelor, a P2Y12 inhibitor used in ACS, is commonly associated with dyspnea as a side effect. Given the normal exam, ECG, and chest X-ray, this is the most likely cause.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Heart failure</span></strong><span style=\"font-size:12.0pt\">: Unlikely given the normal physical exam and imaging findings. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Stent thrombosis</span></strong><span style=\"font-size:12.0pt\">: Usually presents with acute coronary syndrome symptoms and ECG changes. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ventricular septal rupture</span></strong><span style=\"font-size:12.0pt\">: Rare complication of MI, usually presents with shock and a new murmur.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dyspnea is a well-recognized and often self-limited side effect of ticagrelor therapy.</span></span></span></p>",
    "correct_choice_id": 26263,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6690,
    "choices": [
      {
        "id": 26729,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac catheterization </span></span></span></p>"
      },
      {
        "id": 26730,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography </span></span></span></p>"
      },
      {
        "id": 26731,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Permanent pacemaker implantation </span></span></span></p>"
      },
      {
        "id": 26732,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Temporary pacing</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old woman with hypertension and type 2 diabetes mellitus presents to the ER with acute chest pain and diaphoresis. Her BP is 100/60 mm Hg and PR is. ECG is shown. Troponins are elevated. What is the most appropriate next step?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/21/screenshot-2024-08-21-111130.png\" style=\"height:246px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q6256504",
    "question_audio": null,
    "question_video": null,
    "map_id": 19665,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Cardiac catheterization</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The diagnosis is acute inferior STEMI (and a possible posterior MI) with Mobitz type 1 AV block. Wenckebach second degree type I AV block is usually benign when it occurs with an inferior infarction, and although he must obviously be monitored until sinus rhythm with normal conduction returns, temporary pacing is not necessary.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Echocardiography</span></strong><span style=\"font-size:12.0pt\">: While useful for assessing LV function and complications of MI, it does not address the underlying cause of the arrhythmia (ischemia). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Permanent pacemaker implantation</span></strong><span style=\"font-size:12.0pt\">: May be required if the conduction disturbance is persistent after revascularization. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Temporary pacing</span></strong><span style=\"font-size:12.0pt\">: This could be considered if the patient becomes hemodynamically unstable or of there is a high grade AV block. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute inferior MI, Mobitz type I block and sinus bradycardia can be managed without pacing and the immediate treatment of choice would be reperfusion. </span></span></span></p>",
    "correct_choice_id": 26729,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6691,
    "choices": [
      {
        "id": 26733,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV lidocaine </span></span></span></p>"
      },
      {
        "id": 26734,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnesium repletion </span></span></span></p>"
      },
      {
        "id": 26735,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol </span></span></span></p>"
      },
      {
        "id": 26736,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium repletion</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Thiru is admitted after an anterior MI. In the ICU, he has frequent premature ventricular contractions (PVCs) and lab results show S. K of 2.9 mEq/L and S. Mg of 1 mg/dL. Which of the following is NOT indicated in this setting?</span></span></p>",
    "unique_key": "Q2022295",
    "question_audio": null,
    "question_video": null,
    "map_id": 19666,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) IV lidocaine</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute MI, frequent PVCs can be a precursor to ventricular fibrillation. Beta-blockers (metoprolol), and correction of electrolyte imbalances like hypokalemia and hypomagnesemia, are essential in preventing arrhythmias and reducing mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV lidocaine is an antiarrhythmic drug that is not routinely indicated for suppressing PVCs or asymptomatic non-sustained ventricular tachycardia (NSVT) in this setting. It may be considered if sustained VT or ventricular fibrillation occurs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Magnesium repletion</span></strong><span style=\"font-size:12.0pt\">: Indicated to correct hypomagnesemia, which can trigger arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Metoprolol</span></strong><span style=\"font-size:12.0pt\">: Beta-blocker, reduces myocardial oxygen demand and helps prevent arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Potassium repletion</span></strong><span style=\"font-size:12.0pt\">: Indicated to correct hypokalemia, which can also trigger arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta-blockers and correction of electrolyte imbalances re essential in preventing arrhythmias and reducing mortality in acute MI. </span></span></span></p>",
    "correct_choice_id": 26733,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6697,
    "choices": [
      {
        "id": 26757,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
      },
      {
        "id": 26758,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Colchicine </span></span></span></p>"
      },
      {
        "id": 26759,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids </span></span></span></p>"
      },
      {
        "id": 26760,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoprolol</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following medications should be avoided in patients with an acute ST-elevation myocardial infarction?</span></span></span></p>",
    "unique_key": "Q5341502",
    "question_audio": null,
    "question_video": null,
    "map_id": 19667,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Glucocorticoids</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids and nonsteroidal anti-inflammatory agents, with the exception of aspirin, should be avoided in patients with STSTEMI. They can impair infarct healing and increase the risk of myocardial rupture, and their use may result in a larger infarct scar. In addition, they can increase coronary vascular resistance, thereby potentially reducing flow to ischemic myocardium. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin:</span></strong><span style=\"font-size:12.0pt\"> Aspirin is an antiplatelet medication that is beneficial in STEMI. It helps prevent further clot formation and reduces the risk of complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Colchicine:</span></strong><span style=\"font-size:12.0pt\"> Colchicine is an anti-inflammatory medication that can be used in certain cases of pericarditis, but it is not contraindicated in STEMI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metoprolol:</span></strong><span style=\"font-size:12.0pt\"> Metoprolol is a beta-blocker that reduces heart rate and blood pressure, decreasing the workload on the heart. It is beneficial in STEMI unless there are specific contraindications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NSAIDs (except aspirin) and glucocorticoids are absolutely C/I in STEMI.</span></span></span></p>",
    "correct_choice_id": 26759,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 6699,
    "choices": [
      {
        "id": 26765,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">6-12 hours </span></span></span></p>"
      },
      {
        "id": 26766,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">24 hours </span></span></span></p>"
      },
      {
        "id": 26767,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">48 hours </span></span></span></p>"
      },
      {
        "id": 26768,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">72 hours</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Approximately how long should patients with STEMI be advised to maintain bed rest after revascularization?</span></span></span></p>",
    "unique_key": "Q4576970",
    "question_audio": null,
    "question_video": null,
    "map_id": 19668,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) 6-12 hours</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factors that increase the work of the heart during the initial hours of infarction may increase the size of the infarct. Therefore, patients with STEMI should be kept at bedrest for the first 6&ndash;12 hours. However, in the absence of complications, patients should be encouraged, under supervision, to resume an upright posture by dangling their feet over the side of the bed and sitting in a chair within the first 24 hours. This practice is psychologically beneficial and usually results in a reduction in the pulmonary capillary wedge pressure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the absence of hypotension and other complications, by the second or third day, patients typically are ambulating in their room with increasing duration and frequency, and they may shower or stand at the sink to bathe. By day 3 after infarction, patients should be increasing their ambulation progressively to a goal of 185 m (600 ft) at least three times a day.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 24 hours, Option C. 48 hours&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>Option D. 72 hours:</strong> These durations are too long for bed rest after revascularization. Prolonged bed rest can lead to complications like deconditioning, deep vein thrombosis, and pneumonia. Early mobilization is encouraged to promote recovery and prevent these complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with STEMI should be advised to maintain bed rest for 6-12h after revascularization, followed by early mobilization to promote recovery and prevent complications.</span></span></span></p>",
    "correct_choice_id": 26765,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 54189,
    "choices": [
      {
        "id": 216225,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue aspirin, continue clopidogrel, and proceed with cataract surgery. </span></span></span></p>"
      },
      {
        "id": 216226,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue clopidogrel, continue aspirin, and proceed with cataract surgery.</span></span></span></p>"
      },
      {
        "id": 216227,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue both aspirin and clopidogrel and proceed with cataract surgery. </span></span></span></p>"
      },
      {
        "id": 216228,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Postpone the surgery for 6 months.</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mrs. Hinduja, a 64-year-old woman, had a drug-eluting (everolimus) stent placed one month ago for a recent MI. She is on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. Her ophthalmologist wants to know if these can be stopped for a cataract surgery next week. What is the most appropriate advice?</span></span></p>",
    "unique_key": "Q7148921",
    "question_audio": null,
    "question_video": null,
    "map_id": 25683,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Postpone the surgery for 6 months.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Percutaneous therapy of CAD underwent a paradigm shift with the introduction of coronary stents in 1994. However, metallic stents are also prone to stent thrombosis (1&ndash;3%), either acute (&lt;24 hours) or subacute (1&ndash;30 days), which can be ameliorated by greater attention to full initial stent deployment and the use of dual antiplatelet therapy (DAPT) (aspirin, plus a platelet P2Y12 receptor blocker [clopidogrel, prasugrel, or ticagrelor]).&nbsp; Late (30 days to 1 year) and very late stent thrombosis (&gt;1 year) occur very infrequently with stents but are slightly more common with first-generation drug-eluting stents, necessitating DAPT for up to 1 year or longer. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Use of the second-generation stents (such as Mrs. Hinduja&rsquo;s everolimus-eluting stent) is associated with lower rates of late and very late stent thrombosis, and shorter durations of DAPT may be possible. Premature discontinuation of DAPT, particularly in the first month after implantation, is associated with a significantly increased risk for stent thrombosis (3&ndash;9&times; greater). Stent thrombosis results in death in 10&ndash;20% and myocardial infarction in 30&ndash;70% of patients. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elective surgery (such as Mrs. Hinduja&rsquo;s cataract removal) that requires discontinuation of antiplatelet therapy after DES implantation should be postponed until after 6 months and preferably after 1 year, if at all possible. At that point, clopidogrel can be reasonably discontinued if no other mitigating factors are present. If at all possible, aspirin should be continued.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue aspirin, continue clopidogrel, and proceed with cataract surgery, Option B. Discontinue clopidogrel, continue aspirin, and proceed with cataract surgery&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option C. Discontinue both aspirin and clopidogrel and proceed with cataract surgery</span></strong><span style=\"font-size:12.0pt\">: Stopping either or both antiplatelet medications prematurely increases the risk of stent thrombosis and is not recommended.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stopping DES in the first 6 months is associated with increased risk of in-stent thrombosis and hence, elective surgeries must be postponed.</span></span></span></p>",
    "correct_choice_id": 216228,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6607,
    "choices": [
      {
        "id": 26397,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add digoxin </span></span></span></p>"
      },
      {
        "id": 26398,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
      },
      {
        "id": 26399,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase carvedilol dosage </span></span></span></p>"
      },
      {
        "id": 26400,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch lisinopril to valsartan-sacubitril</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 67-year-old woman with stable heart failure with reduced ejection fraction (HFrEF) is on maximum doses of lisinopril, among other medications. Which treatment is most appropriate to further reduce HF hospitalizations and mortality?</span></span></span></p>",
    "unique_key": "Q1413244",
    "question_audio": null,
    "question_video": null,
    "map_id": 19669,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Switch lisinopril to valsartan-sacubitril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valsartan-sacubitril has been shown to significantly reduce mortality and HF hospitalizations in patients with HFrEF compared to ACE inhibitors or ARBs alone. This makes it a preferred treatment option for patients who are already on maximum doses of these medications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> While it can reduce HF hospitalizations, it does not improve mortality. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used for patients with HFrEF in sinus rhythm and a high heart rate despite beta-blocker therapy. Not applicable here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increasing carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Might not be tolerated well and has not shown the same mortality benefit as valsartan-sacubitril.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valsartan-sacubitril significantly reduces heart failure hospitalizations and mortality in patients with symptomatic heart failure with reduced ejection fraction and is recommended in preference to an ACE inhibitor or angiotensin receptor blocker.</span></span></span></p>",
    "correct_choice_id": 26400,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6608,
    "choices": [
      {
        "id": 26401,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amiodarone </span></span></span></p>"
      },
      {
        "id": 26402,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing </span></span></span></p>"
      },
      {
        "id": 26403,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
      },
      {
        "id": 26404,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lisinopril</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old athlete experiences cardiac arrest during a race and is successfully resuscitated. Resting ECG is shown. Echocardiogram shows normal LV function but RV dilation and dysfunction. What is the most appropriate management before discharge?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-115610.jpg\" style=\"height:207px; width:500px\" /></span></span></p>",
    "unique_key": "Q2742687",
    "question_audio": null,
    "question_video": null,
    "map_id": 19670,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Implantable cardioverter-defibrillator (ICD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sudden cardiac arrest with &lsquo;&epsilon;&rsquo; wave in ECG and RV dysfunction in echo in young athletes raises suspicion for underlying inherited cardiomyopathies, like arrhythmogenic right ventricular cardiomyopathy (ARVC). An ICD is the most appropriate intervention to prevent sudden cardiac death due to arrhythmias. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone:</span></strong><span style=\"font-size:12.0pt\"> Antiarrhythmic medication, but not as effective as ICD for preventing sudden death. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Genetic testing:</span></strong><span style=\"font-size:12.0pt\"> Important for diagnosis and family screening, but not the immediate priority before discharge.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lisinopril:</span></strong><span style=\"font-size:12.0pt\"> ACE inhibitor for LV dysfunction, not indicated in this case with normal LV function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with sustained ventricular arrhythmias (&gt;30 seconds) or cardiac arrest without a reversible cause have a class 1 recommendation for secondary prevention with implantable cardioverter-defibrillator placement.</span></span></span></p>",
    "correct_choice_id": 26403,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6609,
    "choices": [
      {
        "id": 26405,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac MRI </span></span></p>"
      },
      {
        "id": 26406,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Exercise echocardiography </span></span></p>"
      },
      {
        "id": 26407,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Right and left heart catheterization </span></span></p>"
      },
      {
        "id": 26408,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum &alpha;-galactosidase level</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man presents with ascites, pedal edema and elevated JVP. ECG showed low voltage complexes and echo showed increased LV wall thickness. He also has a history of carpal tunnel syndrome. What is the most appropriate test?</span></span></p>",
    "unique_key": "Q2768512",
    "question_audio": null,
    "question_video": null,
    "map_id": 19671,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Cardiac MRI</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of heart failure, increased wall thickness, low voltage on ECG, and carpal tunnel syndrome raises suspicion for infiltrative cardiomyopathy, like transthyretin amyloid (ATTR) amyloidosis. CMR with gadolinium is the most sensitive and specific test for diagnosing cardiac amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Exercise echocardiography:</span></strong><span style=\"font-size:12.0pt\"> Primarily used to diagnose coronary artery disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Right and left heart catheterization:</span></strong><span style=\"font-size:12.0pt\"> Invasive and not the first-line test for infiltrative cardiomyopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Serum &alpha;-galactosidase level:</span></strong><span style=\"font-size:12.0pt\"> Used to diagnose Fabry disease, which usually causes Hypertrophic Cardiomyopathy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac magnetic resonance imaging with gadolinium is highly sensitive and specific for cardiac amyloidosis, but it does not distinguish between AL (immunoglobulin light-chain) amyloidosis and transthyretin amyloidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with cardiac magnetic resonance imaging findings consistent with cardiac amyloidosis, an abnormal 99m-technetium pyrophosphate scan would confirm transthyretin amyloidosis without the need for a biopsy.</span></span></p>",
    "correct_choice_id": 26405,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 6610,
    "choices": [
      {
        "id": 26409,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digoxin </span></span></span></p>"
      },
      {
        "id": 26410,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin (SGLT2 inhibitor) </span></span></span></p>"
      },
      {
        "id": 26411,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Furosemide </span></span></span></p>"
      },
      {
        "id": 26412,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivabradine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old man with heart failure with mildly reduced ejection fraction (HFmrEF) and type 2 diabetes mellitus is asymptomatic and on appropriate medications. Which additional treatment is most appropriate?</span></span></p>",
    "unique_key": "Q7322336",
    "question_audio": null,
    "question_video": null,
    "map_id": 19672,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Empagliflozin (SGLT2 inhibitor)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors like empagliflozin have been shown to reduce cardiovascular death and HF hospitalizations in patients with type 2 diabetes and HF, regardless of the ejection fraction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> Reduces HF hospitalizations but not mortality, and this patient is asymptomatic. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Furosemide:</span></strong><span style=\"font-size:12.0pt\"> Loop diuretic, indicated for volume overload which is not present in this patient.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used for HF with reduced ejection fraction (HFrEF) with high heart rates despite beta-blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A sodium-glucose cotransporter 2 inhibitor is recommended to reduce risk for worsening heart failure and cardiovascular death in patients with type 2 diabetes mellitus and established heart failure with reduced ejection fraction</span></span></p>",
    "correct_choice_id": 26410,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6611,
    "choices": [
      {
        "id": 26413,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute pulmonary embolism</span></span></span></p>"
      },
      {
        "id": 26414,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ascending aortic dissection </span></span></span></p>"
      },
      {
        "id": 26415,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy </span></span></span></p>"
      },
      {
        "id": 26416,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spontaneous coronary artery dissection</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 8-day postpartum woman presents with acute heart failure symptoms. Echocardiogram shows LV dilation and hypokinesis with an ejection fraction of 38%.RV is normal. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q8366476",
    "question_audio": null,
    "question_video": null,
    "map_id": 19673,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Peripartum cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy is characterized by the development of heart failure in the last month of pregnancy or within 5 months postpartum. The presentation of LV dysfunction with no other identifiable cause fits this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute pulmonary embolism</span></strong><span style=\"font-size:12.0pt\">: Less likely given normal right heart function on echocardiogram. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Ascending aortic dissection:</strong> Usually presents with acute chest pain, and echo would show aortic abnormalities. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Spontaneous coronary artery dissection:</strong> Typically presents with chest pain and ECG changes indicative of ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripartum cardiomyopathy is left ventricular systolic dysfunction with onset toward the end of pregnancy or in the months after delivery in the absence of another identifiable cause; patients often present with features of heart failure.</span></span></p>",
    "correct_choice_id": 26415,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6612,
    "choices": [
      {
        "id": 26417,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous milrinone </span></span></span></p>"
      },
      {
        "id": 26418,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add intravenous nitroglycerin </span></span></span></p>"
      },
      {
        "id": 26419,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase furosemide </span></span></span></p>"
      },
      {
        "id": 26420,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start CVVH (Continuous venovenous hemofiltration)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 72-year-old man with decompensated heart failure is hospitalized and treated with a maximal dose of IV furosemide. He has minimal urine output and persistent signs of volume overload. What is the most appropriate next step?</span></span></span></p>",
    "unique_key": "Q2512177",
    "question_audio": null,
    "question_video": null,
    "map_id": 19674,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Start CVVH (Continuous venovenous hemofiltration)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with acute decompensated heart failure (ADHF) who are unresponsive to maximal diuretic therapy (as evidenced by minimal urine output and persistent volume overload), the next step is to initiate ultrafiltration. CVVH is a form of renal replacement therapy that gently removes excess fluid over a longer period, making it well-suited for patients who may not tolerate the rapid fluid shifts of hemodialysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Add intravenous milrinone:</span></strong><span style=\"font-size:12.0pt\"> Milrinone is an inotrope used to improve cardiac contractility. While it may help with cardiac output, it doesn&#39;t directly address the volume overload and can worsen renal function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add intravenous nitroglycerin:</span></strong><span style=\"font-size:12.0pt\"> Nitroglycerin is a vasodilator that can reduce preload and afterload, but it&#39;s not the primary treatment for volume overload when diuretics fail.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increase furosemide:</span></strong><span style=\"font-size:12.0pt\"> The patient is already on the maximal dose of furosemide, so further increases would not be effective and could lead to adverse effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with ADHF who are unresponsive to maximal diuretic therapy, CVVH is a crucial intervention to manage volume overload and prevent further complications.</span></span></p>",
    "correct_choice_id": 26420,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6613,
    "choices": [
      {
        "id": 26421,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digoxin </span></span></span></p>"
      },
      {
        "id": 26422,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplantation </span></span></span></p>"
      },
      {
        "id": 26423,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left ventricular assist device (LVAD) placement </span></span></span></p>"
      },
      {
        "id": 26424,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tolvaptan</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with ischemic cardiomyopathy (EF 20%) is on maximally tolerated heart failure medications and experiencing significant functional decline. He wishes to pursue care that will restore functionality. What is the most appropriate long-term treatment?</span></span></p>",
    "unique_key": "Q9379264",
    "question_audio": null,
    "question_video": null,
    "map_id": 19675,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Heart transplantation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplantation is the most appropriate long-term treatment for patients with advanced heart failure who have persistent severe symptoms despite optimal medical therapy. It can significantly improve quality of life and survival in suitable candidates. This patient&#39;s young age (56 years old) and desire for functional improvement make him a potential candidate for transplantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Digoxin:</span></strong><span style=\"font-size:12.0pt\"> Although it can reduce hospitalizations, it does not improve survival or functional capacity. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. LVAD placement:</span></strong><span style=\"font-size:12.0pt\"> LVADs are a bridge to transplantation or destination therapy for those who are not transplant candidates. This patient may be eligible for transplant. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tolvaptan:</span></strong><span style=\"font-size:12.0pt\"> Used for hyponatremia, but not a primary treatment for advanced heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with persistent severe heart failure symptoms despite maximal medical therapy are candidates for advanced treatment; acceptable candidates for cardiac transplantation are generally younger than 65 to 70 years with no medical contraindications and have good social support and adherence.</span></span></p>",
    "correct_choice_id": 26422,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6614,
    "choices": [
      {
        "id": 26425,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add eplerenone</span></span></span></p>"
      },
      {
        "id": 26426,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add ivabradine </span></span></span></p>"
      },
      {
        "id": 26427,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch carvedilol to metoprolol succinate </span></span></span></p>"
      },
      {
        "id": 26428,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch losartan to valsartan-sacubitril</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old man with a history of HFrEF and AF, presents for follow-up with stable NYHA class III symptoms. He is currently on losartan, carvedilol, empagliflozin, furosemide, and apixaban. He has a history of ACE inhibitor-induced angioedema and spironolactone-induced gynecomastia. Which medication is the most appropriate addition to his current regimen?</span></span></p>",
    "unique_key": "Q3070788",
    "question_audio": null,
    "question_video": null,
    "map_id": 19676,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Add eplerenone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eplerenone, a selective aldosterone antagonist, is indicated in patients with symptomatic HFrEF and normal kidney function to improve survival. This patient has normal renal function and has not tolerated spironolactone due to gynecomastia. Eplerenone is a suitable alternative as it has a lower risk of endocrine side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Not indicated in patients with atrial fibrillation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Switch carvedilol to metoprolol succinate:</span></strong><span style=\"font-size:12.0pt\"> Not necessary, as there is no evidence of <strong>benefit in switching between beta-blockers in this scenario. </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Switch losartan to valsartan-sacubitril:</span></strong><span style=\"font-size:12.0pt\"> Contraindicated due to the history of ACE inhibitor-induced angioedema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone antagonist therapy (spironolactone, eplerenone) is indicated in all patients with symptomatic heart failure with reduced ejection fraction and normal kidney function to improve survival.</span></span></span></p>",
    "correct_choice_id": 26425,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6615,
    "choices": [
      {
        "id": 26429,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of valsartan-sacubitril </span></span></span></p>"
      },
      {
        "id": 26430,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) therapy </span></span></span></p>"
      },
      {
        "id": 26431,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Replacement of metoprolol with carvedilol </span></span></span></p>"
      },
      {
        "id": 26432,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy (SRT)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old man with hypertrophic cardiomyopathy (HCM) diagnosed at age 38 presents with exertional dyspnea. He is on metoprolol and disopyramide. Echocardiogram shows asymmetric septal hypertrophy, systolic anterior motion of the mitral valve (SAM), and a resting LVOT gradient of 64 mmHg. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q8465237",
    "question_audio": null,
    "question_video": null,
    "map_id": 19677,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Septal reduction therapy (SRT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SRT is indicated for patients with symptomatic HCM and an LVOT gradient &ge;50 mmHg despite optimal medical therapy. This patient&#39;s symptoms and high LVOT gradient warrant consideration for SRT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Valsartan-sacubitril:</span></strong><span style=\"font-size:12.0pt\"> This medication is contraindicated in HCM due to the risk of worsening LVOT obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. ICD therapy:</span></strong><span style=\"font-size:12.0pt\"> Indicated for primary prevention of sudden cardiac death in high-risk HCM patients but not the primary treatment for symptoms. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Replacement of metoprolol with carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Unlikely to be beneficial as both are beta-blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy is indicated for symptomatic HCM patients with a significant LVOT gradient despite optimal medical therapy.</span></span></span></p>",
    "correct_choice_id": 26432,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6616,
    "choices": [
      {
        "id": 26433,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ascending aortic dissection </span></span></span></p>"
      },
      {
        "id": 26434,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery dissection </span></span></span></p>"
      },
      {
        "id": 26435,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary artery embolism </span></span></span></p>"
      },
      {
        "id": 26436,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Takotsubo cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 76-year-old woman presents with acute substernal chest discomfort and dyspnea after seeing her dog being attacked and killed by another dog. Her echocardiogram shows apical and mid-ventricular hypokinesis with preserved basal function, and coronary angiography is normal. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q4638172",
    "question_audio": null,
    "question_video": null,
    "map_id": 19678,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Takotsubo cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Takotsubo cardiomyopathy, also called stress-induced cardiomyopathy, mimics acute coronary syndrome (ACS) with chest pain, dyspnea, and elevated cardiac biomarkers. However, it occurs without obstructive coronary artery disease and typically presents with apical ballooning on echocardiography. Emotional stress is a common trigger.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. &nbsp;Ascending aortic dissection:</span></strong><span style=\"font-size:12.0pt\"> This would typically present with severe tearing chest pain radiating to the back. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Coronary artery dissection:</span></strong><span style=\"font-size:12.0pt\"> This would show abnormalities on angiography. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Coronary artery embolism:</span></strong><span style=\"font-size:12.0pt\"> This would also cause regional wall motion abnormalities on echocardiogram.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Takotsubo cardiomyopathy is a syndrome characterized by transient regional systolic ventricular dysfunction mimicking myocardial infarction in the absence of angiographic evidence of obstructive coronary artery disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of takotsubo cardiomyopathy is similar to that for heart failure of other causes; most patients recover cardiac function over several months.</span></span></p>",
    "correct_choice_id": 26436,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6617,
    "choices": [
      {
        "id": 26437,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac resynchronization therapy (CRT)</span></span></span></p>"
      },
      {
        "id": 26438,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac transplantation </span></span></span></p>"
      },
      {
        "id": 26439,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
      },
      {
        "id": 26440,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary vein isolation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old man with restrictive cardiomyopathy and atrial fibrillation presents with refractory heart failure symptoms despite optimal medical therapy. Echo shows an EF of 50%, severe biatrial enlargement and pulmonary hypertension. What is the most appropriate management?</span></span></span></p>",
    "unique_key": "Q2773853",
    "question_audio": null,
    "question_video": null,
    "map_id": 19679,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Cardiac transplantation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplantation is an effective therapy for select patients with end-stage restrictive cardiomyopathy who have refractory symptoms despite optimal medical therapy. This patient&#39;s clinical presentation and echocardiographic findings suggest a poor prognosis, making him a potential candidate for transplantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. CRT:</span></strong><span style=\"font-size:12.0pt\"> Not indicated in patients with preserved EF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. ICD:</span></strong><span style=\"font-size:12.0pt\"> Not indicated for primary prevention in a patient with preserved EF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Pulmonary vein isolation:</span></strong><span style=\"font-size:12.0pt\"> May not be effective in patients with severe atrial enlargement and underlying restrictive cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Heart transplantation is an effective therapy for select patients with end-stage restrictive cardiomyopathy.</span></span></span></p>",
    "correct_choice_id": 26438,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6618,
    "choices": [
      {
        "id": 26441,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bisoprolol</span></span></span></p>"
      },
      {
        "id": 26442,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diltiazem </span></span></span></p>"
      },
      {
        "id": 26443,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Enalapril </span></span></span></p>"
      },
      {
        "id": 26444,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ivabradine</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 27-year-old woman, 6 days postpartum, presents with acute heart failure symptoms (orthopnea, paroxysmal nocturnal dyspnea, elevated JVP, S3, crackles, edema). Echocardiogram shows an ejection fraction (EF) of 20% and diffuse hypokinesis. She is currently on furosemide and bilevel positive airway pressure (BiPAP). What is the most appropriate additional treatment?</span></span></span></p>",
    "unique_key": "Q2718510",
    "question_audio": null,
    "question_video": null,
    "map_id": 19680,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Enalapril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient presents with peripartum cardiomyopathy (PPCM), a form of heart failure with reduced ejection fraction (HFrEF). ACE inhibitors like enalapril are the cornerstone of HFrEF treatment and have been shown to reduce morbidity and mortality. They can be safely used in breastfeeding women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Bisoprolol (beta-blocker):</span></strong><span style=\"font-size:12.0pt\"> While beneficial in HFrEF, it should be initiated cautiously after volume status is optimized in acute decompensated heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Diltiazem (non-dihydropyridine calcium channel blocker):</span></strong><span style=\"font-size:12.0pt\"> Contraindicated in HFrEF due to negative inotropic effects. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Ivabradine:</span></strong><span style=\"font-size:12.0pt\"> Used in HFrEF patients with sinus rhythm and elevated heart rate despite optimal beta-blocker therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACE inhibitors reduce morbidity and mortality in patients with heart failure with reduced ejection fraction and should be used in both symptomatic and asymptomatic patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol, carvedilol, and bisoprolol reduce mortality in patients with heart failure with reduced ejection fraction, but treatment should be delayed in patients with volume overload until the patient is closer to being euvolemic.</span></span></p>",
    "correct_choice_id": 26443,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6619,
    "choices": [
      {
        "id": 26445,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Athlete&#39;s heart </span></span></span></p>"
      },
      {
        "id": 26446,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fabry disease </span></span></span></p>"
      },
      {
        "id": 26447,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertensive heart disease </span></span></span></p>"
      },
      {
        "id": 26448,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nonobstructive hypertrophic cardiomyopathy (HCM)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old man with no prior medical history undergoes a pre-participation sports examination. ECG shows sinus bradycardia and voltage criteria for left ventricular (LV) hypertrophy. Echocardiogram shows mild LV dilation and symmetric LV hypertrophy with a normal LV ejection fraction and diastolic function. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q8327083",
    "question_audio": null,
    "question_video": null,
    "map_id": 19681,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Athlete&#39;s heart</span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Athlete&#39;s heart is a benign condition characterized by physiological cardiac remodeling in response to intense exercise. The ECG findings of sinus bradycardia and LV hypertrophy are common in athletes. Echocardiogram may also show mild LV dilation and increased wall thickness, but diastolic function remains normal, differentiating it from pathological conditions like HCM. Also, hypertrophy in the athlete&rsquo;s heart regresses with cessation of training and is accompanied by <em><u>supernormal exercise capacity</u></em> (VO2max &gt;50 mL/kg per min). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fabry disease:</span></strong><span style=\"font-size:12.0pt\"> A lysosomal storage disorder that can cause LV hypertrophy but is also associated with other systemic manifestations like angiokeratomas and renal dysfunction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Hypertensive heart disease:</span></strong><span style=\"font-size:12.0pt\"> Usually occurs in older individuals with a history of hypertension. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Nonobstructive HCM:</span></strong><span style=\"font-size:12.0pt\"> A genetic disorder that causes asymmetric LV hypertrophy and often has impaired diastolic function.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increased left ventricular (LV) wall thickness and LV cavity dilatation may be normal findings in highly trained athletes; symmetric wall thickness of 13 mm or less and normal diastolic filling favor the diagnosis of athlete heart over the diagnosis of HCM.</span></span></span></p>",
    "correct_choice_id": 26445,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6620,
    "choices": [
      {
        "id": 26449,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac resynchronization therapy-defibrillator (CRT-D) </span></span></span></p>"
      },
      {
        "id": 26450,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
      },
      {
        "id": 26451,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable pulmonary artery pressure sensor </span></span></span></p>"
      },
      {
        "id": 26452,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Wearable cardioverter-defibrillator</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 63-year-old man who is a known case of HFrEF presents with persistent NYHA III symptoms despite optimal medical therapy. ECG shows LBBB and echo shows an EF of 25%. What is the most appropriate treatment?</span></span></span></p>",
    "unique_key": "Q1009068",
    "question_audio": null,
    "question_video": null,
    "map_id": 19682,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Cardiac resynchronization therapy-defibrillator (CRT-D)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRT-D is indicated in patients with HFrEF (EF &le; 35%), LBBB with QRS duration &ge; 150 ms (or 120-149 ms in some cases), and NYHA class II-IV symptoms despite optimal medical therapy. CRT improves symptoms and survival, and the defibrillator component provides protection against sudden cardiac death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. ICD:</span></strong><span style=\"font-size:12.0pt\"> May be indicated for primary prevention of sudden cardiac death but doesn&#39;t address the LBBB and dyssynchrony. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Implantable pulmonary artery pressure sensor:</span></strong><span style=\"font-size:12.0pt\"> Used for monitoring, not for treating heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Wearable cardioverter-defibrillator:</span></strong><span style=\"font-size:12.0pt\"> Temporary measure, not appropriate for long-term management of heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac resynchronization therapy is indicated in patients with New York Heart Association functional class II to IV symptoms despite guideline-directed medical therapy who have an ejection fraction of 35% or less, sinus rhythm, and left bundle branch block with a QRS duration of 150 ms or longer.</span></span></p>",
    "correct_choice_id": 26449,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6621,
    "choices": [
      {
        "id": 26453,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart failure with preserved ejection fraction (HFpEF) </span></span></span></p>"
      },
      {
        "id": 26454,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-output heart failure </span></span></span></p>"
      },
      {
        "id": 26455,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HOCM </span></span></span></p>"
      },
      {
        "id": 26456,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HFrEF</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old woman with hypertension and paroxysmal AF presents with a 6-month history of exertional dyspnea. She has normal vital signs, clear lungs, and a normal JVP. Echocardiography shows an ejection fraction of 55%, increased left ventricular wall thickness, and an enlarged left atrium. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q3454055",
    "question_audio": null,
    "question_video": null,
    "map_id": 19683,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Heart failure with preserved ejection fraction (HFpEF)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HFpEF is characterized by symptoms of heart failure, preserved ejection fraction, and evidence of diastolic dysfunction (increased LV wall thickness and LA enlargement). This patient&#39;s presentation and echocardiographic findings are consistent with HFpEF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. High-output heart failure:</span></strong><span style=\"font-size:12.0pt\"> This is associated with an elevated cardiac index, which is not present in this case. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. HOCM:</span></strong><span style=\"font-size:12.0pt\"> This would show LV outflow tract obstruction, which is absent in this patient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. HFrEF:</span></strong><span style=\"font-size:12.0pt\"> Unlikley given the normal EF in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">HFpEF should be suspected in patients who meet the following three criteria: symptoms of heart failure, left ventricular ejection fraction of 50% or greater, and no other apparent cause of HF symptoms.</span></span></span></p>",
    "correct_choice_id": 26453,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 7078,
    "choices": [
      {
        "id": 28280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Disopyramide </span></span></span></p>"
      },
      {
        "id": 28281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) </span></span></span></p>"
      },
      {
        "id": 28282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy </span></span></span></p>"
      },
      {
        "id": 28283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman with hypertrophic cardiomyopathy (HCM) experiences an episode of syncope and was admitted. 2D Echo revealed a maximum LV wall thickness of 30 mm and a dynamic LVOT obstruction. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q8344771",
    "question_audio": null,
    "question_video": null,
    "map_id": 19684,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Implantable cardioverter-defibrillator (ICD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Risk factors include SCD judged definitively or likely attributable to HCM in one or more first-degree or close relatives aged 50 years or younger, left ventricular (LV) hypertrophy of 30 mm or greater in any LV segment, one or more recent episodes of syncope suspected by clinical history to be arrhythmic in nature, LV apical aneurysm, and LV ejection fraction less than 50%. Based on the patient&#39;s recent episode of unexplained syncope and LV wall thickness of 30 mm, it is reasonable to refer her for consideration of an ICD to prevent SCD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Disopyramide:</span></strong><span style=\"font-size:12.0pt\"> Primarily used for treating HF symptoms in HCM (in case if &beta;B or CCB therapy is ineffective) </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. &nbsp;Septal reduction therapy:</span></strong><span style=\"font-size:12.0pt\"> Indicated for symptomatic patients with significant LVOT obstruction, but not for primary prevention of SCD. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D. Verapamil:</span></strong><span style=\"font-size:12.0pt\"> Used for symptom relief in HCM, but not for SCD prevention.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Consider ICD therapy for primary prevention of SCD in patients with HCM and high-risk features. </span></span></p>",
    "correct_choice_id": 28281,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7079,
    "choices": [
      {
        "id": 28284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heart transplant </span></span></span></p>"
      },
      {
        "id": 28285,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECMO </span></span></span></p>"
      },
      {
        "id": 28286,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left ventricular assist device (LVAD) placement </span></span></span></p>"
      },
      {
        "id": 28287,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add H-ISDN</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 74-year-old man presents with progressive fatigue, dyspnea and edema. He has a history of ischemic cardiomyopathy with an EF of 10% and had 4 hospitalizations in the last 6 months. He is currently on sacubitril-valsartan, carvedilol, eplerenone, furosemide and empagliflozin. Labs reveal a S. creatinine of 1.7 mg/dL and S. Na of&nbsp; 128 mEq/L. What is the most reasonable next step in management?</span></span></span></p>",
    "unique_key": "Q7504181",
    "question_audio": null,
    "question_video": null,
    "map_id": 19685,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Left ventricular assist device (LVAD) placement</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has advanced heart failure with a very low ejection fraction, multiple comorbidities, and intolerance to standard medical therapy. He is not a suitable candidate for heart transplantation due to his age and comorbidities. LVAD placement is a reasonable option to improve his symptoms, quality of life, and potentially bridge him to transplantation if he becomes eligible in the future.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Heart transplant:</span></strong> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This patient is not a candidate for heart transplant based on his age and recent colon cancer. Most centers have an age cutoff of 65 years (but variable). With the exception of skin cancer, most programs require that a patient be cancer-free for at least 5 years before being considered for heart transplant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Ecmo:</span></strong><span style=\"font-size:12.0pt\"> Ecmo is a short-term life support option and is not suitable for long-term management of heart failure. it is typically reserved for refractory acute heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C.&nbsp; Add H-ISDN:</span></strong><span style=\"font-size:12.0pt\"> Adding another medication would not be expected to provide significant benefit in this case of severe heart failure with maximized GDMT. Typically, H-ISDN is used for patients who are not able to tolerate ARNi/ACEi and ARB. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Left ventricular assist devices, either as a bridge to heart transplant or as primary therapy, are reasonable in patients with advanced heart failure.</span></span></span></p>",
    "correct_choice_id": 28286,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7080,
    "choices": [
      {
        "id": 28288,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular (AV) node ablation with permanent pacemaker implantation</span></span></span></p>"
      },
      {
        "id": 28289,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) placement </span></span></span></p>"
      },
      {
        "id": 28290,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left atrial appendage occlusion (LAAO)</span></span></span></p>"
      },
      {
        "id": 28291,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rhythm control</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old woman with paroxysmal AF and HFrEF (EF 45%) has recurrent hospitalizations due to acute heart failure. She is currently on apixaban, metoprolol, furosemide, and telmisartan. What is the most appropriate treatment?</span></span></span></p>",
    "unique_key": "Q8695744",
    "question_audio": null,
    "question_video": null,
    "map_id": 19686,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Rhythm control</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aggressive rhythm control (with antiarrhythmic drugs or catheter ablation) has been shown to reduce morbidity and mortality in patients with HF and AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with HFrEF, recent clinical trials have shown that catheter ablation of AF is associated with a favorable effect on morbidity and mortality compared with medical therapy. Amiodarone is another option for rhythm control. Although amiodarone carries a risk for toxicity, this patient&#39;s lifetime exposure to the drug is likely to be relatively low given her age, comorbid conditions, and probable amiodarone dosage, which is generally lower for AF than for ventricular arrhythmias. Monitored appropriately, it can be used safely and effectively in patients her age.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. AV node ablation:</span></strong><span style=\"font-size:12.0pt\"> Considered only if rate and rhythm control fails to control tachycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. ICD:</span></strong><span style=\"font-size:12.0pt\"> Indicated for primary prevention of sudden cardiac death in certain patients, but not the primary treatment for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. LAAO:</span></strong><span style=\"font-size:12.0pt\"> Used for stroke prevention in patients who have C/I for anticoagulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aggressive efforts to achieve rhythm control in patients with atrial fibrillation and concomitant heart failure decrease morbidity and mortality.</span></span></p>",
    "correct_choice_id": 28291,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7082,
    "choices": [
      {
        "id": 28296,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Liraglutide</span></span></span></p>"
      },
      {
        "id": 28297,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Glimepiride </span></span></span></p>"
      },
      {
        "id": 28298,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Dapagliflozin </span></span></span></p>"
      },
      {
        "id": 28299,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Saxagliptin</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old woman with ischemic cardiomyopathy (EF 38%) and type 2 diabetes mellitus has well-controlled blood pressure and glycemic control. She is on aspirin, atorvastatin, valsartan-sacubitril, metoprolol succinate, and metformin. Her BNP. What is the most appropriate additional treatment?</span></span></p>",
    "unique_key": "Q6480713",
    "question_audio": null,
    "question_video": null,
    "map_id": 19687,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Dapagliflozin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SGLT2 inhibitors have been shown to reduce cardiovascular death and heart failure hospitalization in patients with HFrEF, regardless of diabetes status. They also slow the progression of diabetic kidney disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glimepiride (sulfonylurea):</span></strong><span style=\"font-size:12.0pt\"> No proven cardiovascular benefit. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Liraglutide:</span></strong><span style=\"font-size:12.0pt\"> Shown to reduce CV events in T2DM but not specifically in HFrEF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Saxagliptin:</span></strong><span style=\"font-size:12.0pt\"> Not recommended in HFrEF due to the potential for increased hospitalizations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Consider adding SGLT2 inhibitors in patients with HFrEF, even if their diabetes is well-controlled, to reduce CV morbidity and mortality.</span></span></span></p>",
    "correct_choice_id": 28298,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7083,
    "choices": [
      {
        "id": 28300,
        "text": "<p><span style=\"font-size:12.0pt;\">Aortic stenosis</span></p>"
      },
      {
        "id": 28301,
        "text": "<p><span style=\"font-size:12.0pt;\">Cardiac tamponade</span></p>"
      },
      {
        "id": 28302,
        "text": "<p><span style=\"font-size:12.0pt;\">Heart failure with reduced ejection fraction</span></p>"
      },
      {
        "id": 28303,
        "text": "<p><span style=\"font-size:12.0pt;\">Large pericardial effusion</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 69-year-old woman is evaluated in the emergency department for a 1-week history of progressive exertional dyspnea and orthopnea. Vital signs are normal. Focused point-of-care cardiac ultrasonography is performed and done and as shown below. Which of the following is the most likely&nbsp;diagnosis?</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/supawork-e53ff9bb04dd417abdf7b818ed4326bc.gif\" width=\"600\" height=\"406\"></p>",
    "unique_key": "Q4189323",
    "question_audio": null,
    "question_video": null,
    "map_id": 19688,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Heart failure with reduced ejection fraction</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Heart failure with reduced ejection fraction (HFrEF) is characterized by a reduced left ventricular ejection fraction (LVEF), typically &lt;40%, as seen in the ultrasonographic findings. Symptoms such as progressive exertional dyspnea and orthopnea are hallmark clinical manifestations of left-sided heart failure, commonly due to impaired myocardial contractility.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Aortic stenosis</strong>: Aortic stenosis typically presents with symptoms such as chest pain, syncope, and heart failure. However, the ultrasound findings do not suggest aortic valve pathology or significant left ventricular outflow obstruction.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Cardiac tamponade</strong>: Cardiac tamponade would present with findings such as hypotension, jugular venous distension, and pulsus paradoxus. The ultrasound in tamponade typically shows a large pericardial effusion with diastolic collapse of the right atrium or right ventricle. These findings are not present in this case.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Large pericardial effusion</strong>: A large pericardial effusion would show a significant fluid accumulation around the heart on ultrasound, often leading to tamponade physiology. This is not observed in the provided ultrasound image.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Recognize the clinical presentation of heart failure with reduced ejection fraction (HFrEF) and correlate it with echocardiographic findings, emphasizing the importance of identifying left ventricular systolic dysfunction in patients presenting with symptoms of heart failure.</span></p>",
    "correct_choice_id": 28302,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 7087,
    "choices": [
      {
        "id": 28316,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Cardiac tamponade</span></span></span></p>"
      },
      {
        "id": 28317,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Eosinophilic pneumonia</span></span></span></p>"
      },
      {
        "id": 28318,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphangioleiomyomatosis</span></span></span></p>"
      },
      {
        "id": 28319,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary edema</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 70-year-old man is evaluated in the emergency department for acute worsening of dyspnea. Chest radiograph is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-115748.jpg\" style=\"height:370px; width:400px\" /></span></span></p>",
    "unique_key": "Q4234359",
    "question_audio": null,
    "question_video": null,
    "map_id": 19689,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Pulmonary edema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient&#39;s chest radiograph shows cardiomegaly and bilateral perihilar alveolar infiltrates, consistent with a diagnosis of pulmonary edema due to heart failure. A small left pleural effusion is seen, as well as fluid in the minor fissure, also consistent with heart failure. Although cardiomegaly can be seen in tamponade, diffuse alveolar infiltrates are not a feature of this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cardiac tamponade</span></strong><span style=\"font-size:12.0pt\">: While cardiomegaly can be seen in cardiac tamponade, which is a condition where fluid accumulates in the sac surrounding the heart, leading to compression of the heart, diffuse alveolar infiltrates are not a feature of cardiac tamponade. Therefore, this diagnosis is unlikely based on the radiographic findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Eosinophilic pneumonia</span></strong><span style=\"font-size:12.0pt\">: Eosinophilic pneumonia is characterized by the presence of eosinophils (a type of white blood cell) in the lung tissue, which typically presents with bilateral infiltrates on a chest radiograph. However, this condition does not usually present with cardiomegaly or pleural effusion, making this option less likely given the findings on the radiograph.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C. Lymphangioleiomyomatosis:</strong> Lymphangioleiomyomatosis is a rare lung disease that affects the lungs and lymphatic system, leading to cystic lung disease. The chest radiograph for this condition would typically show diffuse thin-walled cysts rather than cardiomegaly, alveolar infiltrates, or pleural effusion. Thus, this diagnosis is inconsistent with the radiographic findings in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary edema is characterized by cardiomegaly and bilateral perihilar alveolar infiltrates on a chest radiograph, often associated with pleural effusion and fluid in the minor fissure, especially in the context of heart failure. This is a key diagnostic feature that must be remembered.</span></span></span></p>",
    "correct_choice_id": 28319,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 7088,
    "choices": [
      {
        "id": 28320,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage A </span></span></span></p>"
      },
      {
        "id": 28321,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage B </span></span></span></p>"
      },
      {
        "id": 28322,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage C </span></span></span></p>"
      },
      {
        "id": 28323,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stage D</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with a past medical history of coronary artery disease develops a myocardial infarction. He got treated in CCU and before he is discharged, he undergoes echocardiography, which reveals a left ventricular ejection fraction of 35% to 40%. He is asymptomatic. Repeat Echo after 3 months shows the same findings. What is this patient&rsquo;s heart failure stage?</span></span></span></p>",
    "unique_key": "Q6574719",
    "question_audio": null,
    "question_video": null,
    "map_id": 19690,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Stage B</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has structural heart disease (reduced ejection fraction due to prior myocardial infarction) but no current symptoms of heart failure. This places him in <strong>Stage B</strong> heart failure according to the American College of Cardiology/American Heart Association (ACC/AHA) classification.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Stage A:</span></strong><span style=\"font-size:12.0pt\"> Patients in Stage A have risk factors for HF but no structural heart disease or symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Stage C:</span></strong><span style=\"font-size:12.0pt\"> Patients in Stage C have structural heart disease and current or prior symptoms of HF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Stage D:</span></strong><span style=\"font-size:12.0pt\"> Patients in Stage D have refractory HF requiring specialized interventions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACC/AHA staging system for heart failure, categorizes patients based on the presence or absence of structural heart disease and symptoms of heart failure. </span></span></p>",
    "correct_choice_id": 28321,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 7090,
    "choices": [
      {
        "id": 28328,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Constrictive pericarditis </span></span></span></p>"
      },
      {
        "id": 28329,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fabry disease </span></span></span></p>"
      },
      {
        "id": 28330,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dilated Cardiomyopathy </span></span></span></p>"
      },
      {
        "id": 28331,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Restrictive cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old woman with a history of recurrent heart failure hospitalizations presents with ascites and edema. Her JVP was elevated and there was no change with inspiration. On examination, she has an audible low-pitched late diastolic sound with a pansystolic murmur in the left sternal border. Echo shows diastolic dysfunction with mildly increased LV wall thickness. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q2519408",
    "question_audio": null,
    "question_video": null,
    "map_id": 19691,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Restrictive cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ascites and edema:</span></strong><span style=\"font-size:12.0pt\"> These are signs of right heart failure, which can be a consequence of RCM due to increased left atrial pressure.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated JVP with no inspiratory decline:</span></strong><span style=\"font-size:12.0pt\"> This finding, known as Kussmaul&#39;s sign, is suggestive of impaired right ventricular filling, seen in RCM and constrictive pericarditis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Low-pitched late diastolic sound (S4):</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark of RCM and indicates diastolic dysfunction/ stiff ventricle. Patients can have S3 as well. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pansystolic murmur at the left sternal border:</span></strong><span style=\"font-size:12.0pt\"> This suggests tricuspid regurgitation, a common complication of RCM due to right ventricular dilatation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Echo findings:</span></strong><span style=\"font-size:12.0pt\"> Diastolic dysfunction with mildly increased LV wall thickness is typical of RCM.</span></span></span><br />\r\n\t&nbsp;</li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Constrictive pericarditis:</span></strong><span style=\"font-size:12.0pt\"> While this can also cause elevated JVP and diastolic dysfunction, it usually does not present with a pansystolic murmur or S3 gallop. Pericardial knock is more characteristic.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fabry disease:</span></strong><span style=\"font-size:12.0pt\"> This is a rare genetic disorder that can cause RCM, but it is less likely than other causes in this patient without a specific family history or other suggestive features.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Dilated cardiomyopathy:</span></strong><span style=\"font-size:12.0pt\"> This presents with systolic dysfunction (reduced ejection fraction) and a dilated left ventricle, which are not seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Restrictive cardiomyopathy presents with features of right heart failure, Kussmaul&#39;s sign, S3/S4 gallop, diastolic dysfunction, and associated findings like TR.</span></span></p>",
    "correct_choice_id": 28331,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 7113,
    "choices": [
      {
        "id": 28420,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Addition of valsartan-sacubitril</span></span></span></p>"
      },
      {
        "id": 28421,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Implantable cardioverter-defibrillator (ICD) therapy </span></span></span></p>"
      },
      {
        "id": 28422,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Replacement of metoprolol with carvedilol </span></span></span></p>"
      },
      {
        "id": 28423,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Septal reduction therapy (SRT)</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman with a history HF and HCM presents with NYHA class III dyspnea. She is currently on metoprolol and disopyramide. Echocardiogram shows an EF of 78% and LVOT gradient of 64 mmHg at rest. What is the most appropriate treatment?</span></span></p>",
    "unique_key": "Q6750054",
    "question_audio": null,
    "question_video": null,
    "map_id": 19692,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Septal reduction therapy (SRT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SRT is indicated for patients with symptomatic HCM and an LVOT gradient&ge; 50 mm Hg despite optimal medical therapy. This patient&#39;s symptoms and high LVOT gradient warrant consideration for SRT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Valsartan-sacubitril:</span></strong><span style=\"font-size:12.0pt\"> Contraindicated in HCM as it can worsen LVOT obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. &nbsp;ICD:</span></strong><span style=\"font-size:12.0pt\"> Indicated for primary prevention of sudden cardiac death in high-risk HCM patients, but not for symptomatic relief of LVOT obstruction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Replacing metoprolol with carvedilol:</span></strong><span style=\"font-size:12.0pt\"> Unlikely to be beneficial, as both are beta-blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Septal reduction therapy is the treatment of choice for symptomatic patients with HCM and a high LVOT gradient despite optimal medical therapy.</span></span></p>",
    "correct_choice_id": 28423,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7114,
    "choices": [
      {
        "id": 28424,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sacubitril-Valsartan </span></span></span></p>"
      },
      {
        "id": 28425,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Empagliflozin </span></span></span></p>"
      },
      {
        "id": 28426,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Spironolactone </span></span></span></p>"
      },
      {
        "id": 28427,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">None of the above</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 52-year-old man presents with dyspnea on exertion. His resting ECG is normal. 2D echo revealed diastolic dysfunction, mild concentric LVH, and an LV EF of 65%. His BNP levels were elevated. Which of the following will maximally increase survival in this patient?</span></span></p>",
    "unique_key": "Q1391346",
    "question_audio": null,
    "question_video": null,
    "map_id": 19693,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) None of the above</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with heart failure with preserved ejection fraction (HFpEF). Currently, there are no medications proven to significantly reduce mortality in HFpEF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The medications listed (Sacubitril-Valsartan, Empagliflozin, Spironolactone) are primarily used for heart failure with reduced ejection fraction (HFrEF), where they have shown mortality benefits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Sacubitril-Valsartan:</span></strong><span style=\"font-size:12.0pt\"> This is an angiotensin receptor-neprilysin inhibitor (ARNI) indicated for HFrEF, not HFpEF. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Empagliflozin:</span></strong><span style=\"font-size:12.0pt\"> This is an SGLT2 inhibitor shown to benefit patients with HFrEF and may reduce hospitalizations in HFpEF, but not proven to improve survival. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Spironolactone:</span></strong><span style=\"font-size:12.0pt\"> While this mineralocorticoid receptor antagonist may improve symptoms and reduce hospitalizations in HFpEF, it has not been shown to reduce mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">There are no medications currently proven to significantly improve survival in HFpEF. Management primarily focuses on symptom management. </span></span></span></p>",
    "correct_choice_id": 28427,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 7115,
    "choices": [
      {
        "id": 28428,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Amyloidosis </span></span></span></p>"
      },
      {
        "id": 28429,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcoidosis </span></span></span></p>"
      },
      {
        "id": 28430,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myocarditis </span></span></span></p>"
      },
      {
        "id": 28431,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemic heart disease (IHD)</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Circumferential subendocardial late-gadolinium enhancement (LGE) is seen in?</span></span></p>",
    "unique_key": "Q5395916",
    "question_audio": null,
    "question_video": null,
    "map_id": 19694,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Amyloidosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Late gadolinium enhancement (LGE) on cardiac MRI is a technique used to visualize areas of myocardial fibrosis or scarring. Circumferential subendocardial LGE is a characteristic pattern seen in cardiac amyloidosis. The abnormal protein deposits in amyloidosis lead to diffuse subendocardial fibrosis, resulting in this pattern on LGE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/untitled-2.jpg\" style=\"height:480px; width:700px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sarcoidosis:</span></strong><span style=\"font-size:12.0pt\"> Sarcoidosis typically shows a patchy or focal pattern of LGE, often in the mid-myocardial or subepicardial layers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Myocarditis:</span></strong><span style=\"font-size:12.0pt\"> Myocarditis can have various patterns of LGE, including patchy, focal, or epicardial, depending on the extent and distribution of inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ischemic heart disease (IHD):</span></strong><span style=\"font-size:12.0pt\"> IHD typically shows subendocardial or transmural LGE in a coronary artery distribution, corresponding to areas of infarction or ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Circumferential subendocardial late-gadolinium enhancement (LGE) on cardiac MRI is a hallmark feature of cardiac amyloidosis.</span></span></p>",
    "correct_choice_id": 28428,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 7116,
    "choices": [
      {
        "id": 28432,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class I </span></span></span></p>"
      },
      {
        "id": 28433,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II </span></span></span></p>"
      },
      {
        "id": 28434,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class III </span></span></span></p>"
      },
      {
        "id": 28435,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proportion of sudden cardiac death (SCD) in heart failure is maximum among which of the following NYHA classes?</span></span></p>",
    "unique_key": "Q8331222",
    "question_audio": null,
    "question_video": null,
    "map_id": 19695,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Class II</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While more severe heart failure (HF) is associated with a higher overall mortality rate and a higher absolute rate of SCD, the proportion of deaths attributed to SCD actually decreases as HF severity increases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This trend is highlighted in the MERIT-HF trial:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NYHA Class II: 6.3% risk of SCD at one year (64% of total deaths)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NYHA Class III: 10.5% risk of SCD at one year (59% of total deaths)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NYHA Class IV: 18.6% risk of SCD at one year (33% of total deaths)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This data indicates that while the absolute number of SCD cases is higher in more severe HF, other causes of death become more prominent as HF progresses. Therefore, the highest proportion of deaths due to SCD occurs in NYHA Class II.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proportion of deaths due to SCD is highest in NYHA Class II.</span></span></span></p>",
    "correct_choice_id": 28433,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 7118,
    "choices": [
      {
        "id": 28440,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium channels </span></span></span></p>"
      },
      {
        "id": 28441,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmosomal proteins </span></span></span></p>"
      },
      {
        "id": 28442,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sodium channels</span></span></span></p>"
      },
      {
        "id": 28443,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sarcomere proteins </span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ms. Kalavathy, a 35-year-old Anglo-Indian from Ireland, experienced cardiac arrest due to monomorphic VT with a LBBB morphology. Coronary angiogram and echocardiogram were normal. Echo is shown. Which protein mutation is most likely responsible for her presentation?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/screenshot-2024-08-09-124018.jpg\" style=\"height:106px; width:700px\" /></span></span></span></p>",
    "unique_key": "Q9707186",
    "question_audio": null,
    "question_video": null,
    "map_id": 19696,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Desmosomal proteins</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation (young age, cardiac arrest due to VT, with LBBB morphology, normal coronary arteries and LV function, T-wave inversions in V1-V3 with epsilon wave) is highly suggestive of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is most commonly caused by mutations in genes encoding desmosomal proteins, which are responsible for cell-to-cell adhesion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A. Potassium channels:</span></strong><span style=\"font-size:12.0pt\"> Mutations in these channels cause long QT syndrome, characterized by a prolonged QT interval on ECG and syncope.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C. Sodium channel:</span></strong><span style=\"font-size:12.0pt\"> Mutations in these channels cause Brugada syndrome, characterized by a specific ECG pattern and increased risk of sudden cardiac death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><strong><span style=\"font-size:12.0pt\">. Sarcomere proteins:</span></strong><span style=\"font-size:12.0pt\"> Mutations in these proteins cause hypertrophic cardiomyopathy, which would show LV hypertrophy on echocardiogram.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ARVC is a rare genetic disorder most commonly due to mutations in genes encoding cardiac desmosomal proteins. Approximately 50% have a familial transmission&nbsp;</span></span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">with autosomal dominant inheritance.</span></span></p>",
    "correct_choice_id": 28441,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 7121,
    "choices": [
      {
        "id": 28452,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class I </span></span></span></p>"
      },
      {
        "id": 28453,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II </span></span></span></p>"
      },
      {
        "id": 28454,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class III </span></span></span></p>"
      },
      {
        "id": 28455,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV </span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with a history of MI and HF is comfortable at rest. However, when walking to his car, he develops dyspnea, fatigue, and sometimes palpitations. He must rest for several minutes before these symptoms resolve. Which of the following is his NYHA classification?</span></span></span></p>",
    "unique_key": "Q4923981",
    "question_audio": null,
    "question_video": null,
    "map_id": 19697,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Class III</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The New York Heart Association (NYHA) classification is a system used to categorize the severity of heart failure based on the patient&#39;s functional capacity and symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Class III:</span></strong><span style=\"font-size:12.0pt\"> Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient in this case experiences symptoms with mild exertion (walking to his car) but is comfortable at rest, indicating a marked limitation of activity. Therefore, he falls into <strong>NYHA Class III</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Class I:</span></strong><span style=\"font-size:12.0pt\"> No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath), or angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Class II:</span></strong><span style=\"font-size:12.0pt\"> Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Class IV:</span></strong><span style=\"font-size:12.0pt\"> Unable to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the NYHA classification, Class III heart failure is defined by marked limitation of physical activity where patients are comfortable at rest, but less than ordinary activity (e.g., walking short distances) causes symptoms such as dyspnea, fatigue, and palpitations.</span></span></p>",
    "correct_choice_id": 28454,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 7123,
    "choices": [
      {
        "id": 28460,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Confusion </span></span></span></p>"
      },
      {
        "id": 28461,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early hunger </span></span></span></p>"
      },
      {
        "id": 28462,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nocturia without polyuria </span></span></span></p>"
      },
      {
        "id": 28463,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right upper quadrant pain</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a symptom of heart failure?</span></span></p>",
    "unique_key": "Q9913607",
    "question_audio": null,
    "question_video": null,
    "map_id": 19698,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Early hunger</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early satiety (not early hunger) is a symptom of heart failure. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Confusion:</span></strong><span style=\"font-size:12.0pt\"> This can occur in HF, particularly in older adults or those with severe HF. It is often due to decreased cerebral perfusion caused by reduced cardiac output.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nocturia without polyuria:</span></strong><span style=\"font-size:12.0pt\"> This is a common symptom of HF, especially in the early stages. It is caused by redistribution of fluid from the legs to the central circulation when lying down.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Right upper quadrant pain:</span></strong><span style=\"font-size:12.0pt\"> This can be caused by liver congestion due to right heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize the various symptoms of heart failure.</span></span></span></p>",
    "correct_choice_id": 28461,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53495,
    "choices": [
      {
        "id": 213461,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Advanced maternal age</span></span></span></p>"
      },
      {
        "id": 213462,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malnutrition</span></span></span></p>"
      },
      {
        "id": 213463,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primiparous</span></span></span></p>"
      },
      {
        "id": 213464,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Twin pregnancy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are a risk factor for development of peripartum cardiomyopathy EXCEPT:</span></span></span></p>",
    "unique_key": "Q7405820",
    "question_audio": null,
    "question_video": null,
    "map_id": 25278,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Primiparous</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripartum cardiomyopathy is a rare complication of pregnancy and can occur during the last trimester or within the first 6 months postpartum. Risk factors include advanced age, increased parity, twin pregnancy, malnutrition, use of tocolytic therapy and preeclampsia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A. Advanced maternal age:</strong> Advanced maternal age is a recognized risk factor for peripartum cardiomyopathy due to the increased cardiovascular strain and the higher likelihood of pre-existing heart conditions in older pregnant women.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B. Malnutrition:</strong> Malnutrition is another risk factor because inadequate nutrition can impair the heart muscle&#39;s ability to function properly, thereby increasing the risk of developing cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D. Twin pregnancy:</strong> A twin pregnancy significantly increases the workload on the heart, making it a well-documented risk factor for peripartum cardiomyopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primiparous status (first pregnancy) is not a risk factor for peripartum cardiomyopathy, whereas advanced maternal age, malnutrition, and twin pregnancy are significant risk factors for the development of this condition.</span></span></p>",
    "correct_choice_id": 213463,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 53497,
    "choices": [
      {
        "id": 213469,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ibuprofen</span></span></span></p>"
      },
      {
        "id": 213470,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ramipril</span></span></span></p>"
      },
      {
        "id": 213471,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oseltamivir</span></span></span></p>"
      },
      {
        "id": 213472,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisone</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">You admit a 19-year-old with acute HF and LV dysfunction. After assessment, you suspect acute viral myocarditis, which is confirmed on endomyocardial biopsy. Which of the following therapies is recommended for treatment for acute viral myocarditis?</span></span></span></p>",
    "unique_key": "Q6735971",
    "question_audio": null,
    "question_video": null,
    "map_id": 25279,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Ramipril</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Currently, no specific therapy is recommended for viral myocarditis at any stage. Anti-inflammatory or immunosuppressive medications are avoided during acute infection, as they may increase viral replication and myocardial injury. The use of antiviral agents, like oseltamivir, for cardiac involvement has not been studied. Research is ongoing into antiviral therapy for chronic viral persistence identified through endomyocardial biopsy. Large trials for immunosuppressive therapy in Dallas Criteria&ndash;positive myocarditis have shown negative results, though there are some initial promising findings for immune-mediated myocarditis. However, neither antiviral nor anti-inflammatory therapies are currently recommended. Until further understanding is gained, treatment follows general guidelines for dilated cardiomyopathy, including ACE inhibitors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ibuprofen:</span></strong><span style=\"font-size:12.0pt\"> Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID). Although it is commonly used to reduce inflammation and pain, its use is generally avoided in viral myocarditis. This is because NSAIDs can potentially increase the risk of adverse outcomes by inhibiting prostaglandin synthesis, which is essential for maintaining renal function and controlling inflammatory responses. Furthermore, NSAIDs might increase viral replication, leading to worsening of the condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Oseltamivir:</span></strong><span style=\"font-size:12.0pt\"> Oseltamivir is an antiviral medication primarily used to treat influenza. It is not effective for treating viral myocarditis because it specifically targets the influenza virus and has not been studied for cardiac involvement. Therefore, it is not recommended for the treatment of viral myocarditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prednisone:</span></strong><span style=\"font-size:12.0pt\"> Prednisone is a corticosteroid with potent anti-inflammatory effects. However, the use of immunosuppressive therapies, including corticosteroids like prednisone, is generally avoided in the acute phase of viral myocarditis because they may increase the risk of viral replication and myocardial injury. Current evidence does not support the use of prednisone in acute viral myocarditis, and large trials have shown negative results in treating myocarditis with immunosuppressive therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the management of acute viral myocarditis, Ramipril (an ACE inhibitor) is recommended to manage heart failure symptoms and improve cardiac function, while anti-inflammatory, immunosuppressive, and specific antiviral therapies are generally not recommended.</span></span></p>",
    "correct_choice_id": 213470,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 11327,
    "choices": [
      {
        "id": 45274,
        "text": "<p><span style=\"font-size:12.0pt;\">Add intravenous enalaprilat</span></p>"
      },
      {
        "id": 45275,
        "text": "<p><span style=\"font-size:12.0pt;\">Increase nitroprusside infusion</span></p>"
      },
      {
        "id": 45276,
        "text": "<p><span style=\"font-size:12.0pt;\">Repair the descending aorta</span></p>"
      },
      {
        "id": 45277,
        "text": "<p><span style=\"font-size:12.0pt;\">Switch nitroprusside to amlodipine</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old woman with a recent type B aortic dissection presents with abdominal pain and lower limb ischemia with diminished femoral and popliteal pulses. What is the most appropriate next step?</span></p>",
    "unique_key": "Q2369929",
    "question_audio": null,
    "question_video": null,
    "map_id": 19715,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Repair the descending aorta</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">New-onset abdominal pain and limb ischemia in a patient with type B aortic dissection indicate a complicated dissection, likely due to malperfusion of the mesenteric and lower extremity arteries. This requires urgent surgical or endovascular repair.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Enalaprilat:</strong> Although used for blood pressure control, it doesn't address the underlying issue of malperfusion.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Increasing nitroprusside:</strong> May help with blood pressure control but doesn't solve the urgent need for revascularization.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. &nbsp;Switching to amlodipine:</strong> Not appropriate in an acute setting requiring immediate intervention.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Recognize the signs of complicated type B aortic dissection (malperfusion syndromes) and the need for immediate surgical/endovascular repair.</span></p>",
    "correct_choice_id": 45276,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "RecentNEETPG",
      "TreatmentBased"
    ]
  },
  {
    "id": 19811,
    "choices": [
      {
        "id": 79205,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add atorvastatin</span></span></span></p>"
      },
      {
        "id": 79206,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add losartan</span></span></span></p>"
      },
      {
        "id": 79207,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aortic repair before pregnancy</span></span></span></p>"
      },
      {
        "id": 79208,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Proceed with pregnancy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman with Marfan syndrome has an ascending aortic diameter of 4.3 cm, which has increased by 0.6 cm in the past year. Her mother had an aortic dissection. She is considering pregnancy. What is the most appropriate management?</span></span></p>",
    "unique_key": "Q1720001",
    "question_audio": null,
    "question_video": null,
    "map_id": 19723,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Aortic repair before pregnancy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients with Marfan syndrome have an increased risk of aortic dissection during pregnancy. Aortic repair is recommended before pregnancy in patients with aortic root dilation &gt;4.0 cm and risk factors like family history or rapid aneurysm growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atorvastatin:</span></strong><span style=\"font-size:12.0pt\"> Statins are not indicated for aortic disease management in this context and are contraindicated in pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. &nbsp;Losartan:</span></strong><span style=\"font-size:12.0pt\"> Contraindicated in pregnancy due to fetal toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> &nbsp;Proceeding with pregnancy without aortic repair would be dangerous due to the high risk of dissection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Patients with Marfan syndrome have an increased risk for pregnancy-related aortic dissection and rupture; aortic repair surgery is recommended before conception to reduce this risk in those with an ascending aortic diameter greater than 4.0 cm and who have risk factors for aortic dissection.</span></span></span></p>",
    "correct_choice_id": 79207,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 19814,
    "choices": [
      {
        "id": 79217,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Coronary Angiogram </span></span></span></p>"
      },
      {
        "id": 79218,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Invasive aortography </span></span></span></p>"
      },
      {
        "id": 79219,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Magnetic resonance angiography (MRA) </span></span></span></p>"
      },
      {
        "id": 79220,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT Angiography </span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old man with acute chest pain. ECG shows multifocal ST depressions. His BP is 170/100 mm Hg on the right arm and 140/90 mm Hg in the left arm. He also has a diastolic murmur at the left sternal border. What is the most appropriate diagnostic test?</span></span></p>",
    "unique_key": "Q8715516",
    "question_audio": null,
    "question_video": null,
    "map_id": 19726,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\"> <strong>D) CT Angiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of acute chest pain, unequal arm blood pressures, and a diastolic murmur strongly suggests aortic dissection. CT angiography can rapidly assess for aortic dissection and provides definitive anatomical imaging of the aorta to confirm the diagnosis. It may be combined with a 2D Echo to image aortic regurgitation in this case as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. &nbsp;Coronary angiography:</span></strong><span style=\"font-size:12.0pt\"> Relatively contraindicated in suspected aortic dissection. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> &nbsp;Invasive aortography: Less commonly used compared to CTA for diagnosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. &nbsp;MRA:</span></strong><span style=\"font-size:12.0pt\"> Time consuming and unnecessary in an emergency like in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with suspected aortic dissection, perform TTE and CT angiography promptly for diagnosis and to guide management.</span></span></span></p>",
    "correct_choice_id": 79220,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 19815,
    "choices": [
      {
        "id": 79221,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute coronary syndrome</span></span></span></p>"
      },
      {
        "id": 79222,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aortic dissection</span></span></span></p>"
      },
      {
        "id": 79223,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism</span></span></span></p>"
      },
      {
        "id": 79224,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress-induced cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 73-year-old woman with extensive cardiovascular disease and poorly controlled hypertension is evaluated for acute-onset ripping chest pain that radiates to her back. Chest radiograph is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/09/untitled-3.jpg\" style=\"height:300px; width:300px\" /></span></span></p>",
    "unique_key": "Q5269498",
    "question_audio": null,
    "question_video": null,
    "map_id": 19727,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Aortic dissection</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis is acute aortic dissection. This patient&#39;s chest radiograph shows a widened superior mediastinum and a right pleural effusion consistent with aortic dissection, although these findings are not diagnostic. The diagnosis of aortic dissection can be established with transesophageal echocardiography, CT angiography, or MR angiography, all of which have similar sensitivity and specificity for acute thoracic aortic disease. Because of its wide availability and short image acquisition time, CT angiography has become the primary diagnostic test for acute thoracic aortic disease.</span></span></span></p>",
    "correct_choice_id": 79222,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6578,
    "choices": [
      {
        "id": 26281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left anterior descending (LAD) artery </span></span></span></p>"
      },
      {
        "id": 26282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left circumflex (LCx) artery </span></span></span></p>"
      },
      {
        "id": 26283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right coronary artery (RCA) </span></span></span></p>"
      },
      {
        "id": 26284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left main coronary artery</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with a history of hypertension and hyperlipidemia presents with acute chest pain radiating to the left arm and jaw. ECG is shown. Which coronary artery is most likely occluded?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-174647.png\" style=\"height:143px; width:400px\" /></span></span></p>",
    "unique_key": "Q6215481",
    "question_audio": null,
    "question_video": null,
    "map_id": 19746,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Right coronary artery (RCA)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ST-segment elevation in leads II, III, and aVF is indicative of an inferior myocardial infarction, which is most commonly caused by occlusion of the RCA. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">(This patient also has ST elevations in V1/V2 which may indicate RV infarction. However V4R is needed to confirm this).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Left anterior descending (LAD) artery</span></strong><span style=\"font-size:12.0pt\">: </span><span style=\"font-size:12.0pt\">Occlusion of the LAD artery typically causes ST-segment elevation in anterior leads. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Left circumflex (LCx) artery</span></strong><span style=\"font-size:12.0pt\">:</span><strong> </strong><span style=\"font-size:12.0pt\">Occlusion of the LCx artery typically causes ST-segment elevation in lateral leads. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Left main coronary artery</span></strong><span style=\"font-size:12.0pt\">: </span><span style=\"font-size:12.0pt\">Occlusion of the left main coronary artery typically causes widespread ST-segment elevation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Educational Objective</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize the ECG findings of an inferior myocardial infarction and its association with RCA occlusion.</span></span></span></p>",
    "correct_choice_id": 26283,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6581,
    "choices": [
      {
        "id": 26293,
        "text": "<p><span style=\"font-size:12.0pt;\">Synchronized cardioversion</span></p>"
      },
      {
        "id": 26294,
        "text": "<p><span style=\"font-size:12.0pt;\">Repeat adenosine</span></p>"
      },
      {
        "id": 26295,
        "text": "<p><span style=\"font-size:12.0pt;\">Metoptolol</span></p>"
      },
      {
        "id": 26296,
        "text": "<p><span style=\"font-size:12.0pt;\">Amiodarone</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old woman presents with recurrent palpitations and near-syncope. ECG during the episode is shown. His BP is 130/84 mm Hg and PR is 154/min. Vagal manoeuvrers and IV adenosine (6mg) administration do not terminate the tachycardia. What is the most appropriate next step in management?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-175001.png\" alt=\"\" width=\"400\" height=\"227\"></span></p>",
    "unique_key": "Q9365643",
    "question_audio": null,
    "question_video": null,
    "map_id": 19747,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.</strong> <strong>B) Repeat Adenosine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In a hemodynamically stable patient with AVNRT, the next step after a failed initial dose of adenosine (6 mg) is to repeat adenosine at a higher dose of 12 mg IV push.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Adenosine is a short-acting AV nodal blocker that can effectively terminate AVNRT. The initial dose may not be sufficient in some cases, and a second dose (or even a third dose) is often successful.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation</u>:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Synchronized cardioversion:</strong> This is typically reserved for hemodynamically unstable patients or those who fail medical therapy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Metoprolol:</strong> Beta-blockers like metoprolol (and calcium channel blockers) are used if initial therapy with vagal manoeuvres and adenosine fail.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Amiodarone:</strong> This is an antiarrhythmic drug that can be used if AV nodal blockers fail.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective</u>:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Step wise management of regular narrow complex tachycardia (like AVNRT):</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-175104.png\" alt=\"\" width=\"500\" height=\"540\"></span></p>",
    "correct_choice_id": 26294,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6583,
    "choices": [
      {
        "id": 26301,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brugada syndrome </span></span></span></p>"
      },
      {
        "id": 26302,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Congenital long QT syndrome </span></span></span></p>"
      },
      {
        "id": 26303,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Wolff-Parkinson-White syndrome</span></span></span></p>"
      },
      {
        "id": 26304,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertrophic cardiomyopathy</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 23-year-old intern presents with recurrent episodes of syncope after hearing ambulance siren in the ER. She also experiences light-headedness and dizziness early morning once she wakes up hearing alarms. The ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-180215.png\" style=\"height:242px; width:400px\" /></span></span></p>",
    "unique_key": "Q1244645",
    "question_audio": null,
    "question_video": null,
    "map_id": 19748,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Congenital long QT syndrome</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Congenital long QT syndrome (LQTS) is a genetic disorder characterized by a prolonged QT interval on the ECG (like in this ECG). LQTS can cause syncope, particularly in response to emotional or auditory stimuli (like the ambulance sirens in this case). This patient&#39;s presentation aligns with LQT2, a subtype of LQTS often triggered by sudden noises.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Brugada syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is associated with a specific ECG pattern (ST-elevation in V1-V3) and sudden cardiac death, not typically triggered by sounds.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Wolff-Parkinson-White syndrome:</span></strong><span style=\"font-size:12.0pt\"> This involves an accessory pathway, causing a short PR interval and delta wave, and is not typically associated with syncope triggered by sound.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypertrophic cardiomyopathy:</span></strong><span style=\"font-size:12.0pt\"> This is characterized by left ventricular hypertrophy, which may or may not have a prolonged QT interval and is not typically triggered by sound.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Syncope triggered by auditory stimuli, combined with a prolonged QT interval on ECG, is highly suggestive of congenital long QT syndrome, particularly LQT2. </span></span></span></p>",
    "correct_choice_id": 26302,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6585,
    "choices": [
      {
        "id": 26309,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial fibrillation </span></span></span></p>"
      },
      {
        "id": 26310,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial tachycardia </span></span></span></p>"
      },
      {
        "id": 26311,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular nodal reentrant tachycardia (AVNRT) </span></span></span></p>"
      },
      {
        "id": 26312,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ventricular tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 42-year-old woman presents with abrupt-onset palpitations that she can terminate by coughing. ECG is shown. What is the most likely rhythm diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-180707.png\" style=\"height:211px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q5148909",
    "question_audio": null,
    "question_video": null,
    "map_id": 19749,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Atrioventricular nodal reentrant tachycardia (AVNRT)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AVNRT is the most common type of paroxysmal supraventricular tachycardia. It presents with abrupt onset and termination, a narrow QRS complex tachycardia, and often responds to vagal maneuvers like coughing. The pseudo r&#39; wave in V1 is a characteristic ECG finding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-180802.png\" style=\"height:170px; width:500px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atrial fibrillation:</span></strong><span style=\"font-size:12.0pt\"> Irregular rhythm with no discernible P waves. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Atrial tachycardia:</span></strong><span style=\"font-size:12.0pt\"> Typically slower than AVNRT and less likely to be terminated by vagal maneuvers. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ventricular tachycardia:</span></strong><span style=\"font-size:12.0pt\"> Wide QRS complex tachycardia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;ECG findings of AVNRT = narrow QRS complex tachycardia, pseudo r&#39; wave in V1, and responsiveness to vagal maneuvers. </span></span></span></p>",
    "correct_choice_id": 26311,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6587,
    "choices": [
      {
        "id": 26317,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
      },
      {
        "id": 26318,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30-day event monitor </span></span></span></p>"
      },
      {
        "id": 26319,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">12-lead resting ECG</span></span></span></p>"
      },
      {
        "id": 26320,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">24-hour ambulatory ECG monitor (Holter monitor)</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 41-year-old man is evaluated for daily palpitations lasting minutes at a time. What is the most appropriate initial test?</span></span></p>",
    "unique_key": "Q1217709",
    "question_audio": null,
    "question_video": null,
    "map_id": 19750,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) 12-lead resting ECG</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial evaluation of palpitations should always include a 12-lead resting ECG to identify any underlying arrhythmias or structural abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Exercise ECG:</span></strong><span style=\"font-size:12.0pt\"> Used to assess for exercise-induced arrhythmias or ischemia, not the initial test for palpitations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 30-day event monitor:</span></strong><span style=\"font-size:12.0pt\"> Used for infrequent symptoms. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 24-hour Holter monitor:</span></strong><span style=\"font-size:12.0pt\"> Indicated if the resting ECG is normal but suspicion for arrhythmia remains high.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial test in patients with a history of palpitations, presyncope, or syncope is 12-lead resting ECG.</span></span></span></p>",
    "correct_choice_id": 26319,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 6589,
    "choices": [
      {
        "id": 26325,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac MRI </span></span></span></p>"
      },
      {
        "id": 26326,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography </span></span></span></p>"
      },
      {
        "id": 26327,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multigated acquisition (MUGA) scan </span></span></span></p>"
      },
      {
        "id": 26328,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No surveillance</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old woman with hypertension and hyperlipidemia is starting trastuzumab therapy for early-stage breast cancer. What is the most appropriate cardiac surveillance for this patient?</span></span></p>",
    "unique_key": "Q3609151",
    "question_audio": null,
    "question_video": null,
    "map_id": 19751,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Echocardiography</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Trastuzumab can cause reversible cardiotoxicity. Echocardiography is the recommended surveillance tool for assessing left ventricular function in patients receiving trastuzumab, especially those with cardiovascular risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cardiac MRI:</span></strong><span style=\"font-size:12.0pt\"> More expensive and not routinely needed for initial surveillance. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MUGA scan:</span></strong><span style=\"font-size:12.0pt\"> Less commonly used for surveillance than echocardiography. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No surveillance:</span></strong><span style=\"font-size:12.0pt\"> Inappropriate given the risk of cardiotoxicity with trastuzumab.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients receiving trastuzumab therapy at high risk for cardiac dysfunction, periodic echocardiographic surveillance is recommended.</span></span></span></p>",
    "correct_choice_id": 26326,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 6591,
    "choices": [
      {
        "id": 26333,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECG </span></span></span></p>"
      },
      {
        "id": 26334,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TEE </span></span></span></p>"
      },
      {
        "id": 26335,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SPECT </span></span></span></p>"
      },
      {
        "id": 26336,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PET</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 78-year-old woman with HFrEF (EF 25%) presents with NYHA class III symptoms. She is currently receiving valsartan-sacubitril, carvedilol, spironolactone, empagliflozin, and furosemide. In view of persistent symptoms, she is planned for CRT. Which of the following is the most useful investigation in predicting the usefulness of CRT?</span></span></p>",
    "unique_key": "Q2677253",
    "question_audio": null,
    "question_video": null,
    "map_id": 19752,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) ECG</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most useful investigation in predicting the usefulness of cardiac resynchronization therapy (CRT) is a 12-lead electrocardiogram (ECG). Specifically, the presence of a <strong>wide QRS complex</strong> (&ge; 120 milliseconds) with a <strong>left bundle branch block (LBBB) morphology</strong> is the strongest predictor of CRT response. This is because CRT is most effective in patients with dyssynchronous ventricular contraction, which is often manifested as LBBB on ECG.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. TEE (transesophageal echocardiography):</span></strong><span style=\"font-size:12.0pt\"> While TEE can provide valuable information about cardiac structure and function, it is not the most reliable predictor of CRT response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. SPECT (single-photon emission computed tomography):</span></strong><span style=\"font-size:12.0pt\"> SPECT can assess myocardial perfusion and viability but does not directly predict CRT response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PET (positron emission tomography):</span></strong><span style=\"font-size:12.0pt\"> PET is also used for myocardial viability assessment and is not the primary tool for predicting CRT response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand that a 12-lead ECG demonstrating a wide QRS complex with LBBB morphology is the most useful investigation in predicting the potential benefits of CRT in patients with HFrEF. </span></span></span></p>",
    "correct_choice_id": 26333,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 6592,
    "choices": [
      {
        "id": 26337,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dobutamine echocardiography </span></span></span></p>"
      },
      {
        "id": 26338,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dobutamine myocardial perfusion imaging </span></span></span></p>"
      },
      {
        "id": 26339,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise ECG </span></span></span></p>"
      },
      {
        "id": 26340,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise myocardial perfusion imaging</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman presents with chest pain that worsens with physical activity and improves with rest. Her resting ECG shows left ventricular hypertrophy (LVH) with a strain pattern. What is the most appropriate diagnostic test?</span></span></p>",
    "unique_key": "Q8907952",
    "question_audio": null,
    "question_video": null,
    "map_id": 19753,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Exercise myocardial perfusion imaging</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Exercise myocardial perfusion imaging is the preferred stress test in patients with LVH because it provides better assessment of ischemia compared to exercise ECG alone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dobutamine echocardiography:</span></strong><span style=\"font-size:12.0pt\"> May be considered if the patient cannot exercise, but exercise is preferred. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dobutamine myocardial perfusion imaging</span></strong><span style=\"font-size:12.0pt\">: Can be used, but exercise is preferred if possible.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Exercise ECG:</span></strong><span style=\"font-size:12.0pt\"> Less sensitive for detecting ischemia in patients with LVH due to baseline ECG changes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Exercise myocardial perfusion imaging is the preferred stress test for assessing myocardial ischemia in patients with LVH.</span></span></span></p>",
    "correct_choice_id": 26340,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 6594,
    "choices": [
      {
        "id": 26345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial fibrillation</span></span></span></p>"
      },
      {
        "id": 26346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial tachycardia</span></span></span></p>"
      },
      {
        "id": 26347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multifocal atrial tachycardia</span></span></span></p>"
      },
      {
        "id": 26348,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 63-year-old woman is admitted to the ICU with respiratory failure. ECG is shown. Which of the following abnormalities is demonstrated on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-181657.png\" style=\"height:138px; width:300px\" /></span></span></p>",
    "unique_key": "Q3246876",
    "question_audio": null,
    "question_video": null,
    "map_id": 19754,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Multifocal atrial tachycardia</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ECG shows multifocal atrial tachycardia (MAT). MAT is most commonly seen in acutely ill patients, most often in the setting of pulmonary disease, such as an exacerbation of COPD with associated hypoxia and electrolyte abnormalities. The ECG in MAT is defined by the presence of discrete P waves with at least three different morphologic patterns and varying P-P, P-R, and R-R intervals, as shown. The morphologic features of P waves are generally best seen in leads II, III, and V1. The rate is greater than 100 beats per minute, distinguishing MAT from wandering atrial pacemaker. The rhythm is irregular; however, unlike in atrial fibrillation, P waves are detectable, and there is a 1:1 relationship of each P wave to a QRS complex. Therapy is directed at the underlying disease process because without treatment of the underlying cause, the arrhythmia is often refractory to therapy or may recur.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Atrial fibrillation: </span></strong><span style=\"font-size:12.0pt\">Has no P waves. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Atrial tachycardia: </span></strong><span style=\"font-size:12.0pt\">Usually a regular rhythm and has single &lsquo;P&rsquo; wave morphology</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sinus tachycardia:</span></strong><span style=\"font-size:12.0pt\"> Usually a regular rhythm and has single &lsquo;P&rsquo; wave morphology</span></span></span></p>",
    "correct_choice_id": 26347,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6600,
    "choices": [
      {
        "id": 26369,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Accelerated idioventricular rhythm</span></span></span></p>"
      },
      {
        "id": 26370,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left bundle branch block</span></span></span></p>"
      },
      {
        "id": 26371,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Old inferior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 26372,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right bundle branch block</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 61-year-old man is evaluated following the recent diagnosis of hypertension. ECG is shown. Which of the following abnormalities is seen on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-181851.png\" style=\"height:128px; width:300px\" /></span></span></p>",
    "unique_key": "Q6507737",
    "question_audio": null,
    "question_video": null,
    "map_id": 19755,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Left bundle branch block</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates left bundle branch block. Left bundle branch block is characterized by the following features: (1) QRS widening of at least 120 ms, (2) upright monophasic QRS complex in leads I and V6 (the QRS complex may also be notched), and (3) a predominantly negative QRS complex in lead V1. In the ECG shown, all three features are evident. In both left and right bundle branch block, the ST-T&ndash;wave pattern is inscribed in the opposite direction of the main QRS vectors; these ST-T&ndash;wave abnormalities are secondary to the bundle branch block and do not indicate additional underlying pathology.</span></span></span></p>",
    "correct_choice_id": 26370,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6603,
    "choices": [
      {
        "id": 26381,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute pericarditis</span></span></span></p>"
      },
      {
        "id": 26382,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute anterior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 26383,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nonacute inferior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 26384,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute lateral myocardial infarction</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 58-year-old woman is evaluated prior to an elective total hip arthroplasty. ECG is shown. Which of the following abnormalities is seen on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-182109.png\" style=\"height:190px; width:400px\" /></span></span></p>",
    "unique_key": "Q5215714",
    "question_audio": null,
    "question_video": null,
    "map_id": 19756,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Nonacute inferior myocardial infarction</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG shows evidence of a nonacute inferior myocardial infarction, with Q waves in leads II, III, and aVF and without ST-segment changes. Additionally, it demonstrates a nonacute posterior myocardial infarction (or posterior extension of the inferior infarction) with increased R-wave amplitude and duration (R&gt;S), without ST-segment changes in the anterior precordial leads V1 through V3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">There are no ECG changes consistent with an anterior or lateral infarction.</span></span></span></p>",
    "correct_choice_id": 26383,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6604,
    "choices": [
      {
        "id": 26385,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial fibrillation</span></span></span></p>"
      },
      {
        "id": 26386,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial flutter</span></span></span></p>"
      },
      {
        "id": 26387,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular nodal reentrant tachycardia</span></span></span></p>"
      },
      {
        "id": 26388,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular reciprocating tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 59-year-old man is evaluated following a transient ischemic attack. ECG is shown. Which of the following abnormalities is demonstrated on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-182316.png\" style=\"height:207px; width:400px\" /></span></span></p>",
    "unique_key": "Q5417362",
    "question_audio": null,
    "question_video": null,
    "map_id": 19757,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><strong><span style=\"font-size:12.0pt\"> A) Atrial fibrillation</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG is characteristic of atrial fibrillation, with an irregularly irregular rhythm and no discernible P waves. Atrial fibrillation can present with a rapid ventricular response, with an average rate of more than 110/min; a controlled ventricular response, with an average rate between 60/min and 110/min; or a slow ventricular response, with an average rate of less than 60/min. This patient&#39;s ECG tracing shows an average rate of approximately 75/min.</span></span></span></p>",
    "correct_choice_id": 26385,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6605,
    "choices": [
      {
        "id": 26389,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left bundle branch block</span></span></span></p>"
      },
      {
        "id": 26390,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left ventricular hypertrophy</span></span></span></p>"
      },
      {
        "id": 26391,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myocardial ischemia</span></span></span></p>"
      },
      {
        "id": 26392,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nonspecific intraventricular conduction delay</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 44-year-old man with a newly diagnosed ischemic stroke is evaluated in the emergency department. ECG is shown. Which of the following abnormalities is seen on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-182500.png\" style=\"height:186px; width:400px\" /></span></span></p>",
    "unique_key": "Q5831095",
    "question_audio": null,
    "question_video": null,
    "map_id": 19758,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Left ventricular hypertrophy</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates features of left ventricular hypertrophy, including both of the Sokolow-Lyon electrocardiographic criteria for left ventricular hypertrophy:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The sum of the deepest S wave in lead V1 or V2 and the tallest R wave in lead V5 or V6 is 35 mm or greater; or The R wave in lead aVL is 11 mm or greater.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alternatively, if the deepest S wave plus the S wave in lead V4 sums to 23 mm or greater for women or 28 mm or greater for men, this finding has been found to be more sensitive than the traditional electrocardiographic criteria for diagnosis of left ventricular hypertrophy, with preserved specificity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Secondary ST-T wave abnormalities (asymmetric ST-segment depression and T-wave inversion) is another indication of left ventricular hypertrophy and are seen in leads I, aVL, and V4 through V6 in this tracing.</span></span></span></p>",
    "correct_choice_id": 26390,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 6606,
    "choices": [
      {
        "id": 26393,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial fibrillation</span></span></span></p>"
      },
      {
        "id": 26394,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial flutter</span></span></span></p>"
      },
      {
        "id": 26395,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial tachycardia</span></span></span></p>"
      },
      {
        "id": 26396,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman is evaluated for palpitations. ECG is shown. Which of the following abnormalities is demonstrated on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-182715.png\" style=\"height:213px; width:400px\" /></span></span></p>",
    "unique_key": "Q6707807",
    "question_audio": null,
    "question_video": null,
    "map_id": 19759,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><strong><span style=\"font-size:12.0pt\"> B) Atrial flutter</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates atrial flutter, which is characterized by a regular atrial rate that is often close to 300/min and by a sawtooth pattern. Flutter waves are most easily seen in the inferior leads (II, III, and aVF) and lead V1. Most commonly, there is 2:1 conduction to the ventricles, resulting in a ventricular rate of approximately 150/min, as seen in the first part of this tracing. A 4:1 conduction pattern with a rate of 75/min is also seen.</span></span></span></p>",
    "correct_choice_id": 26394,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 19835,
    "choices": [
      {
        "id": 79301,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
      },
      {
        "id": 79302,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Infiltrative cardiomyopathy</span></span></span></p>"
      },
      {
        "id": 79303,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pericardial effusion</span></span></span></p>"
      },
      {
        "id": 79304,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stress-related cardiomyopathy</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 49-year-old man is evaluated for symptoms of dyspnea, peripheral edema, and exercise intolerance. Echocardiography shows biventricular increased wall thickness. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-182906.png\" style=\"height:216px; width:400px\" /></span></span></p>",
    "unique_key": "Q3522474",
    "question_audio": null,
    "question_video": null,
    "map_id": 19760,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">B) Infiltrative cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis is an infiltrative cardiomyopathy, such as cardiac amyloidosis. This ECG demonstrates low voltage with QRS amplitude of less than 5 mm in the limb leads. Low voltage may also be demonstrated by a QRS amplitude of less than 10 mm in the precordial leads. When low ECG voltage accompanies increased wall thickness on echocardiogram, an infiltrative cardiomyopathy, such as amyloidosis, should be considered. Serum protein electrophoresis/urine protein electrophoresis and free light-chain analysis may help identify immunoglobulin light-chain amyloidosis.</span></span></span></p>",
    "correct_choice_id": 79302,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60043,
    "choices": [
      {
        "id": 239473,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intraventricular conduction delay</span></span></span></p>"
      },
      {
        "id": 239474,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left bundle branch block</span></span></span></p>"
      },
      {
        "id": 239475,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right axis deviation</span></span></span></p>"
      },
      {
        "id": 239476,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right bundle branch block</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old man is evaluated for nonanginal chest pain. ECG is shown. Which of the following is shown on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-183058.png\" style=\"height:163px; width:300px\" /></span></span></p>",
    "unique_key": "Q8229396",
    "question_audio": null,
    "question_video": null,
    "map_id": 26927,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Right bundle branch block</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates right bundle branch block. ECG features of right bundle branch block include QRS widening (&ge;120 ms), an rSR&#39; or rsR&#39; pattern in lead V1, and a wide terminal S wave in leads I and V6. Several premature atrial contractions are also seen. In both left and right bundle branch block, the ST-T wave pattern is inscribed in the opposite direction of the main QRS vectors; these ST-T wave abnormalities are secondary to the bundle branch block and do not indicate additional underlying pathology.</span></span></span></p>",
    "correct_choice_id": 239476,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60044,
    "choices": [
      {
        "id": 239477,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arrhythmogenic right ventricular cardiomyopathy/dysplasia</span></span></span></p>"
      },
      {
        "id": 239478,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brugada syndrome</span></span></span></p>"
      },
      {
        "id": 239479,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pericarditis</span></span></span></p>"
      },
      {
        "id": 239480,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary embolism</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old man is evaluated for the acute onset of severe chest pain. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-183237.png\" style=\"height:214px; width:400px\" /></span></span></p>",
    "unique_key": "Q5244425",
    "question_audio": null,
    "question_video": null,
    "map_id": 26928,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Pericarditis</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis is pericarditis. Electrocardiographic changes characteristic of acute pericarditis include diffuse ST-segment elevations and a depressed PR interval, both of which are present in this patient&#39;s ECG; leads I and II in this ECG demonstrate a depressed PR interval, most notably in the lead II rhythm strip. As pericarditis evolves, the electrocardiographic manifestations change and are classified into stages: Stage 1 is characterized by diffuse ST-segment elevations; stage 2, by &ldquo;pseudonormalization,&rdquo; in which the ST segments normalize; stage 3, by diffuse T-wave inversion and possible slightly depressed ST segments; and stage 4, by a return to normal on ECG.</span></span></span></p>",
    "correct_choice_id": 239479,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60045,
    "choices": [
      {
        "id": 239481,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antidromic atrioventricular reentrant tachycardia</span></span></span></p>"
      },
      {
        "id": 239482,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial tachycardia</span></span></span></p>"
      },
      {
        "id": 239483,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular nodal reentrant tachycardia</span></span></span></p>"
      },
      {
        "id": 239484,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old man is evaluated for palpations and light headedness. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-183439.png\" style=\"height:211px; width:400px\" /></span></span></p>",
    "unique_key": "Q4327406",
    "question_audio": null,
    "question_video": null,
    "map_id": 26929,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Atrioventricular nodal reentrant tachycardia</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;This ECG demonstrates atrioventricular nodal reentrant tachycardia (AVNRT). AVNRT accounts for two thirds of all supraventricular tachycardias. Patients with AVNRT have two electrical conduction pathways that are proximal to or within the atrioventricular node. One pathway conducts the electrical impulse rapidly but has a prolonged refractory period (fast pathway), and the second has slower conduction but a short refractory period (slow pathway). During sinus conduction, the impulse travels down both pathways; however, electrical conduction down the slow pathway is blocked at or below the level of the atrioventricular node because of the &ldquo;refractory wave&rdquo; produced by the previous electrical conduction down the fast pathway. If a premature beat is correctly timed, the conduction can travel down the slow pathway to activate the ventricles and retrograde up the fast pathway to activate the atria, thus creating a circuit and a sustained tachycardia with a ventricular rate between 120/min and 220/min. In the most common variety of AVNRT, the P wave is buried in the QRS complex or a portion of the P wave can be discerned, altering the morphology of the QRS complex. In the accompanying ECG, the P waves are hidden within the QRS complex, indicating AVNRT. In both atrial tachycardia and sinus tachycardia, P waves are visible; in antidromic atrioventricular reentrant tachycardia, the QRS complex is wide owing to impulse conduction over the bypass tract and outside the normal conduction system in the ventricles.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
    "correct_choice_id": 239483,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60046,
    "choices": [
      {
        "id": 239485,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer amiodarone 300mg mg IV</span></span></span></p>"
      },
      {
        "id": 239486,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer flecainide 400 mg orally </span></span></span></p>"
      },
      {
        "id": 239487,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer metoprolol 5 mg IV </span></span></span></p>"
      },
      {
        "id": 239488,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue observation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Karthik, is admitted to CCU after being diagnosed with STEMI. He received Reteplase an hour ago and currently he is asymptomatic and stable. The CCU staff nurse is concerned about the rhythm (shown below) in the monitor and informs you. What is the next step?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-183627.png\" style=\"height:151px; width:400px\" /></span></span></p>",
    "unique_key": "Q8147563",
    "question_audio": null,
    "question_video": null,
    "map_id": 26930,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Continue observation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates an accelerated idioventricular rhythm (AIVR), which is an escape rhythm arising from the ventricular myocardium. The QRS complexes are wide (as in all ventricular arrhythmias) and fairly regular. An idioventricular rhythm is typically at a rate between 30/min and 40/min but is considered accelerated when the rate is more than 50/min but less than 100/min; the heart rate on this tracing is approximately 90/min.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AIVR is a common finding in patients with successful reperfusion after thrombolytic therapy. This rhythm is benign and requires no further therapy. It invariably resolves on its own.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Administer amiodarone 300mg mg IV</span></strong><span style=\"font-size:12.0pt\">:</span><span style=\"font-size:12.0pt\"> Would be appropriate therapy if this was ventricular tachycardia or perhaps supraventricular tachycardia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Administer flecainide 400 mg orally</span></strong><span style=\"font-size:12.0pt\">:</span><span style=\"font-size:12.0pt\"> Class IC antiarrhythmic, contraindicated in post-MI patients due to increased mortality risk (CAST trial).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer metoprolol 5 mg IV</span></strong><span style=\"font-size:12.0pt\">:</span><span style=\"font-size:12.0pt\"> Beta-blocker, may be used for rate control in certain SVTs but not indicated for AIVR. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Accelerated idioventricular rhythm, which commonly arises after reperfusion, is generally benign and transient. The slow rate is a major difference between accelerated idioventricular rhythm and ventricular tachycardia.</span></span></span></p>",
    "correct_choice_id": 239488,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 60047,
    "choices": [
      {
        "id": 239489,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mobitz type 1 second-degree atrioventricular block</span></span></span></p>"
      },
      {
        "id": 239490,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mobitz type 2 second-degree atrioventricular block</span></span></span></p>"
      },
      {
        "id": 239491,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus arrest</span></span></span></p>"
      },
      {
        "id": 239492,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus bradycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man is evaluated for bradycardia prior to cataract surgery. He is asymptomatic. ECG is shown. Which of the following ECG findings is present?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-184015.png\" style=\"height:159px; width:400px\" /></span></span></p>",
    "unique_key": "Q5209160",
    "question_audio": null,
    "question_video": null,
    "map_id": 26931,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">D) Sinus bradycardia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Sinus bradycardia (sinus rhythm with a heart rate &lt;60/min) may be appropriate in several situations, including in trained athletes or during sleep, when the heart rate may fall as low as 30/min. This patient&#39;s heart rate is approximately 47/min. A premature atrial contraction is also seen.</span></span></span></p>",
    "correct_choice_id": 239492,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60048,
    "choices": [
      {
        "id": 239493,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Junctional rhythm</span></span></span></p>"
      },
      {
        "id": 239494,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monomorphic ventricular tachycardia</span></span></span></p>"
      },
      {
        "id": 239495,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Polymorphic ventricular tachycardia</span></span></span></p>"
      },
      {
        "id": 239496,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ventricular fibrillation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old woman with sarcoidosis is evaluated for an irregular pulse, a sensation of pounding in the neck, and an episode of syncope. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-184202.png\" style=\"height:212px; width:400px\" /></span></span></p>",
    "unique_key": "Q9197161",
    "question_audio": null,
    "question_video": null,
    "map_id": 26932,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Monomorphic ventricular tachycardia</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG shows ventricular tachycardia, which is typically caused by organic heart disease. It begins approximately one third of the way into the tracing and is marked by an abrupt change in axis and widening of the QRS complex. Ventricular tachycardia is characterized by fairly regular wide QRS complexes, a pulse rate of more than 120/min, and atrioventricular dissociation. Ventricular tachycardia can be characterized as either sustained (lasting &gt;30 seconds) or nonsustained, and as monomorphic, if all of the QRS complexes have the same morphology, or as polymorphic, if the QRS pattern twists across the baseline (e.g., torsades de pointes). Ventricular tachycardia can degenerate into ventricular fibrillation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
    "correct_choice_id": 239494,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60049,
    "choices": [
      {
        "id": 239497,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ostium primum atrial septal defect</span></span></span></p>"
      },
      {
        "id": 239498,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patent ductus arteriosus</span></span></span></p>"
      },
      {
        "id": 239499,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patent foramen ovale</span></span></span></p>"
      },
      {
        "id": 239500,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ventricular septal defect</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old woman is evaluated for unexplained right heart enlargement and a history of paroxysmal atrial fibrillation. Physical examination reveals a parasternal impulse, fixed splitting of S2, mitral regurgitation, and a pulmonary outflow murmur. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-184317.png\" style=\"height:179px; width:400px\" /></span></span></p>",
    "unique_key": "Q4590448",
    "question_audio": null,
    "question_video": null,
    "map_id": 26933,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) Ostium primum atrial septal defect</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis is ostium primum atrial septal defect (ASD). This ECG demonstrates the typical findings in ostium primum ASD, including left axis deviation, first-degree atrioventricular block, and right bundle branch block. Located in the lowest portion of the atrial septum, ostium primum ASD (15%-20% of ASDs) are a component of endocardial cushion defects. Associated abnormalities include mitral valve, ventricular septum, and subaortic anomalies. Clinical findings in patients with an ASD include a parasternal impulse, fixed splitting of the S2, and a pulmonary outflow murmur. A diastolic flow rumble across the tricuspid valve can occur with a large left-to-right shunt.</span></span></span></p>",
    "correct_choice_id": 239497,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60050,
    "choices": [
      {
        "id": 239501,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial tachycardia with 2:1 block</span></span></span></p>"
      },
      {
        "id": 239502,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Complete heart block</span></span></span></p>"
      },
      {
        "id": 239503,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Junctional rhythm</span></span></span></p>"
      },
      {
        "id": 239504,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mobitz type 2 second-degree atrioventricular block</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 64-year-old woman is evaluated in the emergency department following an episode of syncope. ECG is shown. Which of the following abnormalities is demonstrated on this patient&#39;s ECG?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-184453.png\" style=\"height:210px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q4458388",
    "question_audio": null,
    "question_video": null,
    "map_id": 26934,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Junctional rhythm</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The ECG shown demonstrates a junctional rhythm, or atrioventricular nodal rhythm. Junctional rhythms are regular supraventricular rhythms in which the P wave in lead II is negative (preceding or following the QRS complex) or absent (arrows). An atrioventricular nodal escape rhythm occurs when the junctional rate is between 40/min and 60/min and the sinoatrial node is delayed or fails to function as the pacemaker. An accelerated junctional rhythm occurs when the junctional rate is between 61/min and 99/min and the junctional rate takes over the pacemaker function. Junctional tachycardia occurs when the junctional rate is faster than 99/min and takes over the pacemaker function.</span></span></span></p>",
    "correct_choice_id": 239503,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60051,
    "choices": [
      {
        "id": 239505,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monomorphic ventricular tachycardia</span></span></span></p>"
      },
      {
        "id": 239506,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right bundle branch block with aberrancy</span></span></span></p>"
      },
      {
        "id": 239507,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Torsades de pointes</span></span></span></p>"
      },
      {
        "id": 239508,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ventricular fibrillation</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old man is evaluated in the emergency department for rapid heart rate and dizziness. He was recently started on levofloxacin for community-acquired pneumonia. A telemetry rhythm strip is shown. Which of the following abnormalities is seen on this patient&#39;s telemetry rhythm strip?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-184630.png\" style=\"height:86px; width:400px\" /></span></span></p>",
    "unique_key": "Q8383021",
    "question_audio": null,
    "question_video": null,
    "map_id": 26935,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Torsades de pointes</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient&#39;s telemetry rhythm strip demonstrates torsades de pointes, a polymorphic ventricular tachycardia. The torsades de pointes pattern is associated with QT interval prolongation and is characterized by an undulating QRS pattern that seems to twist across the baseline. This tracing also shows the initiation of ventricular tachycardia with a premature ventricular complex occurring during the repolarization phase of the previous QRS complex (&ldquo;R-on-T&rdquo; event). Macrolides and quinolones may prolong the QT interval, and alternative agents should be considered in patients at risk for torsades de pointes, including history of a long QT interval or use of other medications that prolong the QT interval.</span></span></span></p>",
    "correct_choice_id": 239507,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60052,
    "choices": [
      {
        "id": 239509,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early repolarization</span></span></span></p>"
      },
      {
        "id": 239510,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inferior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 239511,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non&ndash;ST-elevation myocardial infarction</span></span></span></p>"
      },
      {
        "id": 239512,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pericarditis</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman is evaluated for dyspnea associated with nausea and diaphoresis. ECG is shown. Which of the following abnormalities is demonstrated on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-184819.png\" style=\"height:223px; width:400px\" /></span></span></p>",
    "unique_key": "Q5034763",
    "question_audio": null,
    "question_video": null,
    "map_id": 26936,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><strong><span style=\"font-size:12.0pt\"> B) Inferior myocardial infarction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG shows an acute inferior myocardial infarction, with ST-segment elevations in the inferior leads (II, III, and aVF) and reciprocal changes (ST-segment depressions) in lead aVL. There is also subtle ST elevation in leads V5 through V6.</span></span></span></p>",
    "correct_choice_id": 239510,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60053,
    "choices": [
      {
        "id": 239513,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial tachycardia</span></span></span></p>"
      },
      {
        "id": 239514,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular nodal reentrant tachycardia</span></span></span></p>"
      },
      {
        "id": 239515,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrioventricular reciprocating tachycardia</span></span></span></p>"
      },
      {
        "id": 239516,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus tachycardia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman is evaluated for a &ldquo;racing heart&rdquo; sensation. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185004.png\" style=\"height:235px; width:500px\" /></span></span></p>",
    "unique_key": "Q9507075",
    "question_audio": null,
    "question_video": null,
    "map_id": 26937,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Sinus tachycardia</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis is sinus tachycardia. This ECG demonstrates sinus tachycardia, defined as a sinus rhythm (a normal P-wave axis with an upright P wave in lead II and a constant PR interval) with a heart rate of 100/min or faster. The consistent and normal P wave morphology makes the other answer options less likely.</span></span></span></p>",
    "correct_choice_id": 239516,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60054,
    "choices": [
      {
        "id": 239517,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brugada syndrome</span></span></span></p>"
      },
      {
        "id": 239518,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertrophic cardiomyopathy</span></span></span></p>"
      },
      {
        "id": 239519,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long QT syndrome</span></span></span></p>"
      },
      {
        "id": 239520,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neurocardiogenic syncope</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 23-year-old woman is evaluated for recurrent episodes of syncope. She is otherwise well and takes no medications. ECG is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185143.png\" style=\"height:224px; width:400px\" /></span></span></p>",
    "unique_key": "Q4327994",
    "question_audio": null,
    "question_video": null,
    "map_id": 26938,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Long QT syndrome</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates long QT syndrome. A quick way to assess whether the QT interval is prolonged is to note whether the QT interval exceeds half of the R-R interval, as is evident in this patient&#39;s ECG. The QT interval depends on heart rate; if the heart rate is between 60/min and 100/min, the corrected QT interval (QTc) is determined by dividing the actual QT interval by the square root of the R-R interval (in seconds). QTc intervals of 450 ms or less in men and 460 ms or less in women are considered normal. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Long QT syndrome can be acquired or congenital. In adults, the most common causes are drugs, including methadone, fluoroquinolones, antiarrhythmics, and psychotropics.</span></span></span></p>",
    "correct_choice_id": 239519,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60055,
    "choices": [
      {
        "id": 239521,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Idioventricular rhythm</span></span></span></p>"
      },
      {
        "id": 239522,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mobitz type 2 second-degree heart block</span></span></span></p>"
      },
      {
        "id": 239523,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinus bradycardia</span></span></span></p>"
      },
      {
        "id": 239524,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Third-degree heart block</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 79-year-old woman is evaluated for fatigue and bradycardia. ECG is shown. Which of the following abnormalities is seen on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185318.png\" style=\"height:144px; width:400px\" /></span></span></p>",
    "unique_key": "Q4496773",
    "question_audio": null,
    "question_video": null,
    "map_id": 26939,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Third-degree heart block</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;This ECG demonstrates third-degree heart block, which is characterized electrocardiographically by dissociation between the P waves and the QRS complexes. P waves discharge at their inherent rate but cannot be conducted to the ventricles. If the QRS complexes are narrow, the heart block is usually at the level of the His bundle. If the QRS complexes are wide, the heart block is lower (below the His bundle), and the rate will be between 30/min and 40/min.</span></span></span></p>",
    "correct_choice_id": 239524,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60056,
    "choices": [
      {
        "id": 239525,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial septal defect</span></span></span></p>"
      },
      {
        "id": 239526,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lown-Ganong-Levine pattern</span></span></span></p>"
      },
      {
        "id": 239527,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patent foramen ovale</span></span></span></p>"
      },
      {
        "id": 239528,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Wolff-Parkinson-White pattern</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 31-year-old woman is evaluated for episodes of palpitations. ECG is shown. Which of the following abnormalities or underlying conditions is responsible for the changes on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185505.png\" style=\"height:211px; width:400px\" /></span></span></p>",
    "unique_key": "Q4878876",
    "question_audio": null,
    "question_video": null,
    "map_id": 26940,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Wolff-Parkinson-White pattern</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Wolff-Parkinson-White pattern, which is characterized by QRS widening, a delta wave, and a short PR interval, is responsible for the findings on this patient&#39;s ECG. In Wolff-Parkinson-White pattern, an accessory pathway bypasses the atrioventricular node and causes preexcitation, resulting in the short PR interval and delta wave at the beginning of the QRS complex. In this ECG, positive delta waves (initial upsloping of the QRS complex) with a short PR interval are seen in leads I, II, and aVL and precordial leads V2 through V6. Negative delta waves (an initial negative deflection) are seen in leads III, aVF, and aVR, giving the appearance of an inferior infarct pattern. Patients with evidence of preexcitation on their resting ECG and symptomatic supraventricular tachycardia have Wolff-Parkinson-White syndrome.</span></span></span></p>",
    "correct_choice_id": 239528,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60057,
    "choices": [
      {
        "id": 239529,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">First-degree atrioventricular block</span></span></span></p>"
      },
      {
        "id": 239530,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal sinus rhythm</span></span></span></p>"
      },
      {
        "id": 239531,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sick sinus syndrome</span></span></span></p>"
      },
      {
        "id": 239532,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sinoatrial nodal exit block</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 51-year-old man is evaluated for syncope after prolonged standing in a warm environment. ECG is shown. Which of the following ECG findings is shown?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185636.png\" style=\"height:123px; width:400px\" /></span></span></p>",
    "unique_key": "Q5164784",
    "question_audio": null,
    "question_video": null,
    "map_id": 26941,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>A) First-degree atrioventricular block</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">First-degree atrioventricular block is characterized by a prolonged PR interval (&ge;200 ms), as seen on this patient&#39;s ECG. It is usually a benign condition and does not require intervention. It is most commonly secondary to medications that slow atrioventricular node conduction, degeneration of the node, infiltrative cardiomyopathies, or, as in this case, high vagal tone.</span></span></span></p>",
    "correct_choice_id": 239529,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60058,
    "choices": [
      {
        "id": 239533,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bifascicular block conduction delay</span></span></span></p>"
      },
      {
        "id": 239534,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left anterior fascicular block</span></span></span></p>"
      },
      {
        "id": 239535,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left posterior fascicular block</span></span></span></p>"
      },
      {
        "id": 239536,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right bundle branch block</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 57-year-old woman with peripheral artery disease is evaluated prior to elective cholecystectomy. ECG is shown. Which of the following is the most likely electrocardiographic diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185806.png\" style=\"height:130px; width:400px\" /></span></span></p>",
    "unique_key": "Q7905464",
    "question_audio": null,
    "question_video": null,
    "map_id": 26942,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Left posterior fascicular block</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates left posterior fascicular block, which occurs when conduction system disease involves the posterior fascicle of the left bundle branch. It is defined as a pathologic right axis (&gt;+90 degrees) with no other cause (such as right ventricular hypertrophy). The QRS duration is less than 120 ms with a negative QRS complex (small R wave and deep S wave) in leads I and aVL and a qR pattern in leads III and aVF. Left anterior fascicular block is recognized by a positive QRS complex in lead I and a negative QRS complex in lead aVF. Right bundle branch conduction disturbance combined with anterior or posterior left bundle branch block is called bifascicular block.</span></span></span></p>",
    "correct_choice_id": 239535,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased"
    ]
  },
  {
    "id": 60059,
    "choices": [
      {
        "id": 239537,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute posterior myocardial infarction</span></span></span></p>"
      },
      {
        "id": 239538,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Brugada pattern</span></span></span></p>"
      },
      {
        "id": 239539,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Left ventricular hypertrophy</span></span></span></p>"
      },
      {
        "id": 239540,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right ventricular hypertrophy</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following conditions is demonstrated on this electrocardiogram?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-185926.png\" style=\"height:138px; width:400px\" /></span></span></p>",
    "unique_key": "Q8121136",
    "question_audio": null,
    "question_video": null,
    "map_id": 26943,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>D) Right ventricular hypertrophy</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This electrocardiogram demonstrates right ventricular hypertrophy. Electrocardiographic features characteristic of right ventricular hypertrophy include the following:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Evidence of right atrial enlargement</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right axis deviation or indeterminate axis</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Incomplete right bundle branch block (or an rSr&rsquo; in lead V1)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low voltage</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Persistent precordial S waves</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Right ventricular strain pattern</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tall R wave in lead V1</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of several of these features supports a diagnosis of right ventricular hypertrophy. Features in this electrocardiogram include right axis deviation, persistent precordial S waves, a right ventricular strain pattern with downward concave ST-T&ndash;wave abnormality in V1&ndash;V3, and a tall R wave in lead V1.</span></span></span></p>",
    "correct_choice_id": 239540,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 60060,
    "choices": [
      {
        "id": 239541,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Hypercalcemia</span></span></span></p>"
      },
      {
        "id": 239542,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Hyperkalemia</span></span></span></p>"
      },
      {
        "id": 239543,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\">Hypocalcemia</span></span></span></p>"
      },
      {
        "id": 239544,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothermia</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following is the most likely cause of the findings on this electrocardiogram?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-190037.png\" style=\"height:196px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q9521633",
    "question_audio": null,
    "question_video": null,
    "map_id": 26944,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>C) Hypocalcemia</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypocalcemia is the most likely cause of these electrocardiographic findings. Hypocalcemia typically causes prolongation of the QT interval due to an increase in the second phase of the ventricular action potential. QT prolongation may predispose the patient to ventricular arrhythmias and high-grade heart block.</span></span></span></p>",
    "correct_choice_id": 239543,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 60061,
    "choices": [
      {
        "id": 239545,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atenolol </span></span></span></p>"
      },
      {
        "id": 239546,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Electrophysiology (EP) study </span></span></span></p>"
      },
      {
        "id": 239547,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flecainide </span></span></span></p>"
      },
      {
        "id": 239548,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Verapamil</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman experiences intermittent palpitations, shortness of breath, and light headedness. ECG is shown. Echocardiogram is normal. What is the most appropriate next step in management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-190157.png\" style=\"height:263px; width:400px\" /></span></span></p>",
    "unique_key": "Q5900107",
    "question_audio": null,
    "question_video": null,
    "map_id": 26945,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.</span></strong><span style=\"font-size:12.0pt\"> <strong>B) Electrophysiology (EP) study</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECG shows short PR interval and delta wave in multiple leads which is characteristic of Wolff-Parkinson-White (WPW) syndrome. An EP study is necessary to determine the risk of sudden cardiac death and to consider ablation of the accessory pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A. Atenolol and D. Verapamil (AV nodal blockers):</span></strong><span style=\"font-size:12.0pt\"> These medications are atrioventricular nodal blockers and may be unsafe if the patient has anterograde conduction down the accessory pathway during atrial fibrillation. These drugs promote rapid 1:1 conduction from the atria to the ventricles over the accessory pathway during atrial fibrillation, which can lead to very rapid ventricular rates and ventricular fibrillation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Flecainide:</span></strong><span style=\"font-size:12.0pt\"> It is an antiarrhythmic drug that is frequently used to treat paroxysmal atrial fibrillation and other arrhythmias. Flecainide is not indicated in this patient because the type and mechanism of the arrhythmia are unknown. This patient requires risk stratification, which can be accomplished with an electrophysiology study.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;In patients with suspected WPW syndrome, an EP study is indicated to assess arrhythmia risk and consider ablation of the accessory pathway.</span></span></span></p>",
    "correct_choice_id": 239546,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 60062,
    "choices": [
      {
        "id": 239549,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dobutamine echocardiography </span></span></span></p>"
      },
      {
        "id": 239550,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiography</span></span></span></p>"
      },
      {
        "id": 239551,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prophylactic pacemaker insertion </span></span></span></p>"
      },
      {
        "id": 239552,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No further testing or intervention</span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 81-year-old man with a history of hypertension and osteoarthritis is scheduled for elective hip arthroplasty. He is asymptomatic and has no history of cardiovascular disease. His ECG is shown. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/05/screenshot-2024-10-05-190419.png\" style=\"height:228px; width:400px\" /></span></span></p>",
    "unique_key": "Q1700728",
    "question_audio": null,
    "question_video": null,
    "map_id": 26946,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. </span></strong><strong><span style=\"font-size:12.0pt\">D) No further testing or intervention</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient is having an asymptomatic Tri-fascicular block (RBBB + left posterior fascicular block + first-degree AV block) and it does not require further testing or intervention before elective surgery. The risk of progression to complete heart block is low (less than 2-3% per year).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dobutamine echocardiography:</span></strong><span style=\"font-size:12.0pt\"> Not indicated as there are no signs or symptoms of heart failure or ischemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Echocardiography:</span></strong><span style=\"font-size:12.0pt\"> Not necessary as the ECG findings are not suggestive of structural heart disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Prophylactic pacemaker insertion:</span></strong><span style=\"font-size:12.0pt\"> Not indicated in asymptomatic patients with bifascicular block and first-degree AV block.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Asymptomatic Tri-fascicular block does not require pacemaker implantation</span></span></span></p>",
    "correct_choice_id": 239552,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6814,
    "choices": [
      {
        "id": 27225,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Hospital admission </span></span></p>"
      },
      {
        "id": 27226,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Pacemaker implantation </span></span></p>"
      },
      {
        "id": 27227,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Switch lisinopril to amlodipine </span></span></p>"
      },
      {
        "id": 27228,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Reassurance and clinical monitoring</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 84-year-old man presents with fatigue and loss of energy. His ECG is shown. Upon vigorous exercise his heart rate reaches a maximum of 72/min. What is the most appropriate management?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-091643.png\" style=\"height:139px; width:300px\" /></span></span></p>",
    "unique_key": "Q2417207",
    "question_audio": null,
    "question_video": null,
    "map_id": 19761,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Pacemaker implantation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has sinus nide dysfunction and he is symptomatic. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Symptomatic bradycardia, especially with an inadequate heart rate response to exercise, often requires pacemaker implantation to improve quality of life and prevent complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hospital admission:</span></strong><span style=\"font-size:12.0pt\"> Not necessary unless the patient is hemodynamically unstable. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Switching medications:</span></strong><span style=\"font-size:12.0pt\"> Unlikely to address the underlying bradycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Reassurance and monitoring:</span></strong><span style=\"font-size:12.0pt\"> Inadequate for symptomatic bradycardia with potential for adverse outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treat a patient with symptomatic bradycardia.</span></span></span></p>",
    "correct_choice_id": 27226,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6815,
    "choices": [
      {
        "id": 27229,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Left atrial appendage occlusion </span></span></p>"
      },
      {
        "id": 27230,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Pacemaker implantation </span></span></p>"
      },
      {
        "id": 27231,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Rhythm control </span></span></p>"
      },
      {
        "id": 27232,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">No additional therapy</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 70-year-old man with history of hypertension and stroke has been diagnosed with mildly symptomatic paroxysmal AF. He is currently taking rivaroxaban and metoprolol. What is the most appropriate treatment?</span></span></span></p>",
    "unique_key": "Q9625805",
    "question_audio": null,
    "question_video": null,
    "map_id": 19762,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Rhythm control</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early rhythm control (antiarrhythmic drugs or ablation) has been shown to reduce cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome in patients with recent-onset AF and cardiovascular comorbidities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Left atrial appendage occlusion:</span></strong><span style=\"font-size:12.0pt\"> Indicated for stroke prevention in non-valvular AF but not the primary treatment for rhythm control. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pacemaker implantation: </span></strong><span style=\"font-size:12.0pt\">Not indicated for paroxysmal AF without symptomatic bradycardia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. No additional therapy:</span></strong><span style=\"font-size:12.0pt\"> Early rhythm control is recommended for this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with recently diagnosed atrial fibrillation and concomitant cardiovascular conditions, early rhythm control (antiarrhythmic drugs or ablation) reduces the primary composite end point of cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome compared with usual care.</span></span></span></p>",
    "correct_choice_id": 27231,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6816,
    "choices": [
      {
        "id": 27233,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Amiodarone </span></span></p>"
      },
      {
        "id": 27234,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Catheter ablation </span></span></p>"
      },
      {
        "id": 27235,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Flecainide </span></span></p>"
      },
      {
        "id": 27236,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;Metoprolol</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 56-year-old man with hypertension presents with acute shortness of breath, hypotension and palpitations. He has jugular venous distention and pulmonary crackles. ECG was done and is shown below. After successful cardioversion, what is the best treatment?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-091936.png\" style=\"height:276px; width:500px\" /></span></span></p>",
    "unique_key": "Q4730483",
    "question_audio": null,
    "question_video": null,
    "map_id": 19763,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Catheter ablation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and ECG findings are consistent with atrial flutter, a type of supraventricular tachycardia. Catheter ablation is the most appropriate additional treatment because it offers a high success rate (&gt;95%) and a low complication rate. It is considered the first-line therapy for typical atrial flutter.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Amiodarone: &nbsp;</span></strong><span style=\"font-size:12.0pt\">Antiarrhythmic drug that can be used for atrial flutter, but catheter ablation is more definitive. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Flecainide: </span></strong><span style=\"font-size:12.0pt\">&nbsp;&nbsp;Another antiarrhythmic drug, but catheter ablation is preferred. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metoprolol: &nbsp;</span></strong><span style=\"font-size:12.0pt\">Beta-blocker, primarily used for rate control, not as effective for rhythm control in atrial flutter. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catheter ablation is the definitive treatment for typical atrial flutter due to its high success rate and low complication rate.</span></span></span></p>",
    "correct_choice_id": 27234,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6817,
    "choices": [
      {
        "id": 27237,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Exercise ECG </span></span></p>"
      },
      {
        "id": 27238,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Implantable loop recorder </span></span></p>"
      },
      {
        "id": 27239,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Holter Monitoring </span></span></p>"
      },
      {
        "id": 27240,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">30-day event monitor</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 26-year-old woman presents with recurrent palpitations lasting 5-15 minutes, occue a few times per month and relieved by rest or deep breathing. The resting ECG is normal. What is the most appropriate diagnostic test?</span></span></p>",
    "unique_key": "Q9383591",
    "question_audio": null,
    "question_video": null,
    "map_id": 19764,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) 30-day event monitor</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-day event monitor is the most appropriate initial test for capturing infrequent and symptomatic arrhythmias (occurring less than daily but occurring over a month). The patient can activate the monitor when symptoms occur, provided that the symptoms last long enough to be captured by the device&#39;s active and retrospective capture. Symptoms that last longer than 1 to 2 minutes are ideally suited for event monitors</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Exercise ECG: </span></strong><span style=\"font-size:12.0pt\">Not indicated for evaluating palpitations occurring at rest. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Implantable loop recorder:</span></strong><span style=\"font-size:12.0pt\"> Reserved for very infrequent or unexplained syncope (which prevents the patient from triggering the devices). Records symptomatic and asymptomatic events (brady/tachy) over a very long period (months to years).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Holter monitoring</span></strong><span style=\"font-size:12.0pt\">: &nbsp;Usually records electrical activity continuously for 24-28 hours and most suited for patients with more frequent symptoms (e.g., daily). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 30-day event monitor is most appropriate for evaluating patients with palpitations who have symptoms that occur less than daily but frequently over the course of a month.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">An implantable looping event recorder is most appropriate for infrequent or highly symptomatic arrhythmias in which the symptoms might preclude a patient from activating the device, such as syncope.</span></span></span></p>",
    "correct_choice_id": 27240,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 6819,
    "choices": [
      {
        "id": 27245,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Brugada syndrome </span></span></p>"
      },
      {
        "id": 27246,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Coronary artery disease </span></span></p>"
      },
      {
        "id": 27247,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Long QT syndrome </span></span></p>"
      },
      {
        "id": 27248,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Vasovagal syncope</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old man presents with recurrent syncope without prodrome. His father died suddenly at age 45. ECG is shown. Physical examination and 2D Echo is normal. What is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-092311.png\" style=\"height:194px; width:500px\" /></span></span></p>",
    "unique_key": "Q7168209",
    "question_audio": null,
    "question_video": null,
    "map_id": 19766,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Brugada syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of recurrent syncope, family history of sudden death, and the characteristic ECG findings of coved ST-segment elevation in V1-V3 strongly suggest Brugada syndrome, a genetic disorder that predisposes to ventricular arrhythmias and sudden cardiac death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Coronary artery disease: </span></strong><span style=\"font-size:12.0pt\">Unlikely in a young patient with no risk factors and normal ECG findings. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Long QT syndrome:</span></strong><span style=\"font-size:12.0pt\"> ECG would show a prolonged QT interval, not the Brugada pattern. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vasovagal syncope:</span></strong><span style=\"font-size:12.0pt\"> Typically has prodromal symptoms (lightheadedness, nausea) and normal ECG.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cardiovascular syncopal events often occur suddenly and usually without a significant prodrome, although chest pain and palpitations may be present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Causes of cardiovascular syncope include cardiac arrhythmia; coronary artery disease; and structural and obstructive disease, including aortic and pulmonary valve stenosis, obstructive hypertrophic cardiomyopathy, aortic dissection, and cardiac tamponade.</span></span></span></p>",
    "correct_choice_id": 27245,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6820,
    "choices": [
      {
        "id": 27249,
        "text": "<p><span style=\"font-size:11pt;\">Add aspirin</span></p>"
      },
      {
        "id": 27250,
        "text": "<p><span style=\"font-size:11pt;\">Increase metoprolol dose</span></p>"
      },
      {
        "id": 27251,
        "text": "<p><span style=\"font-size:11pt;\">Initiate oral anticoagulation</span></p>"
      },
      {
        "id": 27252,
        "text": "<p><span style=\"font-size:11pt;\">Reassurance</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">A 76-year-old woman presents with palpitations. Her ECG is shown. She is a known diabetic and hypertensive and currently taking metformin and metoprolol. What is the most appropriate management?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-092619.png\" alt=\"\" width=\"500\" height=\"261\"></span></p>",
    "unique_key": "Q3593297",
    "question_audio": null,
    "question_video": null,
    "map_id": 19767,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>C) Initiate oral anticoagulation</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This patient has an AF with controlled rate (78/min). Patients with nonvalvular AF and a CHA2DS2-VASc score \u2265 2 in men or \u2265 3 in women should be initiated on oral anticoagulation for stroke prevention (this patient has a CHA2DS2-VASc score of 4).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Aspirin: </strong>Insufficient for stroke prevention in high-risk patients.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Increase metoprolol dosage:</strong> Not necessary as the ventricular rate is controlled.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Reassurance:</strong> Inappropriate as the patient is at high risk for stroke.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In stable patients with atrial fibrillation, the primary goals of therapy are to (1) prevent stroke, (2) control heart rate, (3) minimize or eliminate symptoms, and (4) modify underlying risk factors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Anticoagulation is indicated for stroke prevention in patients with nonvalvular atrial fibrillation who have a CHA2DS2-VASc score of 2 or greater in men or 3 or greater in women.</span></p>",
    "correct_choice_id": 27251,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6821,
    "choices": [
      {
        "id": 27253,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Cardiac MRI with stress perfusion</span></span></p>"
      },
      {
        "id": 27254,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Electrophysiology (EP) study</span></span></p>"
      },
      {
        "id": 27255,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Implantable cardioverter-defibrillator (ICD)</span></span></p>"
      },
      {
        "id": 27256,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Implantable loop recorder (ILR)</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 42-year-old man presents with palpitations and lightheadedness. He was having significant work pressure over the last 2 weeks and he has not been sleeping well. ECG showed VT and he is successfully cardioverted in the ER. Echocardiogram is normal. What is the most appropriate initial management?</span></span></span></p>",
    "unique_key": "Q8720335",
    "question_audio": null,
    "question_video": null,
    "map_id": 19768,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Cardiac magnetic resonance imaging (MRI) with stress perfusion</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Idiopathic VT typically manifests as palpitations in the third to fifth decades of life, often triggered by stress, emotion, or sleeplessness. Sudden death is rare. </span><span style=\"font-size:12.0pt\">Before making a diagnosis of idiopathic VT, structural heart disease has to be ruled out. First test for structural heart disease would be echocardiogram and in patients with normal echo, cardiac MRI with stress perfusion is recommended to rule out subtle structural abnormalities (e.g., cardiomyopathies) that could be the cause of the arrhythmia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Most idiopathic VT originate in the RV outflow tract, which gives rise to VT that has a LBBB morphology in V1 and an axis that is directed inferiorly, with tall R waves in II, III, and aVF. Idiopathic VT can also arise in the left ventricular outflow tract or in sleeves of myocardium that extend along the aortic root. Left ventricular origin is suspected when leads V1 or V2 have prominent R waves.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. EP study:</span></strong><span style=\"font-size:12.0pt\"> May be indicated later if diagnosis of sustained VT is in doubt or if ablation is being considered (to localize the arrhythmogenic focus).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ICD:</span></strong><span style=\"font-size:12.0pt\"> May be considered if there is VT + structural heart disease or HF with EF &le; 35%. In idiopathic VT, it is unnecessary. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ILR:</span></strong> <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It would be premature to consider ILR placement before assessment for structural heart disease. An ILR may be valuable to assess rare recurrences of arrhythmia and/or to assess symptoms, but further evaluation is needed first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac MRI with stress perfusion is a valuable tool for evaluating the underlying cause of VT in patients with structurally normal hearts on echocardiography.</span></span></span></p>",
    "correct_choice_id": 27253,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6822,
    "choices": [
      {
        "id": 27257,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Complete heart block</span></span></p>"
      },
      {
        "id": 27258,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">High-grade atrioventricular block</span></span></p>"
      },
      {
        "id": 27259,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Mobitz type 1 second-degree atrioventricular block</span></span></p>"
      },
      {
        "id": 27260,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Mobitz type 2 second-degree atrioventricular block</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old man is evaluated in the emergency department for an irregular heart rhythm. He is otherwise asymptomatic. A representative sample from an ECG rhythm strip is shown. Which of the following abnormalities is seen on this patient&#39;s ECG?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-092929.png\" style=\"height:66px; width:400px\" /></span></span></p>",
    "unique_key": "Q8155966",
    "question_audio": null,
    "question_video": null,
    "map_id": 19769,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Mobitz type 1 second-degree atrioventricular block</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This ECG demonstrates Mobitz type 1 second-degree (Wenckebach) atrioventricular block, which is characterized electrocardiographically by a PR interval that progressively prolongs until, eventually, the beat is dropped. In the tracing shown, the PR interval widens over the first six beats and no ventricular complex follows the seventh atrial beat.</span></span></span></p>",
    "correct_choice_id": 27259,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6823,
    "choices": [
      {
        "id": 27261,
        "text": "<p><span style=\"font-size:11pt;\">Administer 100% oxygen by NRBM</span></p>"
      },
      {
        "id": 27262,
        "text": "<p><span style=\"font-size:11pt;\">Administer procainamide IV</span></p>"
      },
      {
        "id": 27263,
        "text": "<p><span style=\"font-size:11pt;\">Administer 1 g calcium gluconate IV</span></p>"
      },
      {
        "id": 27264,
        "text": "<p><span style=\"font-size:11pt;\">Unsynchronized defibrillation with 200 J</span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt;\">An 81-year-old man is evaluated in the emergency department for chest pain. During the evaluation, he becomes unresponsive and pulseless. ECG is shown. what is the next best step in the management&nbsp;of&nbsp;this&nbsp;patient?</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-093042.png\" alt=\"\" width=\"400\" height=\"187\"></span></p>",
    "unique_key": "Q5620988",
    "question_audio": null,
    "question_video": null,
    "map_id": 19770,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>D) Unsynchronized defibrillation with 200 J</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This patient is in ventricular fibrillation. Immediate defibrillation&nbsp; is required and treatment should proceed along advanced cardiac life support protocol. Defibrillation in this case should precede administration of oxygen. Medications will not be effective in the absence of circulation.</span></p>",
    "correct_choice_id": 27264,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6824,
    "choices": [
      {
        "id": 27265,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Hypocalcemia</span></span></p>"
      },
      {
        "id": 27266,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Hypokalemia</span></span></p>"
      },
      {
        "id": 27267,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Hypophosphatemia</span></span></p>"
      },
      {
        "id": 27268,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Hypothermia</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following disorders could account for the findings on the rhythm strip of a homeless man who was found unresponsive on the street?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-093143.png\" style=\"height:70px; width:400px\" /></span></span></p>",
    "unique_key": "Q2066701",
    "question_audio": null,
    "question_video": null,
    "map_id": 19771,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Hypothermia</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothermia most likely accounts for the findings&nbsp;shown&nbsp;on this electrocardiogram. In hypothermia, all of the electrocardiographic intervals are prolonged, including the PR interval, the QRS complex, the QT interval, and the R-R interval, owing to slowed impulse conduction through potassium channels. In addition, the J point is elevated, producing a characteristic J wave (Osborn wave) that represents distortion of the earliest phase of membrane repolarization. These changes are most prominent in the precordial leads V2&nbsp;through V5. This electrocardiogram demonstrates Osborn waves (arrows).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-093206.png\" style=\"height:99px; width:500px\" /></p>",
    "correct_choice_id": 27268,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6825,
    "choices": [
      {
        "id": 27269,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Dual chamber Pacemaker</span></span></p>"
      },
      {
        "id": 27270,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Single chamber pacemaker</span></span></p>"
      },
      {
        "id": 27271,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">CRT device</span></span></p>"
      },
      {
        "id": 27272,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Swan Ganz catheter</span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following diagnoses is most consistent with the radiographic findings shown?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-112453.png\" style=\"height:195px; width:400px\" /></span></span></p>",
    "unique_key": "Q5689864",
    "question_audio": null,
    "question_video": null,
    "map_id": 19772,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Dual chamber Pacemaker</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The radiographic image shows leads in the right atrium (RA) and right ventricle (RV), consistent with a dual chamber pacemaker. This type of pacemaker is used to provide electrical stimulation to both the atrium and the ventricle, helping to coordinate the heart&#39;s rhythm. This patient in addition has features of pulmonary edema as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B. Single chamber pacemaker:</span></strong><span style=\"font-size:12.0pt\"> A single chamber pacemaker has only one lead, typically in the RV. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. CRT device:</span></strong><span style=\"font-size:12.0pt\"> A CRT device would include an additional lead positioned to pace the left ventricle via the coronary sinus, which is not seen in this image. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Swan Ganz catheter:</span></strong><span style=\"font-size:12.0pt\"> A Swan-Ganz catheter, used for measuring hemodynamic parameters, is not an implantable device and would appear as a different configuration on imaging.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A dual chamber pacemaker has leads placed in both the right atrium and right ventricle. This device is used to maintain coordinated atrial and ventricular pacing in patients with specific types of heart block or other cardiac rhythm disturbances.</span></span></span></p>",
    "correct_choice_id": 27269,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6826,
    "choices": [
      {
        "id": 27273,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Urgent transcutaneous pacing</span></span></p>"
      },
      {
        "id": 27274,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Urgent transvenous pacing</span></span></p>"
      },
      {
        "id": 27275,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Atropine 0.5 mg IV push</span></span></p>"
      },
      {
        "id": 27276,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Emergency defibrillation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old gentleman presents with complaints of dizziness and one episode of syncope. On examination, you notice a pulse rate of around 38/min and blood pressure of approximately 88/56 mmHg. What will be your next step in management?</span></span></p>",
    "unique_key": "Q2701187",
    "question_audio": null,
    "question_video": null,
    "map_id": 19773,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C)&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Atropine 0.5 mg IV push</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is experiencing symptomatic bradycardia with hemodynamic compromise (hypotension and syncope). While the exact cause of the bradycardia is unknown without an ECG, the initial management should focus on increasing the heart rate to stabilize the patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atropine is a parasympatholytic agent that can quickly increase heart rate in cases of symptomatic bradycardia. It is a reasonable first-line treatment in this scenario, as it can be administered rapidly and may be effective if the bradycardia is caused by excessive vagal tone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Management of bradycardia with a pulse (ACLS) is given below. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Urgent transcutaneous pacing:</strong> While TCP may be necessary if atropine is ineffective or if the bradycardia is due to complete heart block, it is not the initial treatment of choice in this situation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Urgent transvenous pacing:</span></strong><span style=\"font-size:12.0pt\"> Similar to TCP, transvenous pacing is a more definitive treatment but is not the immediate priority in an unstable patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Emergency defibrillation:</span></strong><span style=\"font-size:12.0pt\"> Defibrillation is indicated for ventricular fibrillation or pulseless ventricular tachycardia, not for bradycardia with a pulse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Symptomatic bradycardia with hemodynamic instability is a medical emergency. Initial treatment as per ACLS protocol is atropine administration. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/picture1.jpg\" style=\"height:859px; width:700px\" /></span></span></span></p>",
    "correct_choice_id": 27275,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 6827,
    "choices": [
      {
        "id": 27277,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">PR varying </span></span></p>"
      },
      {
        "id": 27278,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Wide QRS </span></span></p>"
      },
      {
        "id": 27279,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Bundle branch block </span></span></p>"
      },
      {
        "id": 27280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Defect lies below AV node</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are true regarding Mobitz II block except?</span></span></span></p>",
    "unique_key": "Q8825356",
    "question_audio": null,
    "question_video": null,
    "map_id": 19774,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) PR varying</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In Mobitz II second-degree heart block, the PR interval remains constant before the dropped beat. This is a key distinguishing feature from Mobitz I (Wenckebach), where the PR interval progressively lengthens before the dropped beat.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Wide QRS:</span></strong><span style=\"font-size:12.0pt\"> This is often present in Mobitz II due to the block occurring below the AV node, affecting the His-Purkinje system.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bundle branch block:</span></strong><span style=\"font-size:12.0pt\"> Mobitz II is frequently associated with bundle branch block as the block occurs within the bundle branches or more distally in the conduction system.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Defect lies below AV node:</span></strong><span style=\"font-size:12.0pt\"> The conduction defect in Mobitz II is located below the AV node, typically in the His-Purkinje system.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mobitz II second-degree block is associated with a constant PR interval, wide QRS complex and bundle branch block due to the conduction defect located below the AV node.</span></span></span></p>",
    "correct_choice_id": 27277,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 6828,
    "choices": [
      {
        "id": 27281,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Carotid sinus massage </span></span></p>"
      },
      {
        "id": 27282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Adenosine </span></span></p>"
      },
      {
        "id": 27283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Cardioversion </span></span></p>"
      },
      {
        "id": 27284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">IV metoprolol</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old male presents with palpitations and giddiness for 2 hours. On arrival, BP is 80/60 mmHg. ECG is shown. What is the next step in management of this patient?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-093714.png\" style=\"height:272px; width:500px\" /></span></span></p>",
    "unique_key": "Q4066841",
    "question_audio": null,
    "question_video": null,
    "map_id": 19775,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Cardioversion</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is presenting with hemodynamic instability (low blood pressure) due to AVNRT (atrioventricular nodal re-entrant tachycardia). In this scenario, the immediate goal is to restore normal sinus rhythm and stabilize the patient. Synchronized cardioversion is the most appropriate initial treatment for hemodynamically unstable tachyarrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Carotid sinus massage:</span></strong><span style=\"font-size:12.0pt\"> This maneuver can sometimes terminate AVNRT, but it is not recommended in the setting of hemodynamic instability due to the risk of further complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Adenosine:</span></strong><span style=\"font-size:12.0pt\"> Adenosine is a first-line agent for stable AVNRT, but it is contraindicated in patients with asthma or bronchospasm and may not be effective in cases of hemodynamic instability.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IV metoprolol:</span></strong><span style=\"font-size:12.0pt\"> Beta-blockers like metoprolol are used for rate control in AVNRT, but they should not be the initial treatment in hemodynamically unstable patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">&lsquo;</span></strong><span style=\"font-size:12.0pt\">If the patient is in shock, shock the patient !&rsquo;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/picture2.jpg\" style=\"height:708px; width:700px\" /></p>",
    "correct_choice_id": 27283,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 6829,
    "choices": [
      {
        "id": 27285,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">IV MgSO4 </span></span></p>"
      },
      {
        "id": 27286,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">IV lignocaine </span></span></p>"
      },
      {
        "id": 27287,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">IV amiodarone </span></span></p>"
      },
      {
        "id": 27288,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Defibrillation</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A pregnant lady G2P1L1 currently 37 weeks POG (period of gestation) presented with worsening headache, blurring of vision, reduced perception of fetal movements. On arrival, BP was 200/100 mmHg. ECG is shown. Which of the following is the best management?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-093914.png\" style=\"height:188px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q8364286",
    "question_audio": null,
    "question_video": null,
    "map_id": 19776,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) IV MgSO4</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ECG shows polymorphic VT (PMVT).<strong> </strong>MgSO4 is the first-line treatment for seizure prevention and treatment in pre-eclampsia and eclampsia. It also has antiarrhythmic properties and can be effective in terminating PMVT, particularly when associated with hypomagnesemia (which is common in pre-eclampsia).</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IV lignocaine:</span></strong><span style=\"font-size:12.0pt\"> While lidocaine is an antiarrhythmic, it is not effective in PMVT. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. IV amiodarone:</span></strong><span style=\"font-size:12.0pt\"> Amiodarone is effective for monomorphic VT but can prolong QTc interval and potentially can trigger PMVT. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Defibrillation:</span></strong><span style=\"font-size:12.0pt\"> Can be tried in case of unstable PMVT or if the patient is in cardiac arrest.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong><span style=\"font-size:12.0pt\">IV MgSO4 is the treatment of choice for stable PMVT.</span></span></span></p>",
    "correct_choice_id": 27285,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6830,
    "choices": [
      {
        "id": 27289,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">No anticoagulation required</span></span></p>"
      },
      {
        "id": 27290,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Warfarin for 4 weeks</span></span></p>"
      },
      {
        "id": 27291,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Long term Warfarin</span></span></p>"
      },
      {
        "id": 27292,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Anticoagulation is contraindicated</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 44-year-old patient with HCM presents with palpitations over the last 1 week. ECG showed AF. His CHA2DS2-Vasc score is 0. What is the treatment?</span></span></p>",
    "unique_key": "Q5417212",
    "question_audio": null,
    "question_video": null,
    "map_id": 19777,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Long-term Warfarin (or alternative anticoagulant)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AF is the most common sustained arrhythmia in patients with HCM. In patients with HCM and AF, anticoagulation is recommended regardless of their CHA2DS2-VASc score. This is because the risk of thromboembolic events (stroke, systemic embolism) is significantly increased in HCM patients with AF, independent of traditional risk factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While the CHA2DS2-VASc score is a useful tool for assessing stroke risk in general AF population, it is not studied in HCM population and should not be used. Therefore, current guidelines recommend long-term anticoagulation for all HCM patients with AF, even if their CHA2DS2-VASc score is 0.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. No anticoagulation required:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect as anticoagulation is strongly recommended for HCM patients with AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Warfarin for 4 weeks:</span></strong><span style=\"font-size:12.0pt\"> This is insufficient duration. Long-term anticoagulation is necessary for stroke prevention in HCM patients with AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Anticoagulation contraindicated:</span></strong><span style=\"font-size:12.0pt\"> This is incorrect. Anticoagulation is indicated for stroke prevention in HCM patients with AF.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><strong> </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF), long-term anticoagulation is recommended regardless of their CHA2DS2-VASc score due to the increased risk of thromboembolic events.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>",
    "correct_choice_id": 27291,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6831,
    "choices": [
      {
        "id": 27293,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Blood cultures </span></span></p>"
      },
      {
        "id": 27294,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Empiric therapy with cephalexin </span></span></p>"
      },
      {
        "id": 27295,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Pacemaker pocket aspiration </span></span></p>"
      },
      {
        "id": 27296,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">PET/CT scanning</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 71-year-old man with a pacemaker presents with malaise, fatigue, and localized discomfort at the pacemaker site and the appearance is shown in the image. He has no fever, chills, or weight loss. What is the most appropriate management?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-094129.png\" style=\"height:253px; width:300px\" /></span></span></p>",
    "unique_key": "Q8115540",
    "question_audio": null,
    "question_video": null,
    "map_id": 19778,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Blood cultures</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient has signs and symptoms suggestive of a possible cardiac device infection (fever, localized pain/discomfort). Blood cultures are the essential initial step in the evaluation of suspected device infection to identify the causative organism and guide appropriate antibiotic therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Empiric therapy with cephalexin:</span></strong><span style=\"font-size:12.0pt\"> Premature before confirming infection and identifying the causative organism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pacemaker pocket aspiration:</span></strong><span style=\"font-size:12.0pt\"> Not recommended as it can introduce infection into a previously sterile pocket. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. PET/CT scanning:</span></strong><span style=\"font-size:12.0pt\"> May be helpful later if the diagnosis is unclear, but blood cultures are the priority.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In all patients suspected of having infection of a cardiac implanted electronic device, a minimum of two blood cultures should be drawn from separate sites.</span></span></span></p>",
    "correct_choice_id": 27293,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 6832,
    "choices": [
      {
        "id": 27297,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Sick sinus syndrome </span></span></p>"
      },
      {
        "id": 27298,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Pacemaker syndrome </span></span></p>"
      },
      {
        "id": 27299,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Lead displacement </span></span></p>"
      },
      {
        "id": 27300,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Ventricular tachycardia</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 75-year-old patient with long-standing atrial fibrillation (AF) received a VVIR pacemaker. After a few months, he presents with dizziness, fatigue, and visible pulsations in the neck. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q1716418",
    "question_audio": null,
    "question_video": null,
    "map_id": 19779,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Pacemaker syndrome</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Pacemaker syndrome</span></strong><span style=\"font-size:12.0pt\"> is a collection of symptoms caused by a loss of atrioventricular (AV) synchrony due to ventricular pacing. This can occur in patients with single-chamber pacemakers (like VVIR) who have underlying sinus node dysfunction (as suggested by the history of AF).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms of pacemaker syndrome include:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Dizziness and fatigue:</span></strong><span style=\"font-size:12.0pt\"> Due to decreased cardiac output caused by loss of AV synchrony.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Visible neck pulsations:</span></strong><span style=\"font-size:12.0pt\"> Prominent irregular cannon A waves in the JVP due to atrial contraction against a closed tricuspid valve.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sick sinus syndrome:</span></strong><span style=\"font-size:12.0pt\"> Would not be associated with elevated JVP or cannon &lsquo;a&rsquo; waves. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lead displacement:</span></strong><span style=\"font-size:12.0pt\"> Lead displacement would likely cause pacing failure or erratic pacing, not the specific symptoms described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ventricular tachycardia:</span></strong><span style=\"font-size:12.0pt\"> This would present with a rapid, regular heart rhythm and different symptoms (palpitations, chest pain, syncope).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Pacemaker syndrome is a potential complication of single-chamber ventricular pacing (usually VVIR), and presents with dizziness and syncope due to AV dissociation.</span></span></span></p>",
    "correct_choice_id": 27298,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6833,
    "choices": [
      {
        "id": 27301,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Re-entry </span></span></p>"
      },
      {
        "id": 27302,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Delayed afterdepolarizations (DADs) </span></span></p>"
      },
      {
        "id": 27303,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Early afterdepolarizations (EADs) </span></span></p>"
      },
      {
        "id": 27304,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Enhanced automaticity</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most common mechanism of digitalis-induced ventricular arrhythmias?</span></span></p>",
    "unique_key": "Q9225576",
    "question_audio": null,
    "question_video": null,
    "map_id": 19780,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Delayed afterdepolarizations (DADs)</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Digitalis toxicity leads to an increase in intracellular calcium levels within cardiac myocytes. This calcium overload triggers abnormal electrical impulses known as delayed afterdepolarizations (DADs) that occur during phase 4 of action potential. These DADs can reach a threshold and initiate ectopic beats, leading to various ventricular arrhythmias. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Re-entry:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While re-entry is the <em>most common mechanism for arrhythmias</em> in general, it&#39;s not the primary mechanism for digitalis-induced ventricular arrhythmias.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Early afterdepolarizations (EADs):</span></strong><span style=\"font-size:12.0pt\"> EADs are associated with prolonged repolarization (long QT syndrome), which is not a direct effect of digitalis toxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Enhanced automaticity:</span></strong><span style=\"font-size:12.0pt\"> Although digitalis can increase automaticity, it&#39;s not the predominant mechanism; DADs caused by calcium overload play a more significant role.</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand that the primary mechanism of digitalis-induced ventricular arrhythmias is delayed afterdepolarizations (DADs) caused by intracellular calcium overload.</span></span></span></p>",
    "correct_choice_id": 27302,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 6834,
    "choices": [
      {
        "id": 27305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Decremental response </span></span></p>"
      },
      {
        "id": 27306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Sodium-dependent conduction </span></span></p>"
      },
      {
        "id": 27307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Increased gap junctions </span></span></p>"
      },
      {
        "id": 27308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Speed of conduction is 1-2 m/s</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following describes the AV node accurately?</span></span></p>",
    "unique_key": "Q4117785",
    "question_audio": null,
    "question_video": null,
    "map_id": 19781,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Decremental response</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrionodal transitional connections exhibit decremental conduction, defined as slowing of conduction with increasingly rapid rates of stimulation. This property of the atrioventricular (AV) node is physiologically important. If a very rapid atrial arrhythmia occurs, the AV node acts as a sort of &ldquo;gatekeeper&rdquo; to the ventricles due to its decremental conduction. Thus, in the case of atrial fibrillation (where atrial rates often exceed 300 beats/min) the ventricular rate never approaches these very rapid rates. Some accessory conduction pathways, in contrast, do not exhibit decremental conduction properties and will very rapidly conduct tachycardias (such as atrial fibrillation) to the ventricles, leading to hemodynamic collapse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sodium-dependent conduction:</span></strong><span style=\"font-size:12.0pt\"> The action potential upstroke in the AV node is dependent on the smaller and slower inward Ca2+ current, which is the reason why the upstroke velocity of the action potential is low&mdash;one of the factors responsible for the slow conduction velocity in the AV node.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased gap junctions:</span></strong><span style=\"font-size:12.0pt\"> The AV node actually has fewer gap junctions than other parts of the conduction system, contributing to its slower conduction speed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Speed of conduction is 1-2 m/s:</span></strong><span style=\"font-size:12.0pt\"> The conduction speed in the AV node is much slower, around 0.05 m/s (50 mm/s).</span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AV node acts as a &lsquo;gatekeeper&rsquo; to the ventricles.</span></span></span></p>",
    "correct_choice_id": 27305,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 6852,
    "choices": [
      {
        "id": 27376,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">First-degree heart block </span></span></p>"
      },
      {
        "id": 27377,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Mobitz type I, second-degree heart block </span></span></p>"
      },
      {
        "id": 27378,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Mobitz type II, second-degree heart block </span></span></p>"
      },
      {
        "id": 27379,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Complete Heart Block</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You are seeing Mr. Aravind, a 24-year-old previously healthy athlete, for his routine physical examination. Which of the following rhythms is demonstrated?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-094521.png\" style=\"height:76px; width:400px\" /></span></span></p>",
    "unique_key": "Q3882837",
    "question_audio": null,
    "question_video": null,
    "map_id": 19782,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Mobitz type I, second-degree heart block</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The periodic failure of conduction in Mobitz type I block is characterized by a progressively lengthening PR interval, shortening of the RR interval, and a pause that is less than two times the immediately preceding RR interval on the electrocardiogram (ECG). The ECG complex after the pause exhibits a shorter PR interval than that immediately preceding the pause. This ECG pattern most often arises because of decremental conduction of electrical impulses in the atrioventricular node. This rhythm is usually benign and may be seen in very fit athletes due to high vagal tone. This pattern is typically caused by decremental conduction in the atrioventricular (AV) node. It is generally a benign rhythm and can be seen in healthy athletes due to high vagal tone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. First-degree heart block:</span></strong><span style=\"font-size:12.0pt\"> This has a prolonged but constant PR interval.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mobitz type II, second-degree heart block:</span></strong><span style=\"font-size:12.0pt\"> This has a constant PR interval with occasional dropped QRS complexes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Type III heart block (complete heart block):</span></strong><span style=\"font-size:12.0pt\"> This has complete dissociation between the atria and ventricles, with no relationship between P waves and QRS complexes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mobitz type I second-degree heart block (Wenckebach) is a relatively benign rhythm often seen in athletes due to high vagal tone.</span></span></span></p>",
    "correct_choice_id": 27377,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 6854,
    "choices": [
      {
        "id": 27384,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Multiple pathways </span></span></p>"
      },
      {
        "id": 27385,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Refractory period &gt; 240 ms </span></span></p>"
      },
      {
        "id": 27386,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Inducible AF or AVRT </span></span></p>"
      },
      {
        "id": 27387,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Accessory pathway in the posteroseptal region</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT indicative of high risk in Wolff-Parkinson-White (WPW) syndrome?</span></span></p>",
    "unique_key": "Q2408918",
    "question_audio": null,
    "question_video": null,
    "map_id": 19783,
    "difficulty_level": "beginner",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Refractory period &gt; 240ms</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A <strong>short</strong> refractory period of the accessory pathway (is a high-risk feature in WPW syndrome, as it allows for rapid conduction of impulses from the atria to the ventricles, potentially leading to life-threatening arrhythmia. A refractory period <strong>&gt; 240 ms</strong> indicates a slower conduction pathway and is generally considered <strong>low risk</strong>. Also, exercise TMT demonstrating disappearance of the delta wave and wide QRS at HR &ge; 120 beats/min is also considered low risk since it indicates inability of the accessory pathway to conduct at higher rates.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Multiple pathways:</span></strong><span style=\"font-size:12.0pt\"> The presence of multiple accessory pathways increases the risk of arrhythmias and is a high-risk feature.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inducible AF or AVRT:</span></strong><span style=\"font-size:12.0pt\"> The ability to induce AF or AV reentrant tachycardia (AVRT) during electrophysiology study indicates a higher risk of spontaneous arrhythmias and is a high-risk feature.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Accessory pathway in the posteroseptal region:</span></strong><span style=\"font-size:12.0pt\"> Poster septal accessory pathways are associated with a higher risk of sudden cardiac death due to their potential to conduct rapidly during AF.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High risk in WPW = multiple accessory pathways, accessory pathway refractory period &lt; 240ms, inducible AVRT or AF in EPS &amp; shortest RR in AF &le; 250ms.</span></span></span></p>",
    "correct_choice_id": 27385,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 6856,
    "choices": [
      {
        "id": 27392,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Adenosine 6 mg IV </span></span></p>"
      },
      {
        "id": 27393,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Synchronized DCC </span></span></p>"
      },
      {
        "id": 27394,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Verapamil 5 mg IV </span></span></p>"
      },
      {
        "id": 27395,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Pain control and IV hydration</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 76-year-old woman with a history of hypertension, COPD, diabetes and osteoporosis presents to the emergency department after a fall, with intense left hip pain, dry mucous membranes, and tachycardia. Her ECG is shown. What is the most appropriate next step?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-095717.png\" style=\"height:258px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q2713815",
    "question_audio": null,
    "question_video": null,
    "map_id": 19784,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Pain control and IV hydration</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This rhythm is multifocal atrial tachycardia (MAT), which is easily confused with atrial fibrillation due to its irregularly irregular nature. However, MAT is distinguished by the multiple different P waves present (at least three different P wave morphologies). MAT is classically present in patients with severe pulmonary disease, and is exacerbated in the presence of acute illness. No anticoagulation is needed for MAT, and direct current cardioversion is not efficacious. Some patients respond to the non-dihydropyridine calcium channel blockers (diltiazem and verapamil), and amiodarone has some limited effect. In this patient controlling the underlying cause of her tachycardia (pain and dehydration) is the most appropriate first therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Adenosine 6 mg IV:</span></strong><span style=\"font-size:12.0pt\"> Primarily used for supraventricular tachycardia (SVT), not MAT. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Synchronized DCC:</span></strong><span style=\"font-size:12.0pt\"> Not effective for MAT and it is C/I. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Verapamil 5 mg IV:</span></strong><span style=\"font-size:12.0pt\"> Verapamil may be in helpful in some patients with MAT (for rate control) but often unnecessary as treatment of underlying cause is sufficient and the most important. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The initial management of MAT should focus on addressing the underlying causes, such as pain and dehydration in this case. </span></span></span></p>",
    "correct_choice_id": 27395,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 6858,
    "choices": [
      {
        "id": 27400,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">It is usually life-threatening. </span></span></p>"
      },
      {
        "id": 27401,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">It relies on enhanced automaticity as a mechanism. </span></span></p>"
      },
      {
        "id": 27402,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">It relies on multiple pathways for conduction from the atrium into the AV node. </span></span></p>"
      },
      {
        "id": 27403,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">It requires systemic anticoagulation for thromboembolic prophylaxis.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements is true regarding the most common form of paroxysmal supraventricular tachycardia (PSVT)?</span></span></span></p>",
    "unique_key": "Q2563783",
    "question_audio": null,
    "question_video": null,
    "map_id": 19785,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) It relies on multiple pathways for conduction from the atrium into the AV node.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common form of PSVT is atrioventricular nodal reentrant tachycardia (AVNRT). AVNRT is caused by the presence of multiple pathways within or near the AV node, allowing for re-entry circuits to form and sustain the tachycardia. Most forms of AVNRT utilize a slowly conducting AV nodal pathway that is located as a right inferior extension that extends from the compact AV node near the His bundle, inferiorly along the tricuspid valve annulus to the floor of the coronary sinus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is usually life-threatening:</span></strong><span style=\"font-size:12.0pt\">&nbsp; AVNRT is usually not life-threatening, though it can cause significant symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. It relies on enhanced automaticity as a mechanism: </span></strong><span style=\"font-size:12.0pt\">&nbsp;AVNRT is a re-entry tachycardia, not caused by enhanced automaticity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It requires systemic anticoagulation for thromboembolic prophylaxis: </span></strong><span style=\"font-size:12.0pt\">Anticoagulation is not typically required for AVNRT unless there are additional risk factors for thromboembolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common form of PSVT is AVNRT, which is caused by re-entry circuits involving multiple pathways within the AV node.</span></span></span></p>",
    "correct_choice_id": 27402,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 6859,
    "choices": [
      {
        "id": 27404,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">AF with pre-excitation </span></span></p>"
      },
      {
        "id": 27405,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">AF with LBBB </span></span></p>"
      },
      {
        "id": 27406,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Monomorphic VT </span></span></p>"
      },
      {
        "id": 27407,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Torsades de pointes</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">You are in the emergency department when a 19-year-old woman, Ms. Vidhya, arrives after collapsing during a Sunday marathon. She is unresponsive and pulseless. ECG is shown. Which of the following rhythms is the cause of her cardiac arrest?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-095925.png\" style=\"height:241px; width:500px\" /></span></span></span></p>",
    "unique_key": "Q1956397",
    "question_audio": null,
    "question_video": null,
    "map_id": 19786,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>A) Atrial fibrillation with pre-excitation</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rapid, irregular, broad complex tachycardia (overall rate ~ 200 bpm) with a LBBB morphology (dominant S wave in V1). This could easily be mistaken for AF with LBBB.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, the morphology is not typical of LBBB, the rate is too rapid (up to 300 bpm in places, i.e. too rapid to be conducted via the AV node), and there is a subtle beat-to-beat variation in the QRS width which is more typical of WPW (LBBB usually has fixed width QRS complexes).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The rhythm is very difficult to differentiate from polymorphic VT but it does not have the twisting morphology to consider it as Torsades de pointes. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Note: </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Approximately 25% of APs causing preexcitation allow minimum R-to-R intervals of &lt;250 ms during AF and are associated with a higher risk of inducing ventricular fibrillation and sudden death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pre-excited AF should be treated with electrical cardioversion or IV procainamide or ibutilide, which may terminate the arrhythmia or slow the ventricular rate. <em><u>AV nodal blockers are absolutely C/I.</u></em> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Atrioventricular nodal reentrant tachycardia: </span></strong><span style=\"font-size:12.0pt\">This is usually a narrow-complex tachycardia, unlike the wide-complex seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Monomorphic ventricular tachycardia:</span></strong><span style=\"font-size:12.0pt\"> This has a regular rhythm with similar QRS complexes, unlike the irregular pattern seen here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Torsades de pointes:</span></strong><span style=\"font-size:12.0pt\"> Difficult to differentiate but the given ECG does not have the twisting morphology to consider it as Torsades de pointes. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AF with preexcitation presents with rapid irregular wide-complex tachycardia and it is lethal. </span></span></span></p>",
    "correct_choice_id": 27404,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 6860,
    "choices": [
      {
        "id": 27408,
        "text": "<p><span style=\"font-size:11pt;\">Catheter ablation has a high success rate in common atrial flutter.</span></p>"
      },
      {
        "id": 27409,
        "text": "<p><span style=\"font-size:11pt;\">It is dependent on the cavotricuspid isthmus for conduction.</span></p>"
      },
      {
        "id": 27410,
        "text": "<p><span style=\"font-size:11pt;\">Rate control is often more easily achieved in atrial flutter than in atrial fibrillation.</span></p>"
      },
      {
        "id": 27411,
        "text": "<p><span style=\"font-size:11pt;\">The wave of depolarization propagates anti-clockwise</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Which of the following statements regarding the below rhythm is false?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-100045.png\" alt=\"\" width=\"500\" height=\"164\"></span></p>",
    "unique_key": "Q6451254",
    "question_audio": null,
    "question_video": null,
    "map_id": 19787,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Rate control is often more easily achieved in atrial flutter than in atrial fibrillation.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Common or typical right atrial flutter is due to a circuit that revolves counterclockwise in the RA (which produces the characteristic negative sawtooth flutter waves in leads II, III, and aVF and positive P waves in lead V1). The wavefront passes in the cavotricuspid isthmus, where it is susceptible to interruption by catheter ablation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Initial management of atrial flutter is similar to that for AF. Rate control can be achieved with administration of AV nodal\u2013blocking agents, but this is <i>often </i>more difficult than for AF. The risk of thromboembolic events is similar to that<i> </i>associated with AF. Anticoagulation is warranted prior to conversion for episodes more than 48 hours in duration and chronically for patients at increased risk of thromboembolic stroke based on the CHA2DS2-VASc scoring system.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">For a first episode of atrial flutter, conversion to sinus rhythm with no long term anti-arrhythmic drug therapy is reasonable. For recurrent episodes, antiarrhythmic drug therapy with sotalol, dofetilide, disopyramide, and amiodarone may be considered, but &gt;70% of patients experience recurrences. For recurrent episodes of common atrial flutter, catheter ablation<i> of the </i>cavotricuspid isthmus abolishes the arrhythmia in &gt;95% of patients<i> </i>with a low risk of complications.</span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-100137.png\" alt=\"\" width=\"500\" height=\"497\"></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p><span style=\"font-size:11pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Catheter ablation has a high success rate in common atrial flutter:</strong> True. It has &gt; 95% success.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. It is dependent on the cavotricuspid isthmus for conduction:</strong> True. Since the wavefront passes in the cavotricuspid isthmus, where it is susceptible to interruption by catheter ablation.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. The wave of depolarization propagates anti-clockwise:</strong> The circuit most commonly revolves in a counterclockwise direction (as viewed looking toward the tricuspid annulus from the ventricular apex), which produces the characteristic negative sawtooth flutter waves in leads II, III, and aVF and positive P waves in lead V1.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Catheter ablation is a highly effective treatment for typical atrial flutter, offering high success rates and a low risk of complications.</span></p>",
    "correct_choice_id": 27410,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6863,
    "choices": [
      {
        "id": 27420,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Incidence increases with age. </span></span></p>"
      },
      {
        "id": 27421,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">More common in women than in men. </span></span></p>"
      },
      {
        "id": 27422,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">It is associated with an increased risk of mortality. </span></span></p>"
      },
      {
        "id": 27423,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">All of the above.</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mr. Sarabesh presents with palpitations. His ECG is shown. Which of the following is false regarding the rhythm?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-100253.png\" style=\"height:121px; width:500px\" /></span></span></p>",
    "unique_key": "Q5913984",
    "question_audio": null,
    "question_video": null,
    "map_id": 19788,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) More common in women than in men.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The rhythm shows AF and it is the most common sustained arrhythmia and is a major public health problem. Prevalence increases with age, and &gt;95% of AF patients are &gt;60 years of age. The prevalence by age 80 is ~10%. The lifetime risk of developing AF for a 40-year-old male is ~25%. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AF is slightly more common in men than women</span><span style=\"font-size:12.0pt\"> and more common in whites than blacks. Risk factors for developing AF in addition to age and underlying cardiac disease include hypertension, diabetes mellitus, cardiac disease, obesity, and sleep apnea. AF is associated with a 1.5- to 1.9-fold increased risk of mortality after controlling for underlying heart disease. AF is also associated with a risk of developing HF and vice-versa&mdash;patients with HF have an increased risk of developing AF. AF increases the risk of stroke by 5x and is estimated to be the cause of 25% of strokes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\">True. The incidence of AF <em>increases</em> with age. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\">True. AF is associated with an increased risk of mortality. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Not all of the above statements are false. Option A and C are true. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atrial fibrillation is the most common sustained arrhythmia. </span></span></span></p>",
    "correct_choice_id": 27421,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 6818,
    "choices": [
      {
        "id": 27241,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Aspiration of the device pocket </span></span></p>"
      },
      {
        "id": 27242,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Pacemaker extraction </span></span></p>"
      },
      {
        "id": 27243,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Topical mupirocin </span></span></p>"
      },
      {
        "id": 27244,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Clinical observation and reassessment</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 68-year-old man with a history of pacemaker insertion presents to you for routine review. You notice the pacemaker site like what is shown in the image. What is the most appropriate additional management?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/22/screenshot-2024-08-22-092200.png\" style=\"height:223px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q7721530",
    "question_audio": null,
    "question_video": null,
    "map_id": 19765,
    "difficulty_level": "difficult",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Pacemaker extraction</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Image reveals erythema over the site of pacemaker, which is highly suggestive of a pocket infection. Cardiac device infection requires prompt removal of all hardware, debridement of the pocket, and antibiotic therapy (even if the patient is asymptomatic).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspiration:</span></strong><span style=\"font-size:12.0pt\"> Not recommended for diagnostic purposes and can worsen infection. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Topical mupirocin:</span></strong><span style=\"font-size:12.0pt\"> Ineffective for deep pocket infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option D. Observation:</strong> Inappropriate as the infection can worsen and lead to serious complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prompt device removal and antibiotic therapy is required in cases of suspected or confirmed cardiac device infection.</span></span></span></p>",
    "correct_choice_id": 27242,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 54253,
    "choices": [
      {
        "id": 216481,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">No anticoagulation</span></span></p>"
      },
      {
        "id": 216482,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Initiate aspirin 325 mg daily </span></span></p>"
      },
      {
        "id": 216483,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Initiate apixaban 5 mg twice daily </span></span></p>"
      },
      {
        "id": 216484,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">Initiate warfarin</span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ms. Kavitha, a 22-year-old woman with rheumatic mitral stenosis develops atrial fibrillation. Her CHA\u2082DS\u2082-VASc is 1. Which of the following is the correct approach to stroke prevention?</span></span></p>",
    "unique_key": "Q2161683",
    "question_audio": null,
    "question_video": null,
    "map_id": 25747,
    "difficulty_level": "intermediate",
    "subjects_id": [
      11
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>D) Initiate warfarin</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While Ms. Kavitha&#39;s CHA\u2082DS\u2082-VASc score is 1, her rheumatic mitral stenosis places her at high risk for stroke due to AF. Warfarin is the recommended anticoagulant for patients with rheumatic mitral stenosis and AF, as the newer direct-acting oral anticoagulants (DOACs) have not been adequately studied in this population.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. No anticoagulation: </span></strong><span style=\"font-size:12.0pt\">&nbsp;Incorrect, since AF increases the risk of stroke by 20-25x in patients with mitral stenosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Initiate aspirin 325 mg daily: </span></strong><span style=\"font-size:12.0pt\">&nbsp;Insufficient for stroke prevention in patients with AF and high risk factors like rheumatic mitral stenosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Initiate apixaban 5 mg twice daily:</span></strong><span style=\"font-size:12.0pt\"> &nbsp;DOACs are not recommended in patients with rheumatic mitral stenosis due to limited data.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong> &nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Warfarin is the recommended anticoagulant for stroke prevention in patients with AF and rheumatic mitral stenosis.</span></span></span></p>",
    "correct_choice_id": 216484,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Cardiology';
        const quizFilename = 'cardiology-1e7d89f6.html';
        let hierarchy = ["Cerebellum", "qBank", "Medicine"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on answer selection
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>